Anti-HBV antibodies and methods of use

Anti-S-HBs antibodies derived from HBV vaccinees and controllers provide a functional cure by neutralizing HBV through robust T cell responses and blocking viral attachment, addressing the limitations of current therapies.

US12799185B2Active Publication Date: 2026-11-17INST PASTEUR +1
View PDF 17 Cites 0 Cited by

Patent Information

Application Number
US18/008093
Authority / Receiving Office
US · United States
Patent Type
Patents(United States)
Current Assignee / Owner
Priority Date
2020-06-08
Filing Date
2021-06-08
Publication Date
2026-11-17
Estimated Expiration
2042-01-02

AI Technical Summary

Technical Problem

Current therapies for chronic hepatitis B virus (HBV) infection rarely achieve a functional cure, defined by HBsAg loss and anti-HBs antibody seroconversion, and there is a need for robust immune responses and neutralizing antibodies to control and eliminate HBV infection.

Method used

Development of anti-S-HBs antibodies derived from HBV vaccinees and controllers, which exhibit broad and robust antigen-specific T cell responses, neutralizing activity, and lifelong protective immunity, targeting the S-HBs antigenic loop and blocking viral attachment to hepatocytes.

Benefits of technology

The anti-S-HBs antibodies effectively neutralize HBV infection in vitro and in vivo, reducing viral load and preventing reactivation, demonstrating potential for a functional cure.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US12799185-D00001
    Figure US12799185-D00001
  • Figure US12799185-D00002
    Figure US12799185-D00002
  • Figure US12799185-D00003
    Figure US12799185-D00003
Patent Text Reader

Abstract

The invention provides anti-S-HBs antibodies and methods of using the same.
Need to check novelty before this filing date? Find Prior Art

Description

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application is a national stage application under 35 U.S.C. § 371 of International Application No. PCT / EP2021 / 065260, filed internationally on Jun. 8, 2021, which claims priority benefit of European Patent Application No. 20305612.2, filed on Jun. 8, 2020, the disclosures of which are incorporated herein by reference in their entirety.SUBMISSION OF SEQUENCE LISTING ON ASCII TEXT FILE

[0002] The content of the following submission on ASCII text file is incorporated herein by reference in its entirety: a computer readable form (CRF) of the Sequence Listing (file name: 008318008_ST25 June 2026.TXT, date recorded: Jun. 4, 2026, size: 292, 142 bytes).TECHNICAL FIELD

[0003] The present invention relates to antibodies against the hepatitis B virus (HBV) and methods of using the same.BACKGROUND

[0004] Chronic hepatitis B virus (HBV) infection is a major healthcare problem affecting more than 250 million people worldwide despite the availability of effective vaccines (WHO, 2017). The infection accounts for approximately 1 million deaths per year due to HBV-associated cirrhosis, liver failure, and hepatocellular carcinoma (WHO, 2017). HBV is a DNA virus belonging to the Hepadnaviridae family, which is produced as infectious virions or Dane particles, but also as non-infectious subviral particles (Seeger et al., 2013). Virions and subviral particles display at their surface three forms of HBV envelope glycoproteins or HBV surface antigens (HBsAg): the L-HBs (large), the M-HBs (middle) and the S-HBs (small). Defective particles outnumbering infectious HBV virions are therefore acting as immune decoys (Seeger et al., 2013). Current therapies for treating chronic HBV rarely achieve functional cure as defined by HBsAg loss and anti-HBs antibody seroconversion. Yet, HBV infection can be successfully controlled by natural immune responses in more than 90% of the patients infected as adults, and in the ~1% of chronically infected patients who spontaneously clear the infection called HBV seroconverters or natural controllers (Bauer et al., 2011; Chu and Liaw, 2016; McMahon, 2009; Rehermann and Nascimbeni, 2005). Robust and multispecific HBV-specific CD4+ and CD8+ T cell responses are key immune effectors in controlling the infection (Bauer et al., 2011). However, B cells and the antibodies are also instrumental for the long-term clearance and protection from viral rebound after functional cure (Bertoletti and Ferrari, 2016; Corti et al., 2018; Rehermann and Nascimbeni, 2005). For instance, despite that HBsAg− / anti-HBs+ antibody seroconversion in patients is correlated with an undetectable level of HBV DNA (McMahon, 2009), functionally cured individuals undergoing B cell depletion therapy to treat Non-Hodgkin Lymphoma have a higher risk of HBV reactivation, which can quickly lead to severe liver dysfunction (Kusumoto et al., 2019; Perrillo et al., 2015). Hence, key immune components to control and eventually eliminate HBV infection likely include a broad and robust antigen-specific T cell response, as well as the development of neutralizing anti-HBs antibodies mediating HBsAg clearance and lifelong protective immunity (Bertoletti and Ferrari, 2016; Corti et al., 2018).

[0005] Neutralizing antibodies produced in response to HBV infection target all 3 HBsAg forms. They recognize either the S-HBs antigenic loop and interfere with the pre-attachment to heparane sulfate proteoglycans (HS) on hepatocytes, or the preS1 domain of the L-HBs and block the binding to the host cellular receptor, the sodium taurocholate co-transporting polypeptide (NTCP) (Corti et al., 2018). IgG antibodies against the “a determinant” part of the S-HBs loop induced by HBV vaccination (based on recombinant S-HBs immunogens), or administrated to individuals at risk of exposure by polyclonal HBV immunoglobulin infusions confer protection against HBV infection (Samuel et al., 1993; West and Calandra, 1996). Several neutralizing anti-preS and anti-S-HBs antibodies have been isolated from immunized mice and from few human immune donors (Corti et al., 2018). S-HBs neutralizing antibodies may contribute to the viral clearance and long-term suppression in HBV seroconverters as they do for protecting vaccinees from infection. However, no studies have been performed on the memory B-cell response to HBV in functionally cured HBV-infected individuals by cloning and charactering human HBsAg-specific antibodies.SUMMARY

[0006] The invention provides anti-S-HBs antibodies and methods of using the same.BRIEF DESCRIPTION OF THE FIGURES

[0007] FIG. 1A-1E. S-HBs memory antibodies cloned from HBV vaccinees and controllers.

[0008] (FIG. 1A) Average S-HBsAg-reactivity of serum IgGs from HBV vaccinees (HBVv, n=6, bottom curve) and controllers (HBVc, n=8, top curve). Shaded regions indicate value ranges. Representative flow-cytometry plots showing S-HBs-binding IgG+ memory B cells in HBV vaccinees and controllers (Bv4 and Bc3 are shown). nS-HBsAg and rS-HBsAg are human-derived native and recombinant S-HBs antigens, respectively.

[0009] (FIG. 1B) S-HBsAg-ELISA reactivities of S-HBsAg-captured IgG+ memory B-cell antibodies (left) and percentage of S-HBs-specific monoclonal antibodies (% S-HBsAg+) isolated from HBVv and HBVc (right). % S-HBsAg+ according to S-HBs antibody titers in HBVc (<150 and >900 IU / ml) are indicated. capt-rHBAgs, rHBAgs capture ELISA.

[0010] (FIG. 1C) Bubble plot showing the level of clonal expansions according to percentages of somatic mutations in the IgH and IgL chain variable domains of S-HBs-specific IgG antibodies. The size of the expansions for each donor is indicated in the bar graph below.

[0011] (FIG. 1D) Volcano plot analysis comparing the immunoglobulin (Ig) gene repertoire of S-HBsAg-specific B cells from HBV immune donors and IgG memory B cells from healthy individuals (Top). Dots above the dashed line indicate statistically significant differences between both Ig gene repertoires. Comparison of the VH(DH)JH rearrangement frequencies are shown (Bottom). pV, p-value; FC, fold changes.

[0012] (FIG. 1E) Distribution of conformational-dependent vs non-conformational antibodies among S-HBs memory IgGs. Total number of tested antibodies is indicated in the center of the pie chart. Infrared immunoblot shows anti-S-HBs IgG memory B-cell antibodies reactive against denatured S-HBs protein (top right). ELISA binding curves of peptide-reactive S-HBs antibodies are shown (bottom right, mean of quadruplicates±SD).

[0013] FIG. 2A-2F. Neutralizing activity of human S-HBs memory antibodies.

[0014] (FIG. 2A) Neutralizing activity of S-HBs IgG antibodies against in vitro infection of HepaRG cells by genotype D HBV. Fifty percent inhibitory concentration (IC50) values for each antibody (n=72) (Top left), and distribution of neutralizing vs non-active antibodies (Bottom left) are shown.

[0015] (FIG. 2B) Neutralization capacity according to bound S-HBs antigens (Top right) and percentage of somatic hypermutations (% SHM) (Bottom right) are indicated.

[0016] (FIG. 2C) In vitro neutralizing activity of selected S-HBs IgG antibodies against HDV using HDV RNA quantification in HepaRG cells by northern blotting. ge, genome equivalents.

[0017] (FIG. 2D) In vivo neutralization activity of human S-HBs antibodies in AAV-HBV-transduced mice. Circulating blood S-HBs levels were monitored in AAV-HBV-transduced mice treated once i.v. with 0.5 mg of anti-S-HBs antibodies PIBv4.104 (n=9), Bc1.187 (n=9), Bc1.263 (n=6), Bc4.204 (n=4) or mGO53 isotype control (n=5). Thick lines represent the average values.

[0018] (FIG. 2E) Logic changes of S-HBs titers at nadir (day post-injection 2, dpi2) upon antibody administration of 0.25 mg (white) and 0.5 mg (black) per mouse are shown. Means are indicated with lines.

[0019] (FIG. 2F) Circulating blood S-HBs and HBV DNA levels were monitored in AAV-HBV-transduced mice (n=6) injected once i.v. with 1 mg of the anti-S-HBs antibody Bc1.187. Average log10 changes overtime of S-HBs and HBV DNA levels are shown on the right.

[0020] FIG. 3A-3E. Cross-reactivity of human HBV neutralizing antibodies.

[0021] (FIG. 3A) Heat map comparing the ELISA reactivity of HBV neutralizing antibodies against Adw and Ayw genotype D S-HBs proteins (measured as AUC values from FIG. 14). Representative ELISA graphs on the right show the reactivity of selected antibodies against recombinant HBV vaccines Engerix-B (Ayw) and GenHevac (Adw). Error bars indicate the SD of assay duplicates.

[0022] (FIG. 3B) Heat map comparing the reactivity of HBV neutralizing antibodies against S-HBs antigens from genotypes depicted in the phylogenic tree (Top left), as % of bound S-HBS-expressing cells determined by flow cytometry. Data represent one of two independent experiments. HB1 and mGO53 are positive and negative controls, respectively. Cytograms in the bottom left shows a representative reactivity profile of HB1 antibody. ELISA graphs on the right show the reactivity of selected antibodies against recombinant S-HBs antigens from all genotypes but G. Error bars indicate the SD of assay duplicates.

[0023] (FIG. 3C) Same as in (FIG. 3B) but for S-HBs mutant proteins depicted on the diagram in the top left.

[0024] (FIG. 3D) Graph comparing the neutralizing activity of Bc1.187 against infection of primary human hepatocytes by HBV viruses from A to D genotypes. Error bars indicate the SEM of assay triplicates.

[0025] (FIG. 3E) Graphs show neutralization curves of HBV viruses from genotype A, C and D by PIBv4.104 and Bc1.187 as determined by the HepaRG neutralization assay. Error bars indicate the SEM of assay triplicates.

[0026] FIG. 4A-4E. Binding features of human HBV neutralizing antibodies.

[0027] (FIG. 4A) Heat map shows the ELISA binding of selected HBV neutralizing antibodies to recombinant HBsAg mutant proteins. Color value is proportional to the reactivity level.

[0028] (FIG. 4B) Heatmap showing competition for S-HBs binding of the HBV neutralizing antibodies. Lighter colors indicate stronger inhibition; black indicates no competition.

[0029] (FIG. 4C) Graphs comparing binding to S-HBs of the selected HBV neutralizing antibodies and their germline counterparts as measured by flow cytometry (top) and ELISA (bottom).

[0030] (FIG. 4D) Neutralizing activity of the germline versions of Bc1.187, Bc4.204 and PIBv4.104 against genotype D HBV viruses as determined by the HepaRG neutralization assay. Error bars indicate the SD of assay triplicates.

[0031] (FIG. 4E) Reactivity profile of selected S-HBs human antibodies on human protein microarrays. Each spot correspond to the z-scores given on a single protein by the reference (Ref: mGO53, y axis) and test antibody (x axis). Labels indicate immunoreactive proteins (z>5).

[0032] FIG. 5A-5B. In vivo therapy with potent HBV cross-neutralizing antibody Bc1.187.

[0033] (FIG. 5A) Evolution of HBV infection overtime in AAV-HBV-transduced mice (n=7 per group) treated every 2 days for 16 days with 0.5 mg i.v. of anti-S-HBs Bc1.187 or isotype control mGO53 chimeric antibody. Circulating blood HBsAg, HBeAg and HBV DNA levels are shown. Thick lines indicate the averages.

[0034] (FIG. 5B) Evolution of HBV infection overtime in HUHEP mice receiving weekly i.p. injections of human anti-S-HBs antibody Bc1.187 (20 mg / kg~0.4 mg, n=7, straight lines; 50 mg / kg~1 mg, n=5, dotted lines) for 3 weeks. Circulating blood HBsAg, HBeAg and HBV DNA levels (left) and Δ log10 values compared to baseline (right) are shown. Thick lines indicate the averages.

[0035] FIG. 6. Table showing clinical and immunovirological characteristics of the HBV immune donors.

[0036] FIG. 7A (SEQ ID NOs: 287-290, 57, 237, 291-292, 129, 293-297, 111, 298-300, 183, 301-303, 21, 3, 304-305, 147, 219, 306-307, 39, 308-312, 201, 313-316, 60, 240, 317-318, 132, 319-323, 114, 324-326, 186, 327-329, 24, 6, 330, 186, 150, 222, 331-332, 42, 333-337 and 204)) and FIG. 7B. (SEQ ID NOs: 370-394, 93, 395-399, 165, 400-427, 96, 428, 78, 429-431, 168, 432-433 and 286) Table showing Immunoglobulin gene repertoire and neutralizing activity of human anti-S-HBs antibodies.

[0037] FIG. 8A-8B. Binding of purified serum IgGs and blood IgG+ memory B cells to S-HBs antigens.

[0038] (FIG. 8A) Representative ELISA graphs showing the reactivity of purified serum IgG antibodies from HBV vaccinees (HBVv) and controllers (HBVc) against recombinant (rS-HBs) and human-derived native (nS-HBs) S-HBs particles. Error bars indicate the SEM of duplicate values. (FIG. 8B) Flow cytometric cytograms showing the gating strategy used to single-cell sort IgG+ memory B cells binding to fluorescently labeled rS-HBs and nS-HBs proteins used as baits. The S-HBS-reactive IgG+ memory B-cell population is shown for all donors.

[0039] FIG. 9A-9B. S-HBs reactivity of S-HBs-captured IgG+ memory B-cell antibodies.

[0040] (FIG. 9A) Heatmap showing the ELISA reactivity against nS-HBs and rS-HBs (immobilized and captured) of S-HBs-binding memory antibodies cloned from HBV vaccinees and seroconverters. Mean of triplicate optical density values are shown. (FIG. 9B) Violin plots showing the cumulative ELISA optical density (COD) values for the bindings shown in (A). The proportion of S-HBs-specific antibodies cloned from S-HBs-captured IgG+ memory B cells is shown per donor (Right).

[0041] FIG. 10A-10H. Immunoglobulin gene repertoire of S-HBs-specific IgG+ memory B-cells.

[0042] (FIG. 10A) Pie charts comparing the distribution of VH / JH gene usage of blood S-HBs-specific IgG+ memory B cells and IgG+ memory B cells from healthy individuals (IgG.mB) (Prigent et al., 2016). The number of antibody sequences analyzed is indicated in the center of each pie chart.

[0043] (FIG. 10B) Bar graph comparing the distribution of single immunoglobulin VH genes expressed by S-HBs-specific and control IgG+ memory B cells. (FIG. 10C) (SEQ ID NOs: 338-339, 218, 340-342, 92, 343-344, 20 and 345) Amino acid alignment of the CDRH2 region (defined by Kabat) of VH1-69-expressing S-HBs antibodies. Residues in grey indicate substitutions compared to the germline VH gene (on the top). (FIG. 10D) Same as (B) but for IgG subtypes (Left) and κ- vs λ-Ig chain usage (Right). (FIG. 10E) Same as (B) but for the CDRH3 lengths and positive charge numbers. The average of CDRH3 lengths is indicated below each histogram. (FIG. 10F) Same as (A) but for Vκ / Jκ and Vλ / Jλ gene usages. (FIG. 10G) Violin plots comparing the number of mutations in VH, Vκ and Vλ genes in S-HBs-specific and control IgG+ memory B cells. The average number of mutations (mut.) is indicated below each dot plot. Numbers of mutations were compared across groups of antibodies using unpaired student t-test with Welch's correction. (FIG. 10H) Graphs showing the Bayesian estimation of antigen-driven selection based on anti-S-HBs IgH and IgL sequences. Groups were compared (in A, B, D, E, and F) using 2× 2 and 2× 5 Fisher's Exact tests.

[0044] FIG. 11A-11C. Reactivity of human anti-S-HBs antibodies against denatured S-HBsAg and S-HBsAg peptides.

[0045] (FIG. 11A) ELISA reactivity of anti-S-HBs antibodies against transmembrane domains-deleted S-HBsAg protein (ATM-rS-HBsAg). HB1 and mGO53 are positive and negative control, respectively. The dotted line indicates the cut-off OD405nm for positive reactivity. (FIG. 11B) Same as (FIG. 11A) but for cyclic peptides corresponding to putative S-HBsAg loops 122-137 (SEQ ID NO: 280) and 139-148 (SEQ ID NO: 281). (FIG. 11C) (SEQ ID NOs: 346-354, 282 and 355-369) Heat mapped reactivity of anti-S-HBs antibodies against S-HBsAg overlapping linear peptides. Amino acid sequences (Right) and values of grand average of hydropathy (GRAVY) (Below) of S-HBsAg peptides are indicated.

[0046] FIG. 12A-12B. In vitro HBV neutralization by human S-HBs antibodies.

[0047] Graphs show neutralization curves of genotype D HBV viruses by selected human S-HBs antibodies as measured in the in vitro HepaRG assay. The dotted horizontal line indicated 50% neutralization, from which the IC50 value can be derived from the antibody concentration on the x-axis.

[0048] FIG. 13A-13B. Passive administration of human S-HBs antibodies in HBV-AAV mice.

[0049] (FIG. 13A) In vivo neutralization activity of human S-HBs antibodies in AAV-HBV-transduced mice. Circulating blood HBsAg levels were monitored in AAV-HBV-transduced mice treated once i.v. with 0.25 mg of anti-S-HBs antibodies Bv4.104 (n=6), Bc1.187 (n=6), Bc1.263 (n=6), Bc4.204 (n=6) or mGO53 isotype control (n=5). Thick lines indicate means. Log 10 changes overtime of HBsAg titers (Δ log 10 S-HBs) upon antibody administration of 0.25 mg i.v. per mouse are shown. (FIG. 13B) Graphs showing the evolution of human IgG titers overtime in mice treated once with 0.25 mg (left) and 0.5 mg (right) of S-HBs antibodies. Thick lines indicate means.

[0050] FIG. 14. Binding of HBV neutralizing antibodies to recombinant serotype-specific S-HBs proteins.

[0051] Representative ELISA graph showing the binding of selected HBV neutralizing antibodies to purified recombinant Adw (Straight lines) and Ayw (Dotted lines) S-HBs proteins. HB1 and mGO53 are positive and negative control, respectively. Mean values±SEM of assay duplicates from one of two independent experiments are shown.

[0052] FIG. 15A-15B. Cross-reactivity of HBV neutralizing antibodies against genotype-specific S-HBs proteins.

[0053] (FIG. 15A) (SEQ ID NOs: 255-258, 254, 262, 260, 259 and 261) Amino acid alignment of the consensus S-HBs protein sequences from different HBV genotypes used in (B). Residue variations are highlighted in grey. (FIG. 15B) Cytograms comparing the reactivity profiles of selected HBV neutralizing antibodies against genotype-specific S-HBs antigens. Data represent one of two independent experiments. HB1 and mGO53 are positive and negative control, respectively. Ctr, non-transfected cell control (first from the bottom); FI, fluorescence intensity.

[0054] FIG. 16. Reactivity of HBV neutralizing antibodies against S-HBs mutant proteins.

[0055] Cytograms comparing the reactivity of selected HBV neutralizing antibodies against genotype D S-HBs mutant proteins displaying naturally occurring escape mutations (T126A, M133T, Y134V or G145R), or a mutation in the S-HBs N-glycosylation site (N126S). Data represent one of two independent experiments. HB1 and mGO53 are positive and negative control, respectively. Ctr, non-transfected cell control (first from the bottom); FI, fluorescence intensity.

[0056] FIG. 17A-17C. Poly- and self-reactivity of potent HBV neutralizing antibodies. (FIG. 17A) Reactivity profiles of selected human S-HBs antibodies (n=8) human protein microarrays. For each protein spot, the mean fluorescence intensity (MFI) given by the reference (Ref: mGO53) and test are depicted on the y and x axis, respectively. Each dot represents the average of duplicate array proteins. The diagonal lines indicate equal binding for reference and test antibodies. Labelled dots indicate immunoreactive proteins with a z-score >5. (FIG. 17B) Frequency histograms showing the log 10 protein displacement (o) of the MFI signals for S-HBs antibodies compared to non-reactive antibody mGO53. The polyreactivity index (PI) corresponds to the Gaussian mean of all array protein displacements. (FIG. 17C) Binding of selected S-HBs antibodies to HEp2-expressing self antigens was assayed by IFA and ELISA. Ctr+, positive control of the kit. mGO53 and ED38 are negative and positive control antibodies, respectively. The scale bars represent 40 μM. Bar graph in the bottom right shows the HEp-2 reactivity as measured by ELISA. Means±SD of values from two independent experiments performed in duplicate are shown.

[0057] FIG. 18A-18E. Passive administration of neutralization antibodies in chronically HBV-infected mice.

[0058] (FIG. 18A) Circulating blood HBsAg levels overtime in AAV-HBV-transduced mice (n=7) treated every 3-4 days for 17 days with 0.5 mg i.p. of human anti-S-HBs antibody Bc1.187 or mGO53 isotype control. Averaged Δ log 10 HBsAg values are shown (Right). Shaded area indicates the antibody therapy period. (FIG. 18B) Murine anti-human IgG antibody levels in the treated mice shown in (A) as measured by ELISA. (FIG. 18C) IgG concentrations of passively-administrated chimeric Bc1.187 antibody (0.5 mg i.v.) in B6 mice (n=4). Half-life in days (t1 / 2) of muBc1.187 antibody is indicated in the upper-right corner. (FIG. 18D) Δ log 10 S-HBs levels overtime in C57BL / 6J mice receiving weekly i.v. injections (0.5 mg) of chimeric anti-S-HBs antibody Bc1.187 and mGO53 isotype control. Thick lines indicate the averages. (FIG. 18E) Δlog 10 HBsAg and HBV DNA levels overtime in AAV-HBV-transduced mice (n=7) treated every 2 days for 16 days with 0.5 mg i.v. of chimeric anti-S-HBs antibody Bc1.187 or mGO53 isotype control. Thick lines indicate the averages. Shaded area indicates the antibody therapy period.

[0059] FIG. 19A-19C. Bc1.187 antibody treatment of HBV-infected HUHEP mice.

[0060] (FIG. 19A) Blood HBsAg, HBeAg and HBV DNA levels overtime for each individual HUHEP mouse infected with genotype D HBV, and treated with anti-HBs Bc1.187 for 3 weeks with either 20 mg / kg or 50 mg / kg human antibody i.p. (FIG. 19B) Evolution of HBV infection overtime in HUHEP mice receiving a treatment with the non-HBV isotype control mGO53 (20 mg / kg i.p.) or Entecavir (ETV) every 3-4 days for 3 weeks. Blood levels of HBsAg, HBeAg and HBV DNA are shown. (FIG. 19C) Graphs showing the levels of human serum albumin overtime in infected HUHEP mice and treated i.p. with 20 mg / kg (straight lines) and 50 mg / kg (dotted lines) of Bc1.187 for 17 days (shaded area).DETAILED DESCRIPTIONI. Definitions

[0061] An “acceptor human framework” for the purposes herein is a framework comprising the amino acid sequence of a light chain variable domain (VL) framework or a heavy chain variable domain (VH) framework derived from a human immunoglobulin framework or a human consensus framework, as defined below. An acceptor human framework “derived from” a human immunoglobulin framework or a human consensus framework may comprise the same amino acid sequence thereof, or it may contain amino acid sequence changes. In some aspects, the number of amino acid changes are 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, or 2 or less. In some aspects, the VL acceptor human framework is identical in sequence to the VL human immunoglobulin framework sequence or human consensus framework sequence.

[0062] “Affinity” refers to the strength of the sum total of noncovalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless indicated otherwise, as used herein, “binding affinity” refers to intrinsic binding affinity which reflects a 1:1 interaction between members of a binding pair (e.g., antibody and antigen). The affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (KD). Affinity can be measured by common methods known in the art, including those described herein. Specific illustrative and exemplary methods for measuring binding affinity are described in the following.

[0063] An “affinity matured” antibody refers to an antibody with one or more alterations in one or more complementary determining regions (CDRs), compared to a parent antibody which does not possess such alterations, such alterations resulting in an improvement in the affinity of the antibody for antigen.

[0064] The terms “anti-S-HBs-antibody” and “an antibody that binds to S-HBs” refer to an antibody that is capable of binding S-HBs with sufficient affinity such that the antibody is useful as a diagnostic and / or therapeutic agent in targeting S-HBs. In one aspect, the extent of binding of an anti-S-HBs antibody to an unrelated, non-S-HBs protein is less than about 10% of the binding of the antibody to S-HBs as measured, e.g., by surface plasmon resonance (SPR) or using ELISA or flow cytometry as disclosed herein. In certain aspects, an antibody that binds to S-HBs has a dissociation constant (KD) of ≤1 μM, ≤100 nM, ≤10 nM, ≤1 nM, ≤0.1 nM, ≤0.01 nM, or ≤0.001 nM (e.g., 10−8 M or less, e.g., from 10−8 M to 10−13 M, e.g., from 10−9 M to 10−13 M). An antibody is said to “specifically bind” to S-HBs when the antibody has a KD of 1 μM or less, and / or or if the extent of binding of an anti-S-HBs antibody to an unrelated, non-S-HBs protein is less than about 10% of the binding of the antibody to S-HBs as above, e.g., as measured by surface plasmon resonance (SPR) or by a flow cytometry or ELISA assay as described herein. In certain aspects, an anti-S-HBs antibody binds to an epitope of S-HBs that is conserved among S-HBs from different HBV genotypes.

[0065] The term “antibody” herein is used in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), other antibody formats (e.g., comprising a VH domain, a VL domain and optionally an Fc domain, in a format different to a regular IgG) and antibody fragments so long as they exhibit the desired antigen-binding activity.

[0066] An “antibody fragment” refers to a molecule other than an intact antibody that comprises a portion of an intact antibody that binds the antigen to which the intact antibody binds. Examples of antibody fragments include but are not limited to Fv, Fab, Fab′, Fab′-SH, F(ab′)2; diabodies; linear antibodies; single-chain antibody molecules (e.g., scFv, and scFab); single domain antibodies (dAbs); and multispecific antibodies formed from antibody fragments. For a review of certain antibody fragments, see Holliger and Hudson, Nature Biotechnology 23:1126-1136 (2005).

[0067] The term “epitope” denotes the site on an antigen, either proteinaceous or nonproteinaceous, to which an anti-S-HBs antibody binds. Epitopes can be formed both from contiguous amino acid stretches (linear epitope) or comprise non-contiguous amino acids (conformational epitope), e.g., coming in spatial proximity due to the folding of the antigen, i.e. by the tertiary folding of a proteinaceous antigen. Linear epitopes are typically still bound by an anti S-HBs antibody after exposure of the proteinaceous antigen to denaturing agents, whereas conformational epitopes are typically destroyed upon treatment with denaturing agents. An epitope comprises at least 3, at least 4, at least 5, at least 6, at least 7, or 8-10 amino acids in a unique spatial conformation.

[0068] Screening for antibodies binding to a particular epitope (i.e., those binding to the same epitope) can be done using methods routine in the art such as, e.g., without limitation, alanine scanning, peptide blots (see Meth. Mol. Biol. 248 (2004) 443-463), peptide cleavage analysis, epitope excision, epitope extraction, chemical modification of antigens (see Prot. Sci. 9 (2000) 487-496), and cross-blocking (see “Antibodies”, Harlow and Lane (Cold Spring Harbor Press, Cold Spring Harb., NY).

[0069] Antigen Structure-based Antibody Profiling (ASAP), also known as Modification-Assisted Profiling (MAP), allows to bin a multitude of monoclonal antibodies specifically binding to S-HBs based on the binding profile of each of the antibodies from the multitude to chemically or enzymatically modified antigen surfaces (see, e.g., US 2004 / 0101920). The antibodies in each bin bind to the same epitope which may be a unique epitope either distinctly different from or partially overlapping with epitope represented by another bin.

[0070] Also competitive binding can be used to easily determine whether an antibody binds to the same epitope of S-HBs as, or competes for binding with, a reference anti-S-HBs antibody. For example, an “antibody that binds to the same epitope” as a reference anti-S-HBs antibody refers to an antibody that blocks binding of the reference anti-S-HBs antibody to its antigen in a competition assay by 50% or more, and conversely, the reference antibody blocks binding of the antibody to its antigen in a competition assay by 50% or more. Also for example, to determine if an antibody binds to the same epitope as a reference anti-S-HBs antibody, the reference antibody is allowed to bind to S-HBs under saturating conditions. After removal of the excess of the reference anti-S-HBs antibody, the ability of an anti-S-HBs antibody in question to bind to S-HBs is assessed. If the anti-S-HBs antibody is able to bind to S-HBs after saturation binding of the reference anti-S-HBs antibody, it can be concluded that the anti-S-HBs antibody in question binds to a different epitope than the reference anti-S-HBs antibody. But, if the anti-S-HBs antibody in question is not able to bind to S-HBs after saturation binding of the reference anti-S-HBs antibody, then the anti-S-HBs antibody in question may bind to the same epitope as the epitope bound by the reference anti-S-HBs antibody. To confirm whether the antibody in question binds to the same epitope or is just hampered from binding by steric reasons routine experimentation can be used (e.g., peptide mutation and binding analyses using ELISA, RIA, surface plasmon resonance, flow cytometry or any other quantitative or qualitative antibody-binding assay available in the art). This assay should be carried out in two set-ups, i.e. with both of the antibodies being the saturating antibody. If, in both set-ups, only the first (saturating) antibody is capable of binding to S-HBs, then it can be concluded that the anti-S-HBs antibody in question and the reference anti-S-HBs antibody compete for binding to S-HBs.

[0071] In some aspects, two antibodies are deemed to bind to the same or an overlapping epitope if a 1-, 5-, 10-, 20- or 100-fold excess of one antibody inhibits binding of the other by at least 50%, at least 75%, at least 90% or even 99% or more as measured in a competitive binding assay (see, e.g., Junghans et al., Cancer Res. 50 (1990) 1495-1502).

[0072] In some aspects, two antibodies are deemed to bind to the same epitope if essentially all amino acid mutations in the antigen that reduce or eliminate binding of one antibody also reduce or eliminate binding of the other. Two antibodies are deemed to have “overlapping epitopes” if only a subset of the amino acid mutations that reduce or eliminate binding of one antibody reduce or eliminate binding of the other.

[0073] The term “chimeric” antibody refers to an antibody in which a portion of the heavy and / or light chain is derived from a particular source or species, while the remainder of the heavy and / or light chain is derived from a different source or species.

[0074] The “class” of an antibody refers to the type of constant domain or constant region possessed by its heavy chain. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. In certain aspects, the antibody is of the IgG1 isotype. In certain aspects, the antibody is of the IgG1 isotype with the P329G, L234A and L235A mutation to reduce Fc-region effector function. In other aspects, the antibody is of the IgG2 isotype. In certain aspects, the antibody is of the IgG4 isotype with the S228P mutation in the hinge region to improve stability of IgG4 antibody. The heavy chain constant domains that correspond to the different classes of immunoglobulins are called α, δ, ε, γ, and μ, respectively. The light chain of an antibody may be assigned to one of two types, called kappa (κ) and lambda (λ), based on the amino acid sequence of its constant domain.

[0075] The terms “constant region derived from human origin” or “human constant region” as used in the current application denotes a constant heavy chain region of a human antibody of the subclass IgG1, IgG2, IgG3, or IgG4 and / or a constant light chain kappa or lambda region. Such constant regions are well known in the state of the art and e.g. described by Kabat, E. A., et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991) (see also e.g. Johnson, G., and Wu, T. T., Nucleic Acids Res. 28 (2000) 214-218; Kabat, E. A., et al., Proc. Natl. Acad. Sci. USA 72 (1975) 2785-2788). Unless otherwise specified herein, numbering of amino acid residues in the constant region is according to the EU numbering system, also called the EU index of Kabat, as described in Kabat, E. A. et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991), NIH Publication 91-3242.

[0076] “Effector functions” refer to those biological activities attributable to the Fc region of an antibody, which vary with the antibody isotype. Examples of antibody effector functions include: C1q binding and complement dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; down regulation of cell surface receptors (e.g., B cell receptor); and B cell activation.

[0077] An “effective amount” of an agent, e.g., a pharmaceutical composition, refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result.

[0078] The term “Fc region” herein is used to define a C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region. The term includes native sequence Fc regions and variant Fc regions. In one aspect, a human IgG heavy chain Fc region extends from Cys226, or from Pro230, to the carboxyl-terminus of the heavy chain. However, antibodies produced by host cells may undergo post-translational cleavage of one or more, particularly one or two, amino acids from the C-terminus of the heavy chain. Therefore, an antibody produced by a host cell by expression of a specific nucleic acid molecule encoding a full-length heavy chain may include the full-length heavy chain, or it may include a cleaved variant of the full-length heavy chain. This may be the case where the final two C-terminal amino acids of the heavy chain are glycine (G446) and lysine (K447, EU numbering system). Therefore, the C-terminal lysine (Lys447), or the C-terminal glycine (Gly446) and lysine (Lys447), of the Fc region may or may not be present. Amino acid sequences of heavy chains including an Fc region are denoted herein with the C-terminal glycine-lysine dipeptide if not indicated otherwise. In one aspect, a heavy chain including an Fc region as specified herein, comprised in an antibody according to the invention, lacks the C-terminal glycine-lysine dipeptide (G446 and K447, EU numbering system). In one aspect, a heavy chain including an Fc region as specified herein, comprised in an antibody according to the invention, lacks the C-terminal lysine residue (K447, numbering according to EU index). Unless otherwise specified herein, numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also called the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991.

[0079] “Framework” or “FR” refers to variable domain residues other than complementary determining regions (CDRs). The FR of a variable domain generally consists of four FR domains: FR1, FR2, FR3, and FR4. Accordingly, the CDR and FR sequences generally appear in the following sequence in VH (or VL): FR1-CDR-H1 (CDR-L1)-FR2-CDR-H2 (CDR-L2)-FR3-CDR-H3 (CDR-L3)-FR4.

[0080] The terms “full length antibody”, “intact antibody”, and “whole antibody” are used herein interchangeably to refer to an antibody having a structure substantially similar to a native antibody structure or having heavy chains that contain an Fc region as defined herein.

[0081] The terms “host cell”, “host cell line”, and “host cell culture” are used interchangeably and refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include “transformants” and “transformed cells”, which include the primary transformed cell and progeny derived therefrom without regard to the number of passages. Progeny may not be completely identical in nucleic acid content to a parent cell, but may contain mutations. Mutant progeny that have the same function or biological activity as screened or selected for in the originally transformed cell are included herein.

[0082] A “human antibody” is one which possesses an amino acid sequence which corresponds to that of an antibody produced by a human or a human cell or derived from a non-human source that utilizes human antibody repertoires or other human antibody-encoding sequences. This definition of a human antibody specifically excludes a humanized antibody comprising non-human antigen-binding residues.

[0083] A “human consensus framework” is a framework which represents the most commonly occurring amino acid residues in a selection of human immunoglobulin VL or VH framework sequences. Generally, the selection of human immunoglobulin VL or VH sequences is from a subgroup of variable domain sequences. Generally, the subgroup of sequences is a subgroup as in Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition, NIH Publication 91-3242, Bethesda MD (1991), vols. 1-3. In one aspect, for the VL, the subgroup is subgroup kappa I as in Kabat et al., supra. In one aspect, for the VH, the subgroup is subgroup III as in Kabat et al., supra.

[0084] A “humanized” antibody refers to a chimeric antibody comprising amino acid residues from non-human CDRs and amino acid residues from human FRs. In certain aspects, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDRs correspond to those of a non-human antibody, and all or substantially all of the FRs correspond to those of a human antibody. A humanized antibody optionally may comprise at least a portion of an antibody constant region derived from a human antibody. A “humanized form” of an antibody, e.g., a non-human antibody, refers to an antibody that has undergone humanization.

[0085] The term “hypervariable region” or “HVR” as used herein refers to each of the regions of an antibody variable domain which are hypervariable in sequence and which determine antigen binding specificity, for example “complementarity determining regions” (“CDRs”).

[0086] Generally, antibodies comprise six CDRs: three in the VH (CDR-H1, CDR-H2, CDR-H3), and three in the VL (CDR-L1, CDR-L2, CDR-L3). Exemplary CDRs herein include:

[0087] (a) hypervariable loops occurring at amino acid residues 26-32 (L1), 50-52 (L2), 91-96 (L3), 26-32 (H1), 53-55 (H2), and 96-101 (H3) (Chothia and Lesk, J. Mol. Biol. 196:901-917 (1987));

[0088] (b) CDRs occurring at amino acid residues 24-34 (L1), 50-56 (L2), 89-97 (L3), 31-35b (H1), 50-65 (H2), and 95-102 (H3) (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (1991)); and

[0089] (c) antigen contacts occurring at amino acid residues 27c-36 (L1), 46-55 (L2), 89-96 (L3), 30-35b (H1), 47-58 (H2), and 93-101 (H3) (MacCallum et al. J. Mol. Biol. 262:732-745 (1996)).

[0090] Unless otherwise indicated, the CDRs are determined according to Kabat et al., supra. One of skill in the art will understand that the CDR designations can also be determined according to Chothia, supra, McCallum, supra, or any other scientifically accepted nomenclature system.

[0091] An “immunoconjugate” is an antibody conjugated to one or more heterologous molecule(s), including but not limited to a cytotoxic agent.

[0092] An “individual” or “subject” is a mammal. Mammals include, but are not limited to, domesticated animals (e.g., cows, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In certain aspects, the individual or subject is a human.

[0093] An “isolated” antibody is one which has been separated from a component of its natural environment. In some aspects, an antibody is purified to greater than 95% or 99% purity as determined by, for example, electrophoretic (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatographic (e.g., ion exchange or reverse phase HPLC) methods. For a review of methods for assessment of antibody purity, see, e.g., Flatman et al., J. Chromatogr. B 848:79-87 (2007). Any of the antibodies described herein may be isolated antibodies.

[0094] The term “nucleic acid molecule” or “polynucleotide” includes any compound and / or substance that comprises a polymer of nucleotides. Each nucleotide is composed of a base, specifically a purine- or pyrimidine base (i.e. cytosine (C), guanine (G), adenine (A), thymine (T) or uracil (U)), a sugar (i.e. deoxyribose or ribose), and a phosphate group. Often, the nucleic acid molecule is described by the sequence of bases, whereby said bases represent the primary structure (linear structure) of a nucleic acid molecule. The sequence of bases is typically represented from 5′ to 3′. Herein, the term nucleic acid molecule encompasses deoxyribonucleic acid (DNA) including e.g., complementary DNA (cDNA) and genomic DNA, ribonucleic acid (RNA), in particular messenger RNA (mRNA), synthetic forms of DNA or RNA, and mixed polymers comprising two or more of these molecules. The nucleic acid molecule may be linear or circular. In addition, the term nucleic acid molecule includes both, sense and antisense strands, as well as single stranded and double stranded forms. Moreover, the herein described nucleic acid molecule can contain naturally occurring or non-naturally occurring nucleotides. Examples of non-naturally occurring nucleotides include modified nucleotide bases with derivatized sugars or phosphate backbone linkages or chemically modified residues. Nucleic acid molecules also encompass DNA and RNA molecules which are suitable as a vector for direct expression of an antibody of the invention in vitro and / or in vivo, e.g., in a host or patient. Such DNA (e.g., cDNA) or RNA (e.g., mRNA) vectors, can be unmodified or modified. For example, mRNA can be chemically modified to enhance the stability of the RNA vector and / or expression of the encoded molecule so that mRNA can be injected into a subject to generate the antibody in vivo (see e.g., Stadler et al, Nature Medicine 2017, published online 12 Jun. 2017, doi: 10.1038 / nm.4356 or EP 2 101 823 B1).

[0095] An “isolated” nucleic acid refers to a nucleic acid molecule that has been separated from a component of its natural environment. An isolated nucleic acid includes a nucleic acid molecule contained in cells that ordinarily contain the nucleic acid molecule, but the nucleic acid molecule is present extrachromosomally or at a chromosomal location that is different from its natural chromosomal location.

[0096] “Isolated nucleic acid encoding an anti-S-HBs antibody” refers to one or more nucleic acid molecules encoding anti-S-HBs antibody heavy and light chains (or fragments thereof), including such nucleic acid molecule(s) in a single vector or separate vectors, and such nucleic acid molecule(s) present at one or more locations in a host cell.

[0097] The term “monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical and / or bind the same epitope, except for possible variant antibodies, e.g., containing naturally occurring mutations or arising during production of a monoclonal antibody preparation, such variants generally being present in minor amounts. In contrast to polyclonal antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen. Thus, the modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies in accordance with the present invention may be made by a variety of techniques, including but not limited to the hybridoma method, recombinant DNA methods, phage-display methods, and methods utilizing transgenic animals containing all or part of the human immunoglobulin loci, such methods and other exemplary methods for making monoclonal antibodies being described herein.

[0098] A “naked antibody” refers to an antibody that is not conjugated to a heterologous moiety (e.g., a cytotoxic moiety) or radiolabel. The naked antibody may be present in a pharmaceutical composition.

[0099] “Native antibodies” refer to naturally occurring immunoglobulin molecules with varying structures. For example, native IgG antibodies are heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light chains and two identical heavy chains that are disulfide-bonded. From N- to C-terminus, each heavy chain has a variable domain (VH), also called a variable heavy domain or a heavy chain variable region, followed by three constant heavy domains (CH1, CH2, and CH3). Similarly, from N- to C-terminus, each light chain has a variable domain (VL), also called a variable light domain or a light chain variable region, followed by a constant light (CL) domain.

[0100] The term “package insert” is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, combination therapy, contraindications and / or warnings concerning the use of such therapeutic products.

[0101] “Percent (%) amino acid sequence identity” with respect to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity for the purposes of the alignment. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, Clustal W, Megalign (DNASTAR) software or the FASTA program package. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. Alternatively, the percent identity values can be generated using the sequence comparison computer program ALIGN-2. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc., and the source code has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087 and is described in WO 2001 / 007611.

[0102] Unless otherwise indicated, for purposes herein, percent amino acid sequence identity values are generated using the ggsearch program of the FASTA package version 36.3.8c or later with a BLOSUM50 comparison matrix. The FASTA program package was authored by W. R. Pearson and D. J. Lipman (1988), “Improved Tools for Biological Sequence Analysis”, PNAS 85:2444-2448; W. R. Pearson (1996) “Effective protein sequence comparison” Meth. Enzymol. 266:227-258; and Pearson et. al. (1997) Genomics 46:24-36 and is publicly available from www.fasta.bioch.virginia.edu / fasta_www2 / fasta_down.shtml or www.ebi.ac.uk / Tools / sss / fasta. Alternatively, a public server accessible at fasta.bioch.virginia.edu / fasta_www2 / index.cgi can be used to compare the sequences, using the ggsearch (global protein:protein) program and default options (BLOSUM50; open: −10; ext: −2; Ktup=2) to ensure a global, rather than local, alignment is performed. Percent amino acid identity is given in the output alignment header.

[0103] The term “pharmaceutical composition” or “pharmaceutical formulation” refers to a preparation which is in such form as to permit the biological activity of an active ingredient contained therein to be effective, and which contains no additional components which are unacceptably toxic to a subject to which the pharmaceutical composition would be administered.

[0104] A “pharmaceutically acceptable carrier” refers to an ingredient in a pharmaceutical composition or formulation, other than an active ingredient, which is nontoxic to a subject. A pharmaceutically acceptable carrier includes, but is not limited to, a buffer, excipient, stabilizer, or preservative.

[0105] The terms “S-HBs” or “S-HBsAg” as used interchangeably herein (referring to small hepatitis B surface antigen) encompass “full-length”, unprocessed S-HBs as well as any form of S-HBs that results from processing in the cell. The term also encompasses naturally occurring variants of S-HBs, e.g., splice variants or allelic variants. The amino acid sequence of an exemplary S-HBs is shown in SEQ ID NO: 253. Antibodies of the present invention may bind at least to S-HBs of SEQ ID NO: 253 e.g., with affinity or binding activity as discussed herein. Optionally, antibodies of the present invention may additionally or alternatively bind to one or more proteins comprising or consisting of consensus sequences selected from SEQ ID NO: 254-262, e.g., to a protein of SEQ ID NO: 257.

[0106] As used herein, “treatment” (and grammatical variations thereof such as “treat” or “treating”) refers to clinical intervention in an attempt to alter the natural course of a disease in the individual being treated, and can be performed either for prophylaxis or during the course of clinical pathology. Desirable effects of treatment include, but are not limited to, preventing occurrence or recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, decreasing the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis. In some aspects, antibodies of the invention are used to delay development of a disease or to slow the progression of a disease.

[0107] Hepatitis B may be either chronic or acute, and the antibodies of the present invention may be used to treat either condition. Acute hepatitis generally refers to an infection within the first six months after exposure to the virus. Chronic hepatitis generally refers to an infection which is ongoing after six months. In some embodiments, treatment of hepatitis may refer to a reduction of HBV virus, an elimination of HBV virus, the reduction of symptoms due to HBV infection, the prevention or reduction of the progression of hepatitis to liver disease such as cirrhosis, liver fibrosis, liver failure and / or liver cancer, a reduction in detectable HBV surface antigen (HBsAg) in serum, and / or HBV surface antigen (HBsAg) seroconversion, i.e., an absence of detectable HBsAg in serum. Detection of HBsAg may be by any of the screening assays well established in the art, such as Elecsys HBsAg II (Roche Diagnostics), Auszyme Monoclonal [overnight incubation] version B, IMx HBsAg (Abbott) or Monolisa S-HBsAg ULTRA (Bio-Rad, France) ELISA.

[0108] The term “variable region” or “variable domain” refers to the domain of an antibody heavy or light chain that is involved in binding the antibody to antigen. The variable domains of the heavy chain and light chain (VH and VL, respectively) of a native antibody generally have similar structures, with each domain comprising four conserved framework regions (FRs) and three complementary determining regions (CDRs). (See, e.g., Kindt et al. Kuby Immunology, 6th ed., W.H. Freeman and Co., page 91 (2007).) A single VH or VL domain may be sufficient to confer antigen-binding specificity. Furthermore, antibodies that bind a particular antigen may be isolated using a VH or VL domain from an antibody that binds the antigen to screen a library of complementary VL or VH domains, respectively. See, e.g., Portolano et al., J. Immunol. 150:880-887 (1993); Clarkson et al., Nature 352:624-628 (1991).

[0109] The term “vector”, as used herein, refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked. The term includes the vector as a self-replicating nucleic acid structure as well as the vector incorporated into the genome of a host cell into which it has been introduced. Certain vectors are capable of directing the expression of nucleic acids to which they are operatively linked. Such vectors are referred to herein as “expression vectors”.II. Compositions and Methods

[0110] In one aspect, the invention is based, in part, on the identification by the inventors of antibodies from individuals that can naturally clear chronic hepatitis B virus (HBV) infection and acquire protection from re-infection (“controllers”) and from individuals vaccinated against HBV (“vaccinees”). The inventors have determined that such antibodies may have advantageous properties, such as high affinity or binding activity to the S-HBs antigen, potent neutralizing activity and / or cross-genotypic reactivity. In certain aspects, antibodies that bind to S-HBs are provided. Antibodies of the invention are useful, e.g., for the diagnosis or treatment of hepatitis B.A. Exemplary Anti-S-HBs Antibodies

[0111] In one aspect, the invention provides antibodies that bind to S-HBs. In one aspect, provided are isolated antibodies that bind to S-HBs. In one aspect, the invention provides antibodies that specifically bind to S-HBs. In certain aspects, an anti-S-HBs antibody has one or more of the following properties:

[0112] binds to S-HBs (e.g., of SEQ ID NO: 253); and / or

[0113] binds to one or more S-HBs proteins having SEQ ID NO: 254 to 262, (e.g., at least SEQ ID NO: 257), optionally to two or more of said proteins (e.g., at least SEQ ID NO: 257 and 258), optionally to three, four, five, six, seven, eight or more of said proteins, optionally to all of said proteins; and / or

[0114] binds to S-HBs of subtype adw and / or ayw, e.g., of genotype D, preferably both adw and ayw subtypes;

[0115] avoids significant cross-reactivity against self-antigens such as galectin-3 / -8 and E3 ubiquitin-protein ligase UBR2; and / or

[0116] has a neutralizing activity (e.g., as measured in vitro or in vivo) against HBV genotype D;

[0117] has a neutralizing activity (e.g., as measured in vitro or in vivo) against each of HBV genotypes A to D; and / or

[0118] can suppress virus viremia in vivo.

[0119] For example, in some embodiments, the antibody may have a neutralizing IC50 value against HBV genome D of ≤1 ng / ml, measured in vitro.

[0120] In other exemplary embodiments, an antibody may have the following properties:

[0121] is cross reactive with each of the proteins of SEQ ID NO: 254 to 262; and

[0122] has neutralizing activity (e.g., as measured in vitro or in vivo) against HBV genotype D.

[0123] Said exemplary antibodies may preferably also avoid significant cross-reactivity against self-antigens such as galectin-3 / -8 and E3 ubiquitin-protein ligase UBR2.

[0124] The antibodies may bind to S-HBs and / or to one or more S-HBs proteins having SEQ ID NO: 254 to 262 with a KD as discussed herein, e.g., ≤1 μM, ≤100 nM, ≤10 nM, ≤1 nM, ≤0.1 nM, ≤0.01 nM, or ≤0.001 nM. In some embodiments, the antibody may bind to S-HBs and / or one or more S-HBs proteins having SEQ ID NO: 254 to 262 with a KD value which is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than the KD of a reference antibody against the same antigen, or which is less than or equal to the KD of said reference antibody, wherein the reference antibody is selected from the group consisting of Bc1.187, Bv4.115, Bc8.159, Bv6.172, Bc1.229, Bc8.111, Bc1.128, Bc3.106, Bc1.180, Bv4.104, Bc8.104, Bc4.204, Bc1.263 and Bv4.105.

[0125] Alternatively, the antibodies may show binding activity against S-HBs and / or to one or more S-HBs proteins having SEQ ID NO: 254 to 262 which is at least 25%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the binding activity of a reference antibody to the same antigen, wherein the reference antibody is selected from the group consisting of Bc1.187, Bv4.115, Bc8.159, Bv6.172, Bc1.229, Bc8.111, Bc1.128, Bc3.106, Bc1.180, Bv4.104, Bc8.104, Bc4.204, Bc1.263 and Bv4.105 (when assessed in the same assay, e.g., an ELISA assay or a flow cytometry assay). In some embodiments, it may be preferred that the activity is at least 50% of the activity of the reference antibody. Optionally the reference antibody may be Bc1.187, i.e., the antibody may show at least 25%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the binding activity of Bc1.187 to the reference antigen, when assessed in the same assay.

[0126] In other aspects, the antibodies may bind to S-HBs / or to one or more S-HBs proteins having SEQ ID NO: 254 to 262 with an EC50 that is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the EC50 of a reference antibody, wherein the EC50 is measured by ELISA or by flow cytometry, and wherein the reference antibody is selected from the group consisting of Bc1.187, Bv4.115, Bc8.159, Bv6.172, Bc1.229, Bc8.111, Bc1.128, Bc3.106, Bc1.180, Bv4.104, Bc8.104, Bc4.204, Bc1.263 and Bv4.105.

[0127] “Avoids significant cross reactivity with” means that the antibody does not show significant binding to the reference protein, e.g., has a KD greater than 1 μM, or has no detectable binding e.g., in an assay described herein.

[0128] In some embodiments antibodies according to the invention which are neutralizing against a HBV genotype, e.g., genotype D, may for instance have an IC50 value for viral infectivity in vitro of ≤50 ng / ml, or ≤10 ng / ml. It may be preferred that the antibody has an IC50 of ≤1 ng / ml, ≤500 pg / ml or in some embodiments ≤100 pg / ml, ≤50 pg / ml, or ≤10 pg / ml. In some embodiments, a neutralizing antibody may have an IC50 value of ≤1 pg / ml, optionally ≤0.1 pg / ml. Optionally the IC50 value may be greater than 0.01 μg / ml or 0.005 pg / ml. In another embodiment, an antibody which is neutralizing against a particular HBV genotype, e.g., genotype D, may have an IC50 value which is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the IC50 value of a reference antibody against the same genotype, wherein the reference antibody is selected from the group consisting of Bc1.187, Bv4.115, Bc8.159, Bv6.172, Bc1.229, Bc8.111, Bc1.128, Bc3.106, Bc1.180, Bv4.104, Bc8.104, Bc4.204, Bc1.263 and Bv4.105 (when assessed in the same assay).

[0129] In another embodiment, an antibody which is neutralizing against a particular HBV genotype may have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the in vivo neutralizing activity or viremia suppressing activity of a reference antibody to the same genotype, e.g., a reference antibody selected from the group consisting of Bc1.187, Bv4.115, Bc8.159, Bv6.172, Bc1.229, Bc8.111, Bc1.128, Bc3.106, Bc1.180, Bv4.104, Bc8.104, Bc4.204, Bc1.263 and Bv4.105 when assessed using the same assay (e.g., an assay as described herein).

[0130] In some embodiments, an antibody may be cross reactive with each of the proteins of SEQ ID NO: 254 to 262 (having binding activity to each e.g., as described above) and have an IC50 for in vitro neutralization of HBV-genotype D of ≤100 pg / ml. Optionally, the IC50 value may be ≤50 pg / ml or ≤10 pg / ml. In some embodiments, the IC50 value may be ≤1 pg / ml, optionally ≤0.1 pg / ml.

[0131] Various embodiments of particular antibodies according to the present invention are set out in sections A-N below.A

[0132] In one aspect, the invention provides an antibody comprising a VH domain comprising at least one, at least two, or all three VH CDR sequences selected from (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:1; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:3. In another aspect, the antibody comprises a VH domain comprising the following CDRs (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:1; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:2; and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; or a variant thereof in which one, two or three amino acids in one or more of CDR-H1, CDR-H2 or CDR-H3 are substituted with another amino acid.

[0133] In one aspect, the VH domain may further comprise one or more heavy chain framework sequences selected from (a) a heavy chain frame work region 1 (HC-FR1) of SEQ ID NO: 7 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, (b) a heavy chain frame work region 2 (HC-FR2) of SEQ ID NO: 8, or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto (c) a heavy chain frame work region 3 (HC-FR3) SEQ ID NO:9, or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto and (d) a heavy chain frame work region 4 (HC-FR4) of SEQ ID NO:10 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto. Optionally, the VH domain comprises each of the heavy chain framework sequences as defined in (a) to (d). Optionally the percentage sequence identity is 95%. Optionally the percentage sequence identity is 98%.

[0134] In another aspect, an anti-S-HBs antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 16. In one aspect, an anti-S-HBs antibody comprises a heavy chain variable domain (VH) sequence having at least 95%, sequence identity to the amino acid sequence of SEQ ID NO:16. In certain aspects, a VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-S-HBs antibody comprising that sequence retains the ability to bind to S-HBs. In certain aspects, a total of 1 to 10 amino acids have been substituted, inserted and / or deleted in SEQ ID NO: 16. In certain aspects, substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs). Optionally, the anti-S-HBs antibody comprises the VH sequence in SEQ ID NO: 16, including post-translational modifications of that sequence. In a particular aspect, the VH comprises one, two or three CDRs selected from: (a) CDR-H1, comprising the amino acid sequence of SEQ ID NO:1, (b) CDR-H2, comprising the amino acid sequence of SEQ ID NO:2, and (c) CDR-H3, comprising the amino acid sequence of SEQ ID NO: 3.

[0135] In another aspect, an anti-S-HBs antibody comprises one or more of the heavy chain CDR sequences of the VH of SEQ ID NO:16. In one aspect, an anti-S-HBs antibody comprises one or more (preferably all three) of the heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO:16 and a framework of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity to the framework amino acid sequence of the VH domain of SEQ ID NO:16. Optionally the sequence identity is 95% or 98%.

[0136] In another aspect, the invention provides an antibody comprising a VL domain comprising at least one, at least two, or all three VL CDR sequences selected from (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:4; (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO:6. In another aspect, the antibody comprises a VL domain comprising the following CDRs (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:4; (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO:5; and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; or a variant thereof in which one, two or three amino acids in one or more of CDR-L1, CDR-L2 or CDR-L3 are substituted with another amino acid.

[0137] In one aspect, the anti-S-HBs antibody VL domain may further comprise one or more light chain framework sequences selected from (a) a light chain frame work region 1 (LC-FR1) of SEQ ID NO: 11 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, (b) a light chain frame work region 2 (LC-FR2) of SEQ ID NO:12 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, (c) a light chain frame work region 3 (LC-FR3) of SEQ ID NO:13 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, and (d) a light chain frame work region 4 (LC-FR4) of SEQ ID NO:14 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto. Optionally, the VL domain comprises each of the light chain framework sequences as defined in (a) to (d). Optionally the percentage sequence identity is 95%. Optionally the percentage sequence identity is 98%.

[0138] In another aspect, an anti-S-HBs antibody is provided, wherein the antibody comprises a light chain variable domain (VL) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:15. In one aspect, an anti-S-HBs antibody comprises a light chain variable domain (VL) sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:15. In certain aspects, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-S-HBs antibody comprising that sequence retains the ability to bind to S-HBs. In certain aspects, a total of 1 to 10 amino acids have been substituted, inserted and / or deleted in SEQ ID NO:15. In certain aspects, the substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs). Optionally, the anti-S-HBs antibody comprises the VL sequence in SEQ ID NO:15, including post-translational modifications of that sequence. In a particular aspect, the VL comprises one, two or three CDRs selected from: (a) CDR-L1, comprising the amino acid sequence of SEQ ID NO:4, (b) CDR-L2, comprising the amino acid sequence of SEQ ID NO:5, and (c) CDR-L3, comprising the amino acid sequence of SEQ ID NO:6.

[0139] In another embodiment, an anti-S-HBs antibody comprises one or more of the CDR sequences of the VL of SEQ ID NO:15. In one aspect, an anti-S-HBs antibody comprises one or more (preferably all three) of the light chain CDR amino acid sequences of the VL domain of SEQ ID NO: 15 and a framework of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity to the framework amino acid sequence of the VL domain of SEQ ID NO:15. Optionally the sequence identity is 95% or 98%.

[0140] In another aspect, an anti-S-HBs antibody is provided, wherein the antibody comprises a VH sequence as in any of the aspects provided above, and a VL sequence as in any of the aspects provided above.

[0141] For instance, in one exemplary embodiment, the antibody comprises a VH domain comprising CDR-H3 of SEQ ID NO:3; and a VL domain comprising CDR-L3 of SEQ ID NO:6. Optionally the VH domain further comprises CDR-H2 of SEQ ID NO: 2.

[0142] In another exemplary embodiment, the antibody comprises:

[0143] i) a VH domain comprising the following CDRs (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:1; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:2; and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:3; or a variant thereof in which one, two or three amino acids in one or more of CDR-H1, CDR-H2 or CDR-H3 are substituted with another amino acid; and

[0144] ii) a VL domain comprising the following CDRs (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:4; (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO:5; and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO:6; or a variant thereof in which one, two or three amino acids in one or more of CDR-L1, CDR-L2 or CDR-L3 are substituted with another amino acid.

[0145] In another exemplary embodiment, the antibody comprises:

[0146] i) a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 16; and

[0147] ii) a light chain variable domain (VL) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 15.

[0148] In another exemplary embodiment, the anti-S-HBs antibody comprises (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:1; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:2; (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:3; (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:4; (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:5; and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:6, and a VH domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 16, and a VL domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:15. In one aspect, the VH domain has at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 16. In one aspect, the VL domain has at least 95% sequence identity to the amino acid sequence of SEQ ID NO:15. In one embodiment, the antibody specifically binds to S-HBs. In another embodiment, the antibody binds to S-HBs having a dissociation constant (KD) that is up to 10 fold reduced or up to 10 fold increased when compared to the dissociation constant (KD) of an antibody comprising a VH sequence of SEQ ID NO:16 and a VL sequence of SEQ ID NO:15.

[0149] In one aspect, the antibody comprises the VH and VL sequences in SEQ ID NO:16 and SEQ ID NO: 15, respectively, including post-translational modifications of those sequences.

[0150] In a further aspect, the antibody may comprise the full length light chain of SEQ ID NO: 17 and / or the full length heavy chain of SEQ ID NO: 18 or 263.

[0151] In a further aspect, the invention provides an antibody that binds to the same epitope as the anti-S-HBs antibody provided herein. For example, in certain aspects, an antibody is provided that binds to the same epitope as an anti-S-HBs antibody comprising a VH sequence of SEQ ID NO: 16 and a VL sequence of SEQ ID NO:15. In certain aspects, an antibody is provided that binds to one or more of the following residues of S-HBs of SEQ ID NO: 253: C137; and optionally C138, K141, G145, and / or C149. In some embodiments the antibody may further bind to one or more of I152, N146, C147, and / or T148; and optionally W156. The antibody may comprise any of the sequences as defined above.

[0152] In a further aspect, the invention provides an antibody that competes for binding to S-HBs with an anti-S-HBs antibody provided herein.

[0153] Antibodies as described in this section may, in some embodiments, have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the binding activity of a reference antibody Bc1.187 to S-HBs (e.g., of SEQ ID NO: 253), when assessed in the same assay, e.g., an ELISA assay or a flow cytometry assay. Additionally or alternatively, antibodies as described in this section may have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the binding activity of a reference antibody Bc1.187 to one or more of SEQ ID NO: 254-262 (e.g., to at least SEQ ID NO: 257), optionally each of the proteins of SEQ ID NO: 254 to 262, when assessed in the same assay, e.g., an ELISA assay or a flow cytometry assay.

[0154] Reference antibody Bc1.187 is an anti-S-HBs antibody comprising a VH sequence of SEQ ID NO: 16 and a VL sequence of SEQ ID NO:15. It has the full length heavy chain of SEQ ID NO: 18 or 263 and the full length light chain of SEQ ID NO: 17. SEQ ID NO: 263 comprises the IgG1 constant region expressed by vector LT615368.1, as used in the examples.

[0155] In some embodiments, the antibody described in this section may bind to S-HBs (e.g., of SEQ ID NO: 253) with a KD value which is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the KD value of reference antibody Bc1.187 to the same antigen, when assessed in the same assay.

[0156] Additionally or alternatively, the antibody as described in this section may bind to one or more of SEQ ID NO: 254-262 (e.g., to at least SEQ ID NO: 257), optionally each of the proteins of SEQ ID NO: 254-262, with a KD value which is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the KD value of reference antibody Bc1.187 to the same antigen, when assessed in the same assay.

[0157] In some embodiments, the antibody as described in this section may bind to S-HBs (e.g., of SEQ ID NO: 253) with an EC50 that is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the EC50 of reference antibody Bc1.187, as measured by ELISA or by flow cytometry. Alternatively or additionally, the antibody may bind one or more of SEQ ID NO: 254-262 (e.g., to at least SEQ ID NO: 257), optionally each of the proteins of SEQ ID NO: 254 to 262 with an EC50 that is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the EC50 of reference antibody Bc1.187, as measured by ELISA or by flow cytometry.

[0158] In some embodiments antibodies as described in this section may have or retain in vitro neutralizing activity against HBV genotype A, B, C and / or D, optionally all of A, B, C and D. For example, antibodies as described in this section may have or retain in vitro neutralizing activity against HBV genotype D with an IC50 value of ≤1 pg / ml, optionally ≤0.1 pg / ml.

[0159] In another embodiment, the antibody may have an IC50 value for neutralization of HBV genotype A, B, C and / or D, optionally at least D, optionally all of A, B, C and D, which is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the IC50 value of reference antibody Bc1.187 against the same genotype, when assessed using the same assay (e.g., an in vitro neutralization assay as described herein).

[0160] In another embodiment, the antibody may have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the in vivo neutralizing activity of reference antibody Bc1.187 against HBV genotype A, B, C and / or D, optionally at least D, optionally all of A, B, C and D, when assessed using the same assay (e.g., an assay as described herein).

[0161] Optionally the antibody can suppress virus viremia in vivo, e.g., in an individual infected with HBV genotype A, B, C or D, optionally D. Optionally, the antibody may have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the in vivo viremia suppressing activity of reference antibody Bc1.187 against HBV genotype A, B, C and / or D, optionally at least D, optionally all of A, B, C and D, when assessed using the same assay (e.g., an assay as described herein).B

[0162] In one aspect, the invention provides an antibody comprising a VH domain comprising at least one, at least two, or all three VH CDR sequences selected from (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:19; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 20; and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:21. In another aspect, the antibody comprises a VH domain comprising the following CDRs (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:19; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:20; and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 21; or a variant thereof in which one, two or three amino acids in one or more of CDR-H1, CDR-H2 or CDR-H3 are substituted with another amino acid.

[0163] In one aspect, the VH domain may further comprise one or more heavy chain framework sequences selected from (a) a heavy chain frame work region 1 (HC-FR1) of SEQ ID NO: 25 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, (b) a heavy chain frame work region 2 (HC-FR2) of SEQ ID NO: 26, or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto (c) a heavy chain frame work region 3 (HC-FR3) SEQ ID NO:27, or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto and (d) a heavy chain frame work region 4 (HC-FR4) of SEQ ID NO:28 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto. Optionally, the VH domain comprises each of the heavy chain framework sequences as defined in (a) to (d). Optionally the percentage sequence identity is 95%. Optionally the percentage sequence identity is 98%.

[0164] In another aspect, an anti-S-HBs antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:34. In one aspect, an anti-S-HBs antibody comprises a heavy chain variable domain (VH) sequence having at least 95%, sequence identity to the amino acid sequence of SEQ ID NO:34. In certain aspects, a VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-S-HBs antibody comprising that sequence retains the ability to bind to S-HBs. In certain aspects, a total of 1 to 10 amino acids have been substituted, inserted and / or deleted in SEQ ID NO: 34. In certain aspects, substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs). Optionally, the anti-S-HBs antibody comprises the VH sequence in SEQ ID NO: 34, including post-translational modifications of that sequence. In a particular aspect, the VH comprises one, two or three CDRs selected from: (a) CDR-H1, comprising the amino acid sequence of SEQ ID NO 19, (b) CDR-H2, comprising the amino acid sequence of SEQ ID NO:20, and (c) CDR-H3, comprising the amino acid sequence of SEQ ID NO: 21.

[0165] In another aspect, an anti-S-HBs antibody comprises one or more of the heavy chain CDR sequences of the VH of SEQ ID NO:34. In one aspect, an anti-S-HBs antibody comprises one or more (preferably all three) of the heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO:34 and a framework of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity to the framework amino acid sequence of the VH domain of SEQ ID NO:34. Optionally the sequence identity is 95% or 98%.

[0166] In another aspect, the invention provides an antibody comprising a VL domain comprising at least one, at least two, or all three VL CDR sequences selected from (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:22; (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 23; and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO:24. In another aspect, the antibody comprises a VL domain comprising the following CDRs (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:22; (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO:23; and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 24; or a variant thereof in which one, two or three amino acids in one or more of CDR-L1, CDR-L2 or CDR-L3 are substituted with another amino acid.

[0167] In one aspect, the anti-S-HBs antibody VL domain may further comprise one or more light chain framework sequences selected from (a) a light chain frame work region 1 (LC-FR1) of SEQ ID NO: 29 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, (b) a light chain frame work region 2 (LC-FR2) of SEQ ID NO:30 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, (c) a light chain frame work region 3 (LC-FR3) of SEQ ID NO:31 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, and (d) a light chain frame work region 4 (LC-FR4) of SEQ ID NO:32 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto. Optionally, the VL domain comprises each of the light chain framework sequences as defined in (a) to (d). Optionally the percentage sequence identity is 95%. Optionally the percentage sequence identity is 98%.

[0168] In another aspect, an anti-S-HBs antibody is provided, wherein the antibody comprises a light chain variable domain (VL) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:33. In one aspect, an anti-S-HBs antibody comprises a light chain variable domain (VL) sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:33. In certain aspects, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-S-HBs antibody comprising that sequence retains the ability to bind to S-HBs. In certain aspects, a total of 1 to 10 amino acids have been substituted, inserted and / or deleted in SEQ ID NO:33. In certain aspects, the substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs). Optionally, the anti-S-HBs antibody comprises the VL sequence in SEQ ID NO:33, including post-translational modifications of that sequence. In a particular aspect, the VL comprises one, two or three CDRs selected from: (a) CDR-L1, comprising the amino acid sequence of SEQ ID NO:22, (b) CDR-L2, comprising the amino acid sequence of SEQ ID NO:23, and (c) CDR-L3, comprising the amino acid sequence of SEQ ID NO:24.

[0169] In another embodiment, an anti-S-HBs antibody comprises one or more of the CDR sequences of the VL of SEQ ID NO:33. In one aspect, an anti-S-HBs antibody comprises one or more (preferably all three) of the light chain CDR amino acid sequences of the VL domain of SEQ ID NO: 33 and a framework of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity to the framework amino acid sequence of the VL domain of SEQ ID NO:33. Optionally the sequence identity is 95% or 98%.

[0170] In another aspect, an anti-S-HBs antibody is provided, wherein the antibody comprises a VH sequence as in any of the aspects provided above, and a VL sequence as in any of the aspects provided above.

[0171] For instance, in one exemplary embodiment, the antibody comprises a VH domain comprising CDR-H3 of SEQ ID NO:21; and a VL domain comprising CDR-L3 of SEQ ID NO: 24. Optionally the VH domain further comprises CDR-H2 of SEQ ID NO: 20.

[0172] In another exemplary embodiment, the antibody comprises:

[0173] i) a VH domain comprising the following CDRs (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:19; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:20; and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:21; or a variant thereof in which one, two or three amino acids in one or more of CDR-H1, CDR-H2 or CDR-H3 are substituted with another amino acid; and

[0174] ii) a VL domain comprising the following CDRs (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:22; (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO:23; and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO:24; or a variant thereof in which one, two or three amino acids in one or more of CDR-L1, CDR-L2 or CDR-L3 are substituted with another amino acid.

[0175] In another exemplary embodiment, the antibody comprises:

[0176] i) a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 34; and

[0177] ii) a light chain variable domain (VL) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 33.

[0178] In another exemplary embodiment, the anti-S-HBs antibody comprises (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:19; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:20; (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:21; (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:22; (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:23; and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:24, and a VH domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:34, and a VL domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:33. In one aspect, the VH domain has at least 95% sequence identity to the amino acid sequence of SEQ ID NO:34. In one aspect, the VL domain has at least 95% sequence identity to the amino acid sequence of SEQ ID NO:33. In one embodiment, the antibody specifically binds to S-HBs. In another embodiment, the antibody binds to S-HBs having a dissociation constant (KD) that is up to 10 fold reduced or up to 10 fold increased when compared to the dissociation constant (KD) of an antibody comprising a VH sequence of SEQ ID NO:34 and a VL sequence of SEQ ID NO:33.

[0179] In one aspect, the antibody comprises the VH and VL sequences in SEQ ID NO:34 and SEQ ID NO: 33, respectively, including post-translational modifications of those sequences.

[0180] In a further aspect, the antibody may comprise the full length light chain of SEQ ID NO: 35 and / or the full length heavy chain of SEQ ID NO: 36 or 264.

[0181] In a further aspect, the invention provides an antibody that binds to the same epitope as the anti-S-HBs antibody provided herein. For example, in certain aspects, an antibody is provided that binds to the same epitope as an anti-S-HBs antibody comprising a VH sequence of SEQ ID NO: 34 and a VL sequence of SEQ ID NO:33. In certain aspects, an antibody is provided that binds one or more of to the following residues of S-HBs of SEQ ID NO: 253: C138, C139 and / or C149, and optionally R169. Optionally the antibody may further bind to one or more of L109, R122, C147, T148, I152, W156, F161, and / or W165. The antibody may comprise any of the sequences as defined above.

[0182] In a further aspect, the invention provides an antibody that competes for binding to S-HBs with an anti-S-HBs antibody provided herein.

[0183] Antibodies as described in this section may, in some embodiments, have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the binding activity of a reference antibody Bc1.180 to S-HBs (e.g., of SEQ ID NO: 253), when assessed in the same assay, e.g., an ELISA assay or a flow cytometry assay.

[0184] Additionally or alternatively, antibodies as described in this section may have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the binding activity of a reference antibody Bc1.180 to one or more of SEQ ID NO: 254-262 (e.g., to at least SEQ ID NO: 257), optionally, each of the proteins of SEQ ID NO: 254 to 262, when assessed in the same assay, e.g., an ELISA assay or a flow cytometry assay.

[0185] Reference antibody Bc1.180 has a VH sequence of SEQ ID NO:34 and a VL sequence of SEQ ID NO:33. It has a full length heavy chain of SEQ ID NO: 36 or 264 and a full length light chain of SEQ ID NO: 35. SEQ ID NO: 264 comprises the IgG1 constant region expressed by vector LT615368.1, as used in the examples.

[0186] In some embodiments, the antibody as described in this section may bind to S-HBs (e.g., of SEQ ID NO: 253) with a KD value which is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the KD value of reference antibody Bc1.180 to the same antigen, when assessed in the same assay.

[0187] Additionally or alternatively, the antibody as described in this section may bind to one or more of SEQ ID NO: 254-262 (e.g., to at least SEQ ID NO: 257), optionally each of the proteins of SEQ ID NO: 254-262, with a KD value which is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the KD value of reference antibody Bc1.180 to the same antigen, when assessed in the same assay.

[0188] In some embodiments, the antibody as described in this section may bind to S-HBs (e.g., of SEQ ID NO: 253) with an EC50 that is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the EC50 of reference antibody Bc1.180, as measured by ELISA or by flow cytometry. Alternatively or additionally, the antibody may bind one or more of SEQ ID NO: 254-262 (e.g., to at least SEQ ID NO: 257), optionally each of the proteins of SEQ ID NO: 254 to 262 with an EC50 that is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the EC50 of reference antibody Bc1.180, as measured by ELISA or by flow cytometry. In some embodiments antibodies as described in this section may have or retain in vitro neutralizing activity against HBV genotype A, B, C and / or D, optionally all of A, B, C and D. For example, antibodies as described in this section may have or retain in vitro neutralizing activity against HBV genotype D, e.g., with an IC50 value of ≤1 pg / ml, optionally ≤0.1 pg / ml.

[0189] In another embodiment, the antibody may have an IC50 value for neutralization of HBV genotype A, B, C and / or D, optionally at least D, optionally all of A, B, C and D, which is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the IC50 value of reference antibody Bc1.180 against the same genotype, when assessed using the same assay (e.g., an assay as described herein).

[0190] In another embodiment, the antibody may have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the in vivo neutralizing activity of reference antibody Bc1.180 against HBV genotype A, B, C and / or D, optionally at least D, optionally all of A, B, C and D, when assessed using the same assay (e.g., an assay as described herein).

[0191] Optionally the antibody can suppress virus viremia in vivo e.g., in an individual infected with HBV genotype A, B, C or D, optionally D. Optionally, the antibody may have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the in vivo viremia suppressing activity of reference antibody Bc1.180 against HBV genotype A, B, C and / or D, optionally at least D, optionally all of A, B, C and D, when assessed using the same assay (e.g., an assay as described herein).C.

[0192] In one aspect, the invention provides an antibody comprising a VH domain comprising at least one, at least two, or all three VH CDR sequences selected from (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:37; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 38; and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:39. In another aspect, the antibody comprises a VH domain comprising the following CDRs (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:37; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:38; and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 39; or a variant thereof in which one, two or three amino acids in one or more of CDR-H1, CDR-H2 or CDR-H3 are substituted with another amino acid.

[0193] In one aspect, the VH domain may further comprise one or more heavy chain framework sequences selected from (a) a heavy chain frame work region 1 (HC-FR1) of SEQ ID NO: 43 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, (b) a heavy chain frame work region 2 (HC-FR2) of SEQ ID NO: 44, or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto (c) a heavy chain frame work region 3 (HC-FR3) SEQ ID NO:45, or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto and (d) a heavy chain frame work region 4 (HC-FR4) of SEQ ID NO:46 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto. Optionally, the VH domain comprises each of the heavy chain framework sequences as defined in (a) to (d). Optionally the percentage sequence identity is 95%. Optionally the percentage sequence identity is 98%.

[0194] In another aspect, an anti-S-HBs antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:52. In one aspect, an anti-S-HBs antibody comprises a heavy chain variable domain (VH) sequence having at least 95%, sequence identity to the amino acid sequence of SEQ ID NO:52. In certain aspects, a VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-S-HBs antibody comprising that sequence retains the ability to bind to S-HBs. In certain aspects, a total of 1 to 10 amino acids have been substituted, inserted and / or deleted in SEQ ID NO: 52. In certain aspects, substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs). Optionally, the anti-S-HBs antibody comprises the VH sequence in SEQ ID NO: 52, including post-translational modifications of that sequence. In a particular aspect, the VH comprises one, two or three CDRs selected from: (a) CDR-H1, comprising the amino acid sequence of SEQ ID NO 37, (b) CDR-H2, comprising the amino acid sequence of SEQ ID NO:38, and (c) CDR-H3, comprising the amino acid sequence of SEQ ID NO: 39.

[0195] In another aspect, an anti-S-HBs antibody comprises one or more of the heavy chain CDR sequences of the VH of SEQ ID NO:52. In one aspect, an anti-S-HBs antibody comprises one or more (preferably all three) of the heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO:52 and a framework of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity to the framework amino acid sequence of the VH domain of SEQ ID NO:52. Optionally the sequence identity is 95% or 98%.

[0196] In another aspect, the invention provides an antibody comprising a VL domain comprising at least one, at least two, or all three VL CDR sequences selected from (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:40; (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 41; and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO:42. In another aspect, the antibody comprises a VL domain comprising the following CDRs (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:40; (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO:41; and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 42; or a variant thereof in which one, two or three amino acids in one or more of CDR-L1, CDR-L2 or CDR-L3 are substituted with another amino acid.

[0197] In one aspect, the anti-S-HBs antibody VL domain may further comprise one or more light chain framework sequences selected from (a) a light chain frame work region 1 (LC-FR1) of SEQ ID NO: 47 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, (b) a light chain frame work region 2 (LC-FR2) of SEQ ID NO:48 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, (c) a light chain frame work region 3 (LC-FR3) of SEQ ID NO:49 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, and (d) a light chain frame work region 4 (LC-FR4) of SEQ ID NO:50 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto. Optionally, the VL domain comprises each of the light chain framework sequences as defined in (a) to (d). Optionally the percentage sequence identity is 95%. Optionally the percentage sequence identity is 98%.

[0198] In another aspect, an anti-S-HBs antibody is provided, wherein the antibody comprises a light chain variable domain (VL) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:51. In one aspect, an anti-S-HBs antibody comprises a light chain variable domain (VL) sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:51. In certain aspects, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-S-HBs antibody comprising that sequence retains the ability to bind to S-HBs. In certain aspects, a total of 1 to 10 amino acids have been substituted, inserted and / or deleted in SEQ ID NO:51. In certain aspects, the substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs). Optionally, the anti-S-HBs antibody comprises the VL sequence in SEQ ID NO:51, including post-translational modifications of that sequence. In a particular aspect, the VL comprises one, two or three CDRs selected from: (a) CDR-L1, comprising the amino acid sequence of SEQ ID NO:40, (b) CDR-L2, comprising the amino acid sequence of SEQ ID NO:41, and (c) CDR-L3, comprising the amino acid sequence of SEQ ID NO:42.

[0199] In another embodiment, an anti-S-HBs antibody comprises one or more of the CDR sequences of the VL of SEQ ID NO:51. In one aspect, an anti-S-HBs antibody comprises one or more (preferably all three) of the light chain CDR amino acid sequences of the VL domain of SEQ ID NO: 51 and a framework of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity to the framework amino acid sequence of the VL domain of SEQ ID NO:51. Optionally the sequence identity is 95% or 98%.

[0200] In another aspect, an anti-S-HBs antibody is provided, wherein the antibody comprises a VH sequence as in any of the aspects provided above, and a VL sequence as in any of the aspects provided above.

[0201] For instance, in one exemplary embodiment, the antibody comprises a VH domain comprising CDR-H3 of SEQ ID NO:39; and a VL domain comprising CDR-L3 of SEQ ID NO: 42. Optionally the VH domain further comprises CDR-H2 of SEQ ID NO: 38.

[0202] In another exemplary embodiment, the antibody comprises:

[0203] i) a VH domain comprising the following CDRs (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:37; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:38; and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:39; or a variant thereof in which one, two or three amino acids in one or more of CDR-H1, CDR-H2 or CDR-H3 are substituted with another amino acid; and

[0204] ii) a VL domain comprising the following CDRs (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:40; (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO:41; and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO:42; or a variant thereof in which one, two or three amino acids in one or more of CDR-L1, CDR-L2 or CDR-L3 are substituted with another amino acid.

[0205] In another exemplary embodiment, the antibody comprises:

[0206] i) a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 52; and

[0207] ii) a light chain variable domain (VL) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 51.

[0208] In another exemplary embodiment, the anti-S-HBs antibody comprises (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:37; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:38; (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:39; (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:40; (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:41; and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:42, and a VH domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:52, and a VL domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:51. In one aspect, the VH domain has at least 95% sequence identity to the amino acid sequence of SEQ ID NO:52. In one aspect, the VL domain has at least 95% sequence identity to the amino acid sequence of SEQ ID NO:51. In one embodiment, the antibody specifically binds to S-HBs. In another embodiment, the antibody binds to S-HBs having a dissociation constant (KD) that is up to 10 fold reduced or up to 10 fold increased when compared to the dissociation constant (KD) of an antibody comprising a VH sequence of SEQ ID NO:52 and a VL sequence of SEQ ID NO:51.

[0209] In one aspect, the antibody comprises the VH and VL sequences in SEQ ID NO:52 and SEQ ID NO: 51, respectively, including post-translational modifications of those sequences.

[0210] In a further aspect, the antibody may comprise the full length light chain of SEQ ID NO: 53 and / or the full length heavy chain of SEQ ID NO: 54 or 265.

[0211] In a further aspect, the invention provides an antibody that binds to the same epitope as the anti-S-HBs antibody provided herein. For example, in certain aspects, an antibody is provided that binds to the same epitope as an anti-S-HBs antibody comprising a VH sequence of SEQ ID NO: 52 and a VL sequence of SEQ ID NO:51. In certain aspects, an antibody is provided that binds to one or more of the following residues of S-HBs of SEQ ID NO: 253: L109, C138, I152, W156, and / or R169. Optionally the antibody further binds to P111 and / or F161. The antibody may comprise any of the sequences as defined above.

[0212] In a further aspect, the invention provides an antibody that competes for binding to S-HBs with an anti-S-HBs antibody provided herein.

[0213] Antibodies as described in this section may, in some embodiments, have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the binding activity of a reference antibody Bc3.106 to S-HBs (e.g., of SEQ ID NO:253), when assessed in the same assay, e.g., an ELISA assay or a flow cytometry assay.

[0214] Additionally or alternatively, antibodies as described in this section may have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the binding activity of a reference antibody Bc3.106 to one or more of the proteins SEQ ID NO: 254-262 (e.g., to at least SEQ ID NO: 257), optionally, to each of the proteins of SEQ ID NO: 254 to 262, when assessed in the same assay, e.g., an ELISA assay or a flow cytometry assay.

[0215] Reference antibody Bc3.106 has the VH sequence of SEQ ID NO:52 and a VL sequence of SEQ ID NO:51. It has the full length heavy chain of SEQ ID NO: 54 or 265 and the full length light chain of SEQ ID NO: 53. SEQ ID NO: 265 comprises the IgG1 constant region expressed by vector LT615368.1, as used in the examples.

[0216] In some embodiments, the antibody as described in this section may bind to S-HBs (e.g., of SEQ ID NO: 253) with a KD value which is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the KD value of reference antibody Bc3.106 to the same antigen, when assessed in the same assay.

[0217] Additionally or alternatively, the antibody may bind to one or more of SEQ ID NO: 254-262 (e.g., to at least SEQ ID NO: 257), optionally each of the proteins of SEQ ID NO: 254-262, with a KD value which is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the KD value of reference antibody Bc3.106 to the same antigen, when assessed in the same assay.

[0218] In some embodiments, the antibody as described in this section may bind to S-HBs (e.g., of SEQ ID NO: 253) with an EC50 that is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the EC50 of reference antibody Bc3.106, as measured by ELISA or by flow cytometry. Alternatively or additionally, the antibody may bind one or more of SEQ ID NO: 254-262 (e.g., to at least SEQ ID NO: 257), optionally each of the proteins of SEQ ID NO: 254 to 262 with an EC50 that is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the EC50 of reference antibody Bc3.106, as measured by ELISA or by flow cytometry.

[0219] In some embodiments antibodies as described in this section may have or retain in vitro neutralizing activity against HBV genotype A, B, C and / or D, optionally all of A, B, C and D. For example, antibodies as described in this section may have or retain in vitro neutralizing activity against HBV genotype D, e.g., with an IC50 value of ≤10 pg / ml, optionally ≤1 pg / ml.

[0220] In another embodiment, the antibody may have an IC50 value for neutralization of HBV genotype A, B, C and / or D, optionally at least D, optionally all of A, B, C and D, which is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the IC50 value of reference antibody Bc3.106 against the same genotype, when assessed using the same assay (e.g., an assay as described herein).

[0221] In another embodiment, the antibody may have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the in vivo neutralizing activity of reference antibody Bc3.106 against HBV genotype A, B, C and / or D, optionally at least D, optionally all of A, B, C and D, when assessed using the same assay (e.g., an assay as described herein).

[0222] Optionally the antibody can suppress virus viremia in vivo e.g., in an individual infected with HBV genotype A, B, C or D, optionally D. Optionally, the antibody may have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the in vivo viremia suppressing activity of reference antibody Bc3.106 against HBV genotype A, B, C and / or D, optionally at least D, optionally all of A, B, C and D, when assessed using the same assay (e.g., an assay as described herein).D.

[0223] In one aspect, the invention provides an antibody comprising a VH domain comprising at least one, at least two, or all three VH CDR sequences selected from (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:55; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 56; and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:57. In another aspect, the antibody comprises a VH domain comprising the following CDRs (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:55; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:56; and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 57; or a variant thereof in which one, two or three amino acids in one or more of CDR-H1, CDR-H2 or CDR-H3 are substituted with another amino acid.

[0224] In one aspect, the VH domain may further comprise one or more heavy chain framework sequences selected from (a) a heavy chain frame work region 1 (HC-FR1) of SEQ ID NO: 61 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, (b) a heavy chain frame work region 2 (HC-FR2) of SEQ ID NO: 62, or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto (c) a heavy chain frame work region 3 (HC-FR3) SEQ ID NO:63, or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto and (d) a heavy chain frame work region 4 (HC-FR4) of SEQ ID NO:64 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto. Optionally, the VH domain comprises each of the heavy chain framework sequences as defined in (a) to (d). Optionally the percentage sequence identity is 95%. Optionally the percentage sequence identity is 98%.

[0225] In another aspect, an anti-S-HBs antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:70. In one aspect, an anti-S-HBs antibody comprises a heavy chain variable domain (VH) sequence having at least 95%, sequence identity to the amino acid sequence of SEQ ID NO:70. In certain aspects, a VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-S-HBs antibody comprising that sequence retains the ability to bind to S-HBs. In certain aspects, a total of 1 to 10 amino acids have been substituted, inserted and / or deleted in SEQ ID NO: 70. In certain aspects, substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs). Optionally, the anti-S-HBs antibody comprises the VH sequence in SEQ ID NO: 70, including post-translational modifications of that sequence. In a particular aspect, the VH comprises one, two or three CDRs selected from: (a) CDR-H1, comprising the amino acid sequence of SEQ ID NO 55, (b) CDR-H2, comprising the amino acid sequence of SEQ ID NO:56, and (c) CDR-H3, comprising the amino acid sequence of SEQ ID NO: 57.

[0226] In another aspect, an anti-S-HBs antibody comprises one or more of the heavy chain CDR sequences of the VH of SEQ ID NO:70. In one aspect, an anti-S-HBs antibody comprises one or more (preferably all three) of the heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO:70 and a framework of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity to the framework amino acid sequence of the VH domain of SEQ ID NO:70. Optionally the sequence identity is 95% or 98%.

[0227] In another aspect, the invention provides an antibody comprising a VL domain comprising at least one, at least two, or all three VL CDR sequences selected from (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:58; (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 59; and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO:60. In another aspect, the antibody comprises a VL domain comprising the following CDRs (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:58; (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO:59; and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 60; or a variant thereof in which one, two or three amino acids in one or more of CDR-L1, CDR-L2 or CDR-L3 are substituted with another amino acid.

[0228] In one aspect, the anti-S-HBs antibody VL domain may further comprise one or more light chain framework sequences selected from (a) a light chain frame work region 1 (LC-FR1) of SEQ ID NO: 65 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, (b) a light chain frame work region 2 (LC-FR2) of SEQ ID NO:66 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, (c) a light chain frame work region 3 (LC-FR3) of SEQ ID NO:67 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, and (d) a light chain frame work region 4 (LC-FR4) of SEQ ID NO:68 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto. Optionally, the VL domain comprises each of the light chain framework sequences as defined in (a) to (d). Optionally the percentage sequence identity is 95%. Optionally the percentage sequence identity is 98%.

[0229] In another aspect, an anti-S-HBs antibody is provided, wherein the antibody comprises a light chain variable domain (VL) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:69. In one aspect, an anti-S-HBs antibody comprises a light chain variable domain (VL) sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:69. In certain aspects, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-S-HBs antibody comprising that sequence retains the ability to bind to S-HBs. In certain aspects, a total of 1 to 10 amino acids have been substituted, inserted and / or deleted in SEQ ID NO:69. In certain aspects, the substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs). Optionally, the anti-S-HBs antibody comprises the VL sequence in SEQ ID NO:69, including post-translational modifications of that sequence. In a particular aspect, the VL comprises one, two or three CDRs selected from: (a) CDR-L1, comprising the amino acid sequence of SEQ ID NO:58, (b) CDR-L2, comprising the amino acid sequence of SEQ ID NO:59, and (c) CDR-L3, comprising the amino acid sequence of SEQ ID NO:60.

[0230] In another embodiment, an anti-S-HBs antibody comprises one or more of the CDR sequences of the VL of SEQ ID NO:69. In one aspect, an anti-S-HBs antibody comprises one or more (preferably all three) of the light chain CDR amino acid sequences of the VL domain of SEQ ID NO: 69 and a framework of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity to the framework amino acid sequence of the VL domain of SEQ ID NO:69. Optionally the sequence identity is 95% or 98%.

[0231] In another aspect, an anti-S-HBs antibody is provided, wherein the antibody comprises a VH sequence as in any of the aspects provided above, and a VL sequence as in any of the aspects provided above.

[0232] For instance, in one exemplary embodiment, the antibody comprises a VH domain comprising CDR-H3 of SEQ ID NO:57; and a VL domain comprising CDR-L3 of SEQ ID NO: 60. Optionally the VH domain further comprises CDR-H2 of SEQ ID NO: 56.

[0233] In another exemplary embodiment, the antibody comprises:

[0234] i) a VH domain comprising the following CDRs (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:55; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:56; and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:57; or a variant thereof in which one, two or three amino acids in one or more of CDR-H1, CDR-H2 or CDR-H3 are substituted with another amino acid; and

[0235] ii) a VL domain comprising the following CDRs (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:58; (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO:59; and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO:60; or a variant thereof in which one, two or three amino acids in one or more of CDR-L1, CDR-L2 or CDR-L3 are substituted with another amino acid.

[0236] In another exemplary embodiment, the antibody comprises:

[0237] i) a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 70; and

[0238] ii) a light chain variable domain (VL) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 69.

[0239] In another exemplary embodiment, the anti-S-HBs antibody comprises (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:55; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:56; (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:57; (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:58; (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:59; and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:60, and a VH domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:70, and a VL domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:69. In one aspect, the VH domain has at least 95% sequence identity to the amino acid sequence of SEQ ID NO:70. In one aspect, the VL domain has at least 95% sequence identity to the amino acid sequence of SEQ ID NO:69. In one embodiment, the antibody specifically binds to S-HBs. In another embodiment, the antibody binds to S-HBs having a dissociation constant (KD) that is up to 10 fold reduced or up to 10 fold increased when compared to the dissociation constant (KD) of an antibody comprising a VH sequence of SEQ ID NO:70 and a VL sequence of SEQ ID NO:69.

[0240] In one aspect, the antibody comprises the VH and VL sequences in SEQ ID NO:70 and SEQ ID NO: 69, respectively, including post-translational modifications of those sequences.

[0241] In a further aspect, the antibody may comprise the full length light chain of SEQ ID NO: 71 and / or the full length heavy chain of SEQ ID NO: 72 or 266.

[0242] In a further aspect, the invention provides an antibody that binds to the same epitope as the anti-S-HBs antibody provided herein. For example, in certain aspects, an antibody is provided that binds to the same epitope as an anti-S-HBs antibody comprising a VH sequence of SEQ ID NO: 70 and a VL sequence of SEQ ID NO:69. In certain aspects, an antibody is provided that binds to one or more of the following residues of S-HBs of SEQ ID NO: 253: C121, R122, C124, C137, C139, K141, N146, C147 and / or C149. In some embodiments the antibody may also bind to one or more of I110, T118, P120, C138, P142, D144, T148 and / or I152. The antibody may comprise any of the sequences as defined above.

[0243] In a further aspect, the invention provides an antibody that competes for binding to S-HBs with an anti-S-HBs antibody provided herein.

[0244] Antibodies as described in this section may, in some embodiments, have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the binding activity of a reference antibody Bv4.104 to S-HBs (e.g., of SEQ ID NO:253), when assessed in the same assay, e.g., an ELISA assay or a flow cytometry assay.

[0245] Additionally or alternatively, antibodies as described in this section may have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the binding activity of a reference antibody Bv4.104 to one or more, or to each of the proteins of SEQ ID NO: 257 and 258, optionally at least to a protein of SEQ ID NO: 257, when assessed in the same assay, e.g., an ELISA assay or a flow cytometry assay.

[0246] Reference antibody Bv4.104 has a VH sequence of SEQ ID NO:70 and a VL sequence of SEQ ID NO:69. It has a full length heavy chain of SEQ ID NO: 72 or 266 and a full length light chain of SEQ ID NO: 71. SEQ ID NO: 266 comprises the IgG1 constant region expressed by vector LT615368.1, as used in the examples.

[0247] In some embodiments, the antibody as described in this section may bind to S-HBs (e.g., of SEQ ID NO: 253) with a KD value which is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the KD value of reference antibody Bv4.104 to the same antigen, when assessed in the same assay.

[0248] Additionally or alternatively, the antibody may bind to one or more, or to each of the proteins of SEQ ID NO: 257 and 258, optionally at least to a protein of SEQ ID NO: 257, with a KD value which is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the KD value of reference antibody Bv4.104 to the same antigen, when assessed in the same assay.

[0249] In some embodiments, the antibody as described in this section may bind to S-HBs (e.g., of SEQ ID NO: 253) with an EC50 that is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the EC50 of reference antibody Bv4.104, as measured by ELISA or by flow cytometry. Alternatively or additionally, the antibody may bind one or more, or to each of the proteins of SEQ ID NO: 257 and 258, optionally at least to a protein of SEQ ID NO: 257, with an EC50 that is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the EC50 of reference antibody Bv4.104, as measured by ELISA or by flow cytometry.

[0250] In some embodiments antibodies as described in this section may have or retain in vitro neutralizing activity against HBV genotype D, e.g., with an IC50 value of ≤100 pg / ml, optionally ≤10 pg / ml.

[0251] In another embodiment, the antibody may have an IC50 value for neutralization of HBV genotype D which is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the IC50 value of reference antibody Bv4.104 against the same genotype, when assessed using the same assay (e.g., an in vitro neutralization assay as described herein).

[0252] In another embodiment, the antibody may have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the in vivo neutralizing activity of reference antibody Bv4.104 against HBV genotype D, when assessed using the same assay (e.g., an assay as described herein).

[0253] Optionally the antibody can suppress virus viremia in vivo e.g., in an individual infected with HBV genotype D. Optionally, the antibody may have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the in vivo viremia suppressing activity of reference antibody Bv4.104 against HBV genotype D, when assessed using the same assay (e.g., an assay as described herein).E.

[0254] In one aspect, the invention provides an antibody comprising a VH domain comprising at least one, at least two, or all three VH CDR sequences selected from (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:73; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 74; and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:75. In another aspect, the antibody comprises a VH domain comprising the following CDRs (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:73; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:74; and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 75; or a variant thereof in which one, two or three amino acids in one or more of CDR-H1, CDR-H2 or CDR-H3 are substituted with another amino acid.

[0255] In one aspect, the VH domain may further comprise one or more heavy chain framework sequences selected from (a) a heavy chain frame work region 1 (HC-FR1) of SEQ ID NO: 79 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, (b) a heavy chain frame work region 2 (HC-FR2) of SEQ ID NO: 80, or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto (c) a heavy chain frame work region 3 (HC-FR3) SEQ ID NO:81, or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto and (d) a heavy chain frame work region 4 (HC-FR4) of SEQ ID NO:82 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto. Optionally, the VH domain comprises each of the heavy chain framework sequences as defined in (a) to (d). Optionally the percentage sequence identity is 95%. Optionally the percentage sequence identity is 98%.

[0256] In another aspect, an anti-S-HBs antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:88. In one aspect, an anti-S-HBs antibody comprises a heavy chain variable domain (VH) sequence having at least 95%, sequence identity to the amino acid sequence of SEQ ID NO:88. In certain aspects, a VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-S-HBs antibody comprising that sequence retains the ability to bind to S-HBs. In certain aspects, a total of 1 to 10 amino acids have been substituted, inserted and / or deleted in SEQ ID NO: 88. In certain aspects, substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs). Optionally, the anti-S-HBs antibody comprises the VH sequence in SEQ ID NO: 88, including post-translational modifications of that sequence. In a particular aspect, the VH comprises one, two or three CDRs selected from: (a) CDR-H1, comprising the amino acid sequence of SEQ ID NO 73, (b) CDR-H2, comprising the amino acid sequence of SEQ ID NO:74, and (c) CDR-H3, comprising the amino acid sequence of SEQ ID NO: 75.

[0257] In another aspect, an anti-S-HBs antibody comprises one or more of the heavy chain CDR sequences of the VH of SEQ ID NO:88. In one aspect, an anti-S-HBs antibody comprises one or more (preferably all three) of the heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO:88 and a framework of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity to the framework amino acid sequence of the VH domain of SEQ ID NO:88. Optionally the sequence identity is 95% or 98%.

[0258] In another aspect, the invention provides an antibody comprising a VL domain comprising at least one, at least two, or all three VL CDR sequences selected from (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:76; (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 77; and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO:78. In another aspect, the antibody comprises a VL domain comprising the following CDRs (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:76; (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO:77; and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 78; or a variant thereof in which one, two or three amino acids in one or more of CDR-L1, CDR-L2 or CDR-L3 are substituted with another amino acid.

[0259] In one aspect, the anti-S-HBs antibody VL domain may further comprise one or more light chain framework sequences selected from (a) a light chain frame work region 1 (LC-FR1) of SEQ ID NO: 83 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, (b) a light chain frame work region 2 (LC-FR2) of SEQ ID NO:84 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, (c) a light chain frame work region 3 (LC-FR3) of SEQ ID NO:85 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, and (d) a light chain frame work region 4 (LC-FR4) of SEQ ID NO:86 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto. Optionally, the VL domain comprises each of the light chain framework sequences as defined in (a) to (d). Optionally the percentage sequence identity is 95%. Optionally the percentage sequence identity is 98%.

[0260] In another aspect, an anti-S-HBs antibody is provided, wherein the antibody comprises a light chain variable domain (VL) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:87. In one aspect, an anti-S-HBs antibody comprises a light chain variable domain (VL) sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:87. In certain aspects, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-S-HBs antibody comprising that sequence retains the ability to bind to S-HBs. In certain aspects, a total of 1 to 10 amino acids have been substituted, inserted and / or deleted in SEQ ID NO:87. In certain aspects, the substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs). Optionally, the anti-S-HBs antibody comprises the VL sequence in SEQ ID NO:87, including post-translational modifications of that sequence. In a particular aspect, the VL comprises one, two or three CDRs selected from: (a) CDR-L1, comprising the amino acid sequence of SEQ ID NO:76, (b) CDR-L2, comprising the amino acid sequence of SEQ ID NO:77, and (c) CDR-L3, comprising the amino acid sequence of SEQ ID NO:78.

[0261] In another embodiment, an anti-S-HBs antibody comprises one or more of the CDR sequences of the VL of SEQ ID NO:87. In one aspect, an anti-S-HBs antibody comprises one or more (preferably all three) of the light chain CDR amino acid sequences of the VL domain of SEQ ID NO: 87 and a framework of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity to the framework amino acid sequence of the VL domain of SEQ ID NO:87. Optionally the sequence identity is 95% or 98%.

[0262] In another aspect, an anti-S-HBs antibody is provided, wherein the antibody comprises a VH sequence as in any of the aspects provided above, and a VL sequence as in any of the aspects provided above.

[0263] For instance, in one exemplary embodiment, the antibody comprises a VH domain comprising CDR-H3 of SEQ ID NO:75; and a VL domain comprising CDR-L3 of SEQ ID NO: 78. Optionally the VH domain further comprises CDR-H2 of SEQ ID NO: 74.

[0264] In another exemplary embodiment, the antibody comprises:

[0265] i) a VH domain comprising the following CDRs (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:73; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:74; and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:75; or a variant thereof in which one, two or three amino acids in one or more of CDR-H1, CDR-H2 or CDR-H3 are substituted with another amino acid; and

[0266] ii) a VL domain comprising the following CDRs (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:76; (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO:77; and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO:78; or a variant thereof in which one, two or three amino acids in one or more of CDR-L1, CDR-L2 or CDR-L3 are substituted with another amino acid.

[0267] In another exemplary embodiment, the antibody comprises:

[0268] i) a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 88; and

[0269] ii) a light chain variable domain (VL) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 87.

[0270] In another exemplary embodiment, the anti-S-HBs antibody comprises (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:73; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:74; (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:75; (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:76; (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:77; and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:78, and a VH domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:88, and a VL domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:87. In one aspect, the VH domain has at least 95% sequence identity to the amino acid sequence of SEQ ID NO:88. In one aspect, the VL domain has at least 95% sequence identity to the amino acid sequence of SEQ ID NO:87. In one embodiment, the antibody specifically binds to S-HBs. In another embodiment, the antibody binds to S-HBs having a dissociation constant (KD) that is up to 10 fold reduced or up to 10 fold increased when compared to the dissociation constant (KD) of an antibody comprising a VH sequence of SEQ ID NO:88 and a VL sequence of SEQ ID NO:87.

[0271] In one aspect, the antibody comprises the VH and VL sequences in SEQ ID NO:88 and SEQ ID NO: 87, respectively, including post-translational modifications of those sequences.

[0272] In a further aspect, the antibody may comprise the full length light chain of SEQ ID NO: 89 and / or the full length heavy chain of SEQ ID NO: 90 or 267.

[0273] In a further aspect, the invention provides an antibody that binds to the same epitope as the anti-S-HBs antibody provided herein. For example, in certain aspects, an antibody is provided that binds to the same epitope as an anti-S-HBs antibody comprising a VH sequence of SEQ ID NO: 88 and a VL sequence of SEQ ID NO:87. In certain aspects, an antibody is provided that binds to one or more of the following residues of S-HBs of SEQ ID NO: 253: C121, and / or one or more of I110, P120, C124, C137, C139, C147, T148 and / or C149. Optionally the antibody may further bind to one or more of C138, K141, P142, D144, G145, P150, I152, and / or W156. The antibody may comprise any of the sequences as defined above.

[0274] In a further aspect, the invention provides an antibody that competes for binding to S-HBs with an anti-S-HBs antibody provided herein.

[0275] Antibodies as described in this section may, in some embodiments, have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the binding activity of a reference antibody Bc8.111 to S-HBs (e.g., of SEQ ID NO:253), when assessed in the same assay, e.g., an ELISA assay or a flow cytometry assay.

[0276] Additionally or alternatively, antibodies as described in this section may have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the binding activity of reference antibody Bc8.111 to one or more of the proteins of SEQ ID NO: 254-262 (e.g., to at least SEQ ID NO: 257), optionally to each of the proteins of SEQ ID NO: 254 to 262, when assessed in the same assay e.g., an ELISA assay or a flow cytometry assay.

[0277] Reference antibody Bc8.111 has a VH sequence of SEQ ID NO:88 and a VL sequence of SEQ ID NO:87. It has a full length heavy chain of SEQ ID NO: 90 or 267 and a full length light chain of SEQ ID NO: 89. SEQ ID NO: 267 comprises the IgG1 constant region expressed by vector LT615368.1, as used in the examples. In some embodiments, the antibody described in this section may bind to S-HBs (e.g., of SEQ ID NO: 253) with a KD value which is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the KD value of reference antibody Bc8.111 to the same antigen, when assessed in the same assay.

[0278] Additionally or alternatively, the antibody may bind to one or more of SEQ ID NO: 254-262 (e.g., to at least SEQ ID NO: 257), optionally each of the proteins of SEQ ID NO: 254-262, with a KD value which is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the KD value of reference antibody Bc8.111 to the same antigen, when assessed in the same assay.

[0279] In some embodiments, the antibody as described in this section may bind to S-HBs (e.g., of SEQ ID NO: 253) with an EC50 that is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the EC50 of reference antibody Bc8.111, as measured by ELISA or by flow cytometry. Alternatively or additionally, the antibody may bind one or more, or to each of the proteins of SEQ ID NO: 254-262, optionally at least to a protein of SEQ ID NO: 257, with an EC50 that is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the EC50 of reference antibody Bc8.111, as measured by ELISA or by flow cytometry.

[0280] In some embodiments antibodies as described in this section may have or retain in vitro neutralizing activity against HBV genotype A, B, C and / or D, optionally all of A, B, C and D. For example, antibodies as described in this section may have or retain in vitro neutralizing activity against HBV genotype D, e.g., with an IC50 value of ≤100 pg / ml, optionally ≤10 pg / ml.

[0281] In another embodiment, the antibody may have an IC50 value for neutralization of HBV genotype A, B, C and / or D, optionally at least D, optionally all of A, B, C and D, which is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the IC50 value of reference antibody Bc8.111 against the same genotype, when assessed using the same assay (e.g., an in vitro neutralization assay as described herein).

[0282] In another embodiment, the antibody may have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the in vivo neutralizing activity of reference antibody Bc8.111 against HBV genotype A, B, C and / or D, when assessed using the same assay (e.g., an assay as described herein).

[0283] Optionally the antibody can suppress virus viremia in vivo e.g., in an individual infected with HBV genotype A, B, C or D, optionally D. Optionally, the antibody may have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the in vivo viremia suppressing activity of reference antibody Bc8.111 against HBV genotype A, B, C and / or D, when assessed using the same assay (e.g., an assay as described herein).F.

[0284] In one aspect, the invention provides an antibody comprising a VH domain comprising at least one, at least two, or all three VH CDR sequences selected from (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:91; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 92; and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:93. In another aspect, the antibody comprises a VH domain comprising the following CDRs (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:91; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:92; and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 93; or a variant thereof in which one, two or three amino acids in one or more of CDR-H1, CDR-H2 or CDR-H3 are substituted with another amino acid.

[0285] In one aspect, the VH domain may further comprise one or more heavy chain framework sequences selected from (a) a heavy chain frame work region 1 (HC-FR1) of SEQ ID NO: 97 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, (b) a heavy chain frame work region 2 (HC-FR2) of SEQ ID NO: 98, or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto (c) a heavy chain frame work region 3 (HC-FR3) SEQ ID NO:99, or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto and (d) a heavy chain frame work region 4 (HC-FR4) of SEQ ID NO:100 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto. Optionally, the VH domain comprises each of the heavy chain framework sequences as defined in (a) to (d). Optionally the percentage sequence identity is 95%. Optionally the percentage sequence identity is 98%.

[0286] In another aspect, an anti-S-HBs antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 106. In one aspect, an anti-S-HBs antibody comprises a heavy chain variable domain (VH) sequence having at least 95%, sequence identity to the amino acid sequence of SEQ ID NO:106. In certain aspects, a VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-S-HBs antibody comprising that sequence retains the ability to bind to S-HBs. In certain aspects, a total of 1 to 10 amino acids have been substituted, inserted and / or deleted in SEQ ID NO: 106. In certain aspects, substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs). Optionally, the anti-S-HBs antibody comprises the VH sequence in SEQ ID NO: 106, including post-translational modifications of that sequence. In a particular aspect, the VH comprises one, two or three CDRs selected from: (a) CDR-H1, comprising the amino acid sequence of SEQ ID NO 91, (b) CDR-H2, comprising the amino acid sequence of SEQ ID NO:92, and (c) CDR-H3, comprising the amino acid sequence of SEQ ID NO: 93.

[0287] In another aspect, an anti-S-HBs antibody comprises one or more of the heavy chain CDR sequences of the VH of SEQ ID NO:106. In one aspect, an anti-S-HBs antibody comprises one or more (preferably all three) of the heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO: 106 and a framework of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity to the framework amino acid sequence of the VH domain of SEQ ID NO:106. Optionally the sequence identity is 95% or 98%.

[0288] In another aspect, the invention provides an antibody comprising a VL domain comprising at least one, at least two, or all three VL CDR sequences selected from (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:94; (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 95; and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO:96. In another aspect, the antibody comprises a VL domain comprising the following CDRs (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:94; (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO:95; and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO:96; or a variant thereof in which one, two or three amino acids in one or more of CDR-L1, CDR-L2 or CDR-L3 are substituted with another amino acid.

[0289] In one aspect, the anti-S-HBs antibody VL domain may further comprise one or more light chain framework sequences selected from (a) a light chain frame work region 1 (LC-FR1) of SEQ ID NO: 101 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, (b) a light chain frame work region 2 (LC-FR2) of SEQ ID NO:102 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, (c) a light chain frame work region 3 (LC-FR3) of SEQ ID NO:103 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, and (d) a light chain frame work region 4 (LC-FR4) of SEQ ID NO:104 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto. Optionally, the VL domain comprises each of the light chain framework sequences as defined in (a) to (d). Optionally the percentage sequence identity is 95%. Optionally the percentage sequence identity is 98%.

[0290] In another aspect, an anti-S-HBs antibody is provided, wherein the antibody comprises a light chain variable domain (VL) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 105. In one aspect, an anti-S-HBs antibody comprises a light chain variable domain (VL) sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 105. In certain aspects, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-S-HBs antibody comprising that sequence retains the ability to bind to S-HBs. In certain aspects, a total of 1 to 10 amino acids have been substituted, inserted and / or deleted in SEQ ID NO:105. In certain aspects, the substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs). Optionally, the anti-S-HBs antibody comprises the VL sequence in SEQ ID NO:105, including post-translational modifications of that sequence. In a particular aspect, the VL comprises one, two or three CDRs selected from: (a) CDR-L1, comprising the amino acid sequence of SEQ ID NO:94, (b) CDR-L2, comprising the amino acid sequence of SEQ ID NO:95, and (c) CDR-L3, comprising the amino acid sequence of SEQ ID NO:96.

[0291] In another embodiment, an anti-S-HBs antibody comprises one or more of the CDR sequences of the VL of SEQ ID NO:105. In one aspect, an anti-S-HBs antibody comprises one or more (preferably all three) of the light chain CDR amino acid sequences of the VL domain of SEQ ID NO: 105 and a framework of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity to the framework amino acid sequence of the VL domain of SEQ ID NO:105. Optionally the sequence identity is 95% or 98%.

[0292] In another aspect, an anti-S-HBs antibody is provided, wherein the antibody comprises a VH sequence as in any of the aspects provided above, and a VL sequence as in any of the aspects provided above.

[0293] For instance, in one exemplary embodiment, the antibody comprises a VH domain comprising CDR-H3 of SEQ ID NO:93; and a VL domain comprising CDR-L3 of SEQ ID NO: 96. Optionally the VH domain further comprises CDR-H2 of SEQ ID NO: 92.

[0294] In another exemplary embodiment, the antibody comprises:

[0295] i) a VH domain comprising the following CDRs (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:91; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:92; and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:93; or a variant thereof in which one, two or three amino acids in one or more of CDR-H1, CDR-H2 or CDR-H3 are substituted with another amino acid; and

[0296] ii) a VL domain comprising the following CDRs (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:94; (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO:95; and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO:96; or a variant thereof in which one, two or three amino acids in one or more of CDR-L1, CDR-L2 or CDR-L3 are substituted with another amino acid.

[0297] In another exemplary embodiment, the antibody comprises:

[0298] i) a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 106; and

[0299] ii) a light chain variable domain (VL) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 105.

[0300] In another exemplary embodiment, the anti-S-HBs antibody comprises (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:91; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:92; (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:93; (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:94; (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:95; and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:96, and a VH domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:106, and a VL domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:105. In one aspect, the VH domain has at least 95% sequence identity to the amino acid sequence of SEQ ID NO:106. In one aspect, the VL domain has at least 95% sequence identity to the amino acid sequence of SEQ ID NO 105. In one embodiment, the antibody specifically binds to S-HBs. In another embodiment, the antibody binds to S-HBs having a dissociation constant (KD) that is up to 10 fold reduced or up to 10 fold increased when compared to the dissociation constant (KD) of an antibody comprising a VH sequence of SEQ ID NO:106 and a VL sequence of SEQ ID NO:105.

[0301] In one aspect, the antibody comprises the VH and VL sequences in SEQ ID NO: 106 and SEQ ID NO:105, respectively, including post-translational modifications of those sequences.

[0302] In a further aspect, the antibody may comprise the full length light chain of SEQ ID NO: 107 and / or the full length heavy chain of SEQ ID NO: 108 or 268.

[0303] In a further aspect, the invention provides an antibody that binds to the same epitope as the anti-S-HBs antibody provided herein. For example, in certain aspects, an antibody is provided that binds to the same epitope as an anti-S-HBs antibody comprising a VH sequence of SEQ ID NO: 106 and a VL sequence of SEQ ID NO:105. In certain aspects, an antibody is provided that binds to one or more of the following residues of S-HBs of SEQ ID NO: 253: W156 and / or R169. Optionally the antibody may additional bind to one or more of I152 and / or C138. The antibody may comprise any of the sequences as defined above.

[0304] In a further aspect, the invention provides an antibody that competes for binding to S-HBs with an anti-S-HBs antibody provided herein.

[0305] Antibodies as described in this section may, in some embodiments, have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the binding activity of a reference antibody Bc8.104 to S-HBs (e.g., of SEQ ID NO:253), when assessed in the same assay, e.g., an ELISA assay or a flow cytometry assay.

[0306] Additionally or alternatively, antibodies as described in this section may have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the binding activity of reference antibody Bc8.104 to one or more of the proteins of SEQ ID NO: 254-262 (e.g., to at least SEQ ID NO: 257), optionally each of the proteins of SEQ ID NO: 254 to 262, when assessed in the same assay, e.g., an ELISA assay or a flow cytometry assay.

[0307] Reference antibody Bc8.104 has a VH sequence of SEQ ID NO:106 and a VL sequence of SEQ ID NO:105. It has a full length heavy chain of SEQ ID NO: 108 or 268 and a full length light chain of SEQ ID NO: 107. SEQ ID NO: 268 comprises the IgG1 constant region expressed by vector LT615368.1, as used in the examples.

[0308] In some embodiments, the antibody described in this section may bind to S-HBs (e.g., of SEQ ID NO: 253) with a KD value which is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the KD value of reference antibody Bc8.104 to the same antigen, when assessed in the same assay.

[0309] Additionally or alternatively, the antibody described in this section may bind to one or more of SEQ ID NO: 254-262 (e.g., to at least SEQ ID NO: 257), optionally each of the proteins of SEQ ID NO: 254-262, with a KD value which is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the KD value of reference antibody Bc8.104 to the same antigen, when assessed in the same assay.

[0310] In some embodiments, the antibody as described in this section may bind to S-HBs (e.g., of SEQ ID NO: 253) with an EC50 that is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the EC50 of reference antibody Bc8.104, as measured by ELISA or by flow cytometry. Alternatively or additionally, the antibody may bind one or more, or to each of the proteins of SEQ ID NO: 254-262, optionally at least to a protein of SEQ ID NO: 257, with an EC50 that is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the EC50 of reference antibody Bc8.104, as measured by ELISA or by flow cytometry.

[0311] In some embodiments antibodies as described in this section may have or retain in vitro neutralizing activity against HBV genotype A, B, C and / or D, optionally all of A, B, C and D. For example, antibodies as described in this section may have or retain in vitro neutralizing activity against HBV genotype D, e.g., with an IC50 value of ≤100 pg / ml, optionally ≤10 pg / ml.

[0312] In another embodiment, the antibody may have an IC50 value for neutralization of HBV genotype A, B, C and / or D, optionally at least D, optionally all of A, B, C and D, which is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the IC50 value of reference antibody Bc8.104 against the same genotype, when assessed using the same assay (e.g., an in vitro neutralization assay as described herein).

[0313] In another embodiment, the antibody may have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the neutralizing activity of reference antibody Bc8.104 against HBV genotype A, B, C and / or D, optionally at least D, optionally all of A, B, C and D, when assessed using the same assay (e.g., an assay as described herein).

[0314] Optionally the antibody can suppress virus viremia in vivo e.g., in an individual infected with HBV genotype A, B, C or D, optionally D. Optionally, the antibody may have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the in vivo viremia suppressing activity of reference antibody Bc8.104 against HBV genotype A, B, C and / or D, optionally at least D, optionally all of A, B, C and D, when assessed using the same assay (e.g., an assay as described herein).G.

[0315] In one aspect, the invention provides an antibody comprising a VH domain comprising at least one, at least two, or all three VH CDR sequences selected from (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:109; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:110; and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:111. In another aspect, the antibody comprises a VH domain comprising the following CDRs (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:109; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:110; and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 111; or a variant thereof in which one, two or three amino acids in one or more of CDR-H1, CDR-H2 or CDR-H3 are substituted with another amino acid.

[0316] In one aspect, the VH domain may further comprise one or more heavy chain framework sequences selected from (a) a heavy chain frame work region 1 (HC-FR1) of SEQ ID NO: 115 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, (b) a heavy chain frame work region 2 (HC-FR2) of SEQ ID NO:116, or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto (c) a heavy chain frame work region 3 (HC-FR3) SEQ ID NO:117, or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto and (d) a heavy chain frame work region 4 (HC-FR4) of SEQ ID NO:118 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto. Optionally, the VH domain comprises each of the heavy chain framework sequences as defined in (a) to (d). Optionally the percentage sequence identity is 95%. Optionally the percentage sequence identity is 98%.

[0317] In another aspect, an anti-S-HBs antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:124. In one aspect, an anti-S-HBs antibody comprises a heavy chain variable domain (VH) sequence having at least 95%, sequence identity to the amino acid sequence of SEQ ID NO:124. In certain aspects, a VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-S-HBs antibody comprising that sequence retains the ability to bind to S-HBs. In certain aspects, a total of 1 to 10 amino acids have been substituted, inserted and / or deleted in SEQ ID NO: 124. In certain aspects, substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs). Optionally, the anti-S-HBs antibody comprises the VH sequence in SEQ ID NO: 124, including post-translational modifications of that sequence. In a particular aspect, the VH comprises one, two or three CDRs selected from: (a) CDR-H1, comprising the amino acid sequence of SEQ ID NO 109, (b) CDR-H2, comprising the amino acid sequence of SEQ ID NO: 110, and (c) CDR-H3, comprising the amino acid sequence of SEQ ID NO: 111.

[0318] In another aspect, an anti-S-HBs antibody comprises one or more of the heavy chain CDR. sequences of the VH of SEQ ID NO:124. In one aspect, an anti-S-HBs antibody comprises one or more (preferably all three) of the heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO:124 and a framework of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity to the framework amino acid sequence of the VH domain of SEQ ID NO:124. Optionally the sequence identity is 95% or 98%.

[0319] In another aspect, the invention provides an antibody comprising a VL domain comprising at least one, at least two, or all three VL CDR sequences selected from (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:112; (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 113; and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO:114. In another aspect, the antibody comprises a VL domain comprising the following CDRs (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:112; (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO:113; and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 114; or a variant thereof in which one, two or three amino acids in one or more of CDR-L1, CDR-L2 or CDR-L3 are substituted with another amino acid.

[0320] In one aspect, the anti-S-HBs antibody VL domain may further comprise one or more light chain framework sequences selected from (a) a light chain frame work region 1 (LC-FR1) of SEQ ID NO: 119 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, (b) a light chain frame work region 2 (LC-FR2) of SEQ ID NO:120 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, (c) a light chain frame work region 3 (LC-FR3) of SEQ ID NO:121 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, and (d) a light chain frame work region 4 (LC-FR4) of SEQ ID NO:122 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto. Optionally, the VL domain comprises each of the light chain framework sequences as defined in (a) to (d). Optionally the percentage sequence identity is 95%. Optionally the percentage sequence identity is 98%.

[0321] In another aspect, an anti-S-HBs antibody is provided, wherein the antibody comprises a light chain variable domain (VL) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:123. In one aspect, an anti-S-HBs antibody comprises a light chain variable domain (VL) sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 123. In certain aspects, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-S-HBs antibody comprising that sequence retains the ability to bind to S-HBs. In certain aspects, a total of 1 to 10 amino acids have been substituted, inserted and / or deleted in SEQ ID NO:123. In certain aspects, the substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs). Optionally, the anti-S-HBs antibody comprises the VL sequence in SEQ ID NO:123, including post-translational modifications of that sequence. In a particular aspect, the VL comprises one, two or three CDRs selected from: (a) CDR-L1, comprising the amino acid sequence of SEQ ID NO:112, (b) CDR-L2, comprising the amino acid sequence of SEQ ID NO:113, and (c) CDR-L3, comprising the amino acid sequence of SEQ ID NO:114.

[0322] In another embodiment, an anti-S-HBs antibody comprises one or more of the CDR sequences of the VL of SEQ ID NO:123. In one aspect, an anti-S-HBs antibody comprises one or more (preferably all three) of the light chain CDR amino acid sequences of the VL domain of SEQ ID NO: 123 and a framework of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity to the framework amino acid sequence of the VL domain of SEQ ID NO:123. Optionally the sequence identity is 95% or 98%.

[0323] In another aspect, an anti-S-HBs antibody is provided, wherein the antibody comprises a VH sequence as in any of the aspects provided above, and a VL sequence as in any of the aspects provided above.

[0324] For instance, in one exemplary embodiment, the antibody comprises a VH domain comprising CDR-H3 of SEQ ID NO:111; and a VL domain comprising CDR-L3 of SEQ ID NO: 114. Optionally the VH domain further comprises CDR-H2 of SEQ ID NO: 110.

[0325] In another exemplary embodiment, the antibody comprises:

[0326] i) a VH domain comprising the following CDRs (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:109; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 110; and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:111; or a variant thereof in which one, two or three amino acids in one or more of CDR-H1, CDR-H2 or CDR-H3 are substituted with another amino acid; and

[0327] ii) a VL domain comprising the following CDRs (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:112; (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 113; and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO:114; or a variant thereof in which one, two or three amino acids in one or more of CDR-L1, CDR-L2 or CDR-L3 are substituted with another amino acid.

[0328] In another exemplary embodiment, the antibody comprises:

[0329] i) a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 124; and

[0330] ii) a light chain variable domain (VL) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 123.

[0331] In another exemplary embodiment, the anti-S-HBs antibody comprises (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:109; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:110; (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 111; (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:112; (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:113; and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:114, and a VH domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 124, and a VL domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:123. In one aspect, the VH domain has at least 95% sequence identity to the amino acid sequence of SEQ ID NO:124. In one aspect, the VL domain has at least 95% sequence identity to the amino acid sequence of SEQ ID NO 123. In one embodiment, the antibody specifically binds to S-HBs. In another embodiment, the antibody binds to S-HBs having a dissociation constant (KD) that is up to 10 fold reduced or up to 10 fold increased when compared to the dissociation constant (KD) of an antibody comprising a VH sequence of SEQ ID NO: 124 and a VL sequence of SEQ ID NO:123.

[0332] In one aspect, the antibody comprises the VH and VL sequences in SEQ ID NO: 124 and SEQ ID NO:123, respectively, including post-translational modifications of those sequences.

[0333] In a further aspect, the antibody may comprise the full length light chain of SEQ ID NO: 125 and / or the full length heavy chain of SEQ ID NO: 126 or 269.

[0334] In a further aspect, the invention provides an antibody that binds to the same epitope as the anti-S-HBs antibody provided herein. For example, in certain aspects, an antibody is provided that binds to the same epitope as an anti-S-HBs antibody comprising a VH sequence of SEQ ID NO: 124 and a VL sequence of SEQ ID NO:123. In certain aspects, an antibody is provided that binds to one or more of the following residues of S-HBs of SEQ ID NO: 253: C137, C138 and / or D144. Optionally, the antibody may further bind to one or more of P142, N146, T148, C149, I152 and / or W156. The antibody may comprise any of the sequences as defined above.

[0335] In a further aspect, the invention provides an antibody that competes for binding to S-HBs with an anti-S-HBs antibody provided herein.

[0336] Antibodies as described in this section may, in some embodiments, have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the binding activity of a reference antibody Bv6.172 to S-HBs (e.g., of SEQ ID NO:253), when assessed in the same assay, e.g., an ELISA assay or a flow cytometry assay.

[0337] Additionally or alternatively, antibodies as described in this section may have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the binding activity of reference antibody Bv6.172 to one or more of the proteins of SEQ ID NO: 254-262 (e.g., to at least SEQ ID NO: 257), optionally each of the proteins of SEQ ID NO: 254 to 262, when assessed in the same assay, e.g., an ELISA assay or a flow cytometry assay.

[0338] Reference antibody Bv6.172 has a VH sequence of SEQ ID NO: 124 and a VL sequence of SEQ ID NO:123. It has a full length heavy chain of SEQ ID NO: 126 or 269 and a full length light chain of SEQ ID NO: 125. SEQ ID NO: 269 comprises the IgG1 constant region expressed by vector LT615368.1, as used in the examples.

[0339] In some embodiments, the antibody as described in this section may bind to S-HBs (e.g., of SEQ ID NO: 253) with a KD value which is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the KD value of reference antibody Bv6.172 to the same antigen, when assessed in the same assay.

[0340] Additionally or alternatively, the antibody may bind to one or more of SEQ ID NO: 254-262 (e.g., to at least SEQ ID NO: 257), optionally each of the proteins of SEQ ID NO: 254-262, with a KD value which is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the KD value of reference antibody Bv6.172 to the same antigen, when assessed in the same assay.

[0341] In some embodiments, the antibody as described in this section may bind to S-HBs (e.g., of SEQ ID NO: 253) with an EC50 that is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the EC50 of reference antibody Bv6.172, as measured by ELISA or by flow cytometry. Alternatively or additionally, the antibody may bind one or more, or to each of the proteins of SEQ ID NO: 254-262, optionally at least to a protein of SEQ ID NO: 257, with an EC50 that is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the EC50 of reference antibody Bv6.172, as measured by ELISA or by flow cytometry.

[0342] In some embodiments antibodies as described in this section may have or retain in vitro neutralizing activity against HBV genotype D, e.g., with an IC50 value of ≤100 pg / ml, optionally ≤10 pg / ml.

[0343] In another embodiment, the antibody may have an IC50 value for neutralization of HBV genotype A, B, C and / or D which is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the IC50 value of reference antibody Bv6.172 against the same genotype, when assessed using the same assay (e.g., an in vitro neutralization assay as described herein).

[0344] In another embodiment, the antibody may have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the in vivo neutralizing activity of reference antibody Bv6.172 against HBV genotype A, B, C and / or D, optionally at least D, optionally all of A, B, C and D, when assessed using the same assay (e.g., an assay as described herein).

[0345] Optionally the antibody can suppress virus viremia in vivo e.g., in an individual infected with HBV genotype A, B, C or D, optionally D. Optionally, the antibody may have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the in vivo viremia suppressing activity of reference antibody Bv6.172 against HBV genotype A, B, C and / or D, optionally at least D, optionally all of A, B, C and D, when assessed using the same assay (e.g., an assay as described herein).H.

[0346] In one aspect, the invention provides an antibody comprising a VH domain comprising at least one, at least two, or all three VH CDR sequences selected from (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:127; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:128; and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:129. In another aspect, the antibody comprises a VH domain comprising the following CDRs (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 127; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:128; and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 129; or a variant thereof in which one, two or three amino acids in one or more of CDR-H1, CDR-H2 or CDR-H3 are substituted with another amino acid.

[0347] In one aspect, the VH domain may further comprise one or more heavy chain framework sequences selected from (a) a heavy chain frame work region 1 (HC-FR1) of SEQ ID NO: 133 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, (b) a heavy chain frame work region 2 (HC-FR2) of SEQ ID NO:134, or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto (c) a heavy chain frame work region 3 (HC-FR3) SEQ ID NO:135, or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto and (d) a heavy chain frame work region 4 (HC-FR4) of SEQ ID NO: 136 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto. Optionally, the VH domain comprises each of the heavy chain framework sequences as defined in (a) to (d). Optionally the percentage sequence identity is 95%. Optionally the percentage sequence identity is 98%.

[0348] In another aspect, an anti-S-HBs antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 142. In one aspect, an anti-S-HBs antibody comprises a heavy chain variable domain (VH) sequence having at least 95%, sequence identity to the amino acid sequence of SEQ ID NO:142. In certain aspects, a VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-S-HBs antibody comprising that sequence retains the ability to bind to S-HBs. In certain aspects, a total of 1 to 10 amino acids have been substituted, inserted and / or deleted in SEQ ID NO: 142. In certain aspects, substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs). Optionally, the anti-S-HBs antibody comprises the VH sequence in SEQ ID NO: 142, including post-translational modifications of that sequence. In a particular aspect, the VH comprises one, two or three CDRs selected from: (a) CDR-H1, comprising the amino acid sequence of SEQ ID NO 127, (b) CDR-H2, comprising the amino acid sequence of SEQ ID NO: 128, and (c) CDR-H3, comprising the amino acid sequence of SEQ ID NO: 129.

[0349] In another aspect, an anti-S-HBs antibody comprises one or more of the heavy chain CDR sequences of the VH of SEQ ID NO:142. In one aspect, an anti-S-HBs antibody comprises one or more (preferably all three) of the heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO:142 and a framework of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity to the framework amino acid sequence of the VH domain of SEQ ID NO: 142. Optionally the sequence identity is 95% or 98%.

[0350] In another aspect, the invention provides an antibody comprising a VL domain comprising at least one, at least two, or all three VL CDR sequences selected from (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:130; (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 131; and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO:132. In another aspect, the antibody comprises a VL domain comprising the following CDRs (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:130; (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO:131; and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 132; or a variant thereof in which one, two or three amino acids in one or more of CDR-L1, CDR-L2 or CDR-L3 are substituted with another amino acid.

[0351] In one aspect, the anti-S-HBs antibody VL domain may further comprise one or more light chain framework sequences selected from (a) a light chain frame work region 1 (LC-FR1) of SEQ ID NO: 137 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, (b) a light chain frame work region 2 (LC-FR2) of SEQ ID NO:138 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, (c) a light chain frame work region 3 (LC-FR3) of SEQ ID NO:139 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, and (d) a light chain frame work region 4 (LC-FR4) of SEQ ID NO:140 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto. Optionally, the VL domain comprises each of the light chain framework sequences as defined in (a) to (d). Optionally the percentage sequence identity is 95%. Optionally the percentage sequence identity is 98%.

[0352] In another aspect, an anti-S-HBs antibody is provided, wherein the antibody comprises a light chain variable domain (VL) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:141. In one aspect, an anti-S-HBs antibody comprises a light chain variable domain (VL) sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:141. In certain aspects, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-S-HBs antibody comprising that sequence retains the ability to bind to S-HBs. In certain aspects, a total of 1 to 10 amino acids have been substituted, inserted and / or deleted in SEQ ID NO:141. In certain aspects, the substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs). Optionally, the anti-S-HBs antibody comprises the VL sequence in SEQ ID NO: 141, including post-translational modifications of that sequence. In a particular aspect, the VL comprises one, two or three CDRs selected from: (a) CDR-L1, comprising the amino acid sequence of SEQ ID NO:130, (b) CDR-L2, comprising the amino acid sequence of SEQ ID NO:131, and (c) CDR-L3, comprising the amino acid sequence of SEQ ID NO:132.

[0353] In another embodiment, an anti-S-HBs antibody comprises one or more of the CDR sequences of the VL of SEQ ID NO:141. In one aspect, an anti-S-HBs antibody comprises one or more (preferably all three) of the light chain CDR amino acid sequences of the VL domain of SEQ ID NO: 141 and a framework of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity to the framework amino acid sequence of the VL domain of SEQ ID NO:141. Optionally the sequence identity is 95% or 98%.

[0354] In another aspect, an anti-S-HBs antibody is provided, wherein the antibody comprises a VH sequence as in any of the aspects provided above, and a VL sequence as in any of the aspects provided above.

[0355] For instance, in one exemplary embodiment, the antibody comprises a VH domain comprising CDR-H3 of SEQ ID NO:129; and a VL domain comprising CDR-L3 of SEQ ID NO: 132. Optionally the VH domain further comprises CDR-H2 of SEQ ID NO: 128.

[0356] In another exemplary embodiment, the antibody comprises:

[0357] i) a VH domain comprising the following CDRs (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:127; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 128; and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:129; or a variant thereof in which one, two or three amino acids in one or more of CDR-H1, CDR-H2 or CDR-H3 are substituted with another amino acid; and

[0358] ii) a VL domain comprising the following CDRs (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:130; (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 131; and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO:132; or a variant thereof in which one, two or three amino acids in one or more of CDR-L1, CDR-L2 or CDR-L3 are substituted with another amino acid.

[0359] In another exemplary embodiment, the antibody comprises:

[0360] i) a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 142; and

[0361] ii) a light chain variable domain (VL) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 141.

[0362] In another exemplary embodiment, the anti-S-HBs antibody comprises (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:127; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:128; (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 129; (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:130; (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:131; and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:132, and a VH domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 142, and a VL domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:141. In one aspect, the VH domain has at least 95% sequence identity to the amino acid sequence of SEQ ID NO:142. In one aspect, the VL domain has at least 95% sequence identity to the amino acid sequence of SEQ ID NO 141. In one embodiment, the antibody specifically binds to S-HBs. In another embodiment, the antibody binds to S-HBs having a dissociation constant (KD) that is up to 10 fold reduced or up to 10 fold increased when compared to the dissociation constant (KD) of an antibody comprising a VH sequence of SEQ ID NO:142 and a VL sequence of SEQ ID NO:141.

[0363] In one aspect, the antibody comprises the VH and VL sequences in SEQ ID NO: 142 and SEQ ID NO:141, respectively, including post-translational modifications of those sequences.

[0364] In a further aspect, the antibody may comprise the full length light chain of SEQ ID NO: 143 and / or the full length heavy chain of SEQ ID NO: 144 or 270.

[0365] In a further aspect, the invention provides an antibody that binds to the same epitope as the anti-S-HBs antibody provided herein. For example, in certain aspects, an antibody is provided that binds to the same epitope as an anti-S-HBs antibody comprising a VH sequence of SEQ ID NO: 142 and a VL sequence of SEQ ID NO:141. In certain aspects, an antibody is provided that binds to one or more of the following residues of S-HBs of SEQ ID NO: 253: C137, C138 and / or C139. Optionally, the antibody also binds to C124, optionally further to W156, and optionally to one or more of N146, T148 and / or I152. The antibody may comprise any of the sequences as defined above.

[0366] In a further aspect, the invention provides an antibody that competes for binding to S-HBs with an anti-S-HBs antibody provided herein.

[0367] Antibodies as described in this section may, in some embodiments, have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the binding activity of a reference antibody Bv4.115 to S-HBs (e.g., of SEQ ID NO:253), when assessed in the same assay, e.g., an ELISA or flow cytometry assay.

[0368] Additionally or alternatively, antibodies as described in this section may have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the binding activity of reference antibody Bv4.115 to one or more of the proteins of SEQ ID NO: 254-262 (e.g., to at least SEQ ID NO: 257), optionally each of the proteins of SEQ ID NO: 254 to 262, when assessed in the same assay, e.g., an ELISA or flow cytometry assay.

[0369] Reference antibody Bv4.115 has a VH sequence of SEQ ID NO: 142 and a VL sequence of SEQ ID NO:141. It has a full length heavy chain of SEQ ID NO: 144 or 270 and a full length light chain of SEQ ID NO: 143. SEQ ID NO: 270 comprises the IgG1 constant region expressed by vector LT615368.1, as used in the examples.

[0370] In some embodiments, the antibody as described in this section may bind to S-HBs (e.g., of SEQ ID NO: 253) with a KD value which is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the KD value of reference antibody Bv4.115 to the same antigen, when assessed in the same assay.

[0371] Additionally or alternatively, the antibody may bind to one or more of SEQ ID NO: 254-262 (e.g., to at least SEQ ID NO: 257), optionally each of the proteins of SEQ ID NO: 254-262, with a KD value which is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the KD value of reference antibody Bv4.115 to the same antigen, when assessed in the same assay.

[0372] In some embodiments, the antibody as described in this section may bind to S-HBs (e.g., of SEQ ID NO: 253) with an EC50 that is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the EC50 of reference antibody Bv4.115, as measured by ELISA or by flow cytometry. Alternatively or additionally, the antibody may bind one or more, or to each of the proteins of SEQ ID NO: 254-262, optionally at least to a protein of SEQ ID NO: 257, with an EC50 that is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the EC50 of reference antibody Bv4.115, as measured by ELISA or by flow cytometry.

[0373] In some embodiments antibodies as described in this section may have or retain in vitro neutralizing activity against HBV genotype A, B, C and / or D, optionally all of A, B, C and D. For example, antibodies as described in this section may have or retain in vitro neutralizing activity against HBV genotype D, e.g., with an IC50 value of ≤100 pg / ml, optionally ≤10 pg / ml.

[0374] In another embodiment, the antibody may have an IC50 value for neutralization of HBV genotype A, B, C and / or D, optionally at least D, optionally all of A, B, C and D, which is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the IC50 value of reference antibody Bv4.115 against the same genotype, when assessed using the same assay (e.g., an in vitro neutralization assay as described herein).

[0375] In another embodiment, the antibody may have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the in vivo neutralizing activity of reference antibody Bv4.115 against HBV genotype A, B, C and / or D, optionally at least D, optionally all of A, B, C and D, when assessed using the same assay (e.g., an assay as described herein).

[0376] Optionally the antibody can suppress virus viremia in vivo e.g., in an individual infected with HBV genotype A, B, C or D, optionally D. Optionally, the antibody may have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the in vivo viremia suppressing activity of reference antibody Bv4.115 against HBV genotype A, B, C and / or D, optionally at least D, optionally all of A, B, C and D, when assessed using the same assay (e.g., an assay as described herein).I.

[0377] In one aspect, the invention provides an antibody comprising a VH domain comprising at least one, at least two, or all three VH CDR sequences selected from (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:145; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:146; and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:147. In another aspect, the antibody comprises a VH domain comprising the following CDRs (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:145; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:146; and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 147; or a variant thereof in which one, two or three amino acids in one or more of CDR-H1, CDR-H2 or CDR-H3 are substituted with another amino acid.

[0378] In one aspect, the VH domain may further comprise one or more heavy chain framework sequences selected from (a) a heavy chain frame work region 1 (HC-FR1) of SEQ ID NO: 151 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, (b) a heavy chain frame work region 2 (HC-FR2) of SEQ ID NO:152, or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto (c) a heavy chain frame work region 3 (HC-FR3) SEQ ID NO:153, or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto and (d) a heavy chain frame work region 4 (HC-FR4) of SEQ ID NO: 154 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto. Optionally, the VH domain comprises each of the heavy chain framework sequences as defined in (a) to (d). Optionally the percentage sequence identity is 95%. Optionally the percentage sequence identity is 98%.

[0379] In another aspect, an anti-S-HBs antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:160. In one aspect, an anti-S-HBs antibody comprises a heavy chain variable domain (VH) sequence having at least 95%, sequence identity to the amino acid sequence of SEQ ID NO:160. In certain aspects, a VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-S-HBs antibody comprising that sequence retains the ability to bind to S-HBs. In certain aspects, a total of 1 to 10 amino acids have been substituted, inserted and / or deleted in SEQ ID NO: 160. In certain aspects, substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs). Optionally, the anti-S-HBs antibody comprises the VH sequence in SEQ ID NO: 160, including post-translational modifications of that sequence. In a particular aspect, the VH comprises one, two or three CDRs selected from: (a) CDR-H1, comprising the amino acid sequence of SEQ ID NO 145, (b) CDR-H2, comprising the amino acid sequence of SEQ ID NO: 146, and (c) CDR-H3, comprising the amino acid sequence of SEQ ID NO: 147.

[0380] In another aspect, an anti-S-HBs antibody comprises one or more of the heavy chain CDR sequences of the VH of SEQ ID NO:160. In one aspect, an anti-S-HBs antibody comprises one or more (preferably all three) of the heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO: 160 and a framework of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity to the framework amino acid sequence of the VH domain of SEQ ID NO: 160. Optionally the sequence identity is 95% or 98%.

[0381] In another aspect, the invention provides an antibody comprising a VL domain comprising at least one, at least two, or all three VL CDR sequences selected from (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:148; (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 149; and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO:150. In another aspect, the antibody comprises a VL domain comprising the following CDRs (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:148; (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO:149; and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 150; or a variant thereof in which one, two or three amino acids in one or more of CDR-L1, CDR-L2 or CDR-L3 are substituted with another amino acid.

[0382] In one aspect, the anti-S-HBs antibody VL domain may further comprise one or more light chain framework sequences selected from (a) a light chain frame work region 1 (LC-FR1) of SEQ ID NO: 155 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, (b) a light chain frame work region 2 (LC-FR2) of SEQ ID NO:156 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, (c) a light chain frame work region 3 (LC-FR3) of SEQ ID NO:157 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, and (d) a light chain frame work region 4 (LC-FR4) of SEQ ID NO:158 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto. Optionally, the VL domain comprises each of the light chain framework sequences as defined in (a) to (d). Optionally the percentage sequence identity is 95%. Optionally the percentage sequence identity is 98%.

[0383] In another aspect, an anti-S-HBs antibody is provided, wherein the antibody comprises a light chain variable domain (VL) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:159. In one aspect, an anti-S-HBs antibody comprises a light chain variable domain (VL) sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 159. In certain aspects, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-S-HBs antibody comprising that sequence retains the ability to bind to S-HBs. In certain aspects, a total of 1 to 10 amino acids have been substituted, inserted and / or deleted in SEQ ID NO:159. In certain aspects, the substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs). Optionally, the anti-S-HBs antibody comprises the VL sequence in SEQ ID NO: 159, including post-translational modifications of that sequence. In a particular aspect, the VL comprises one, two or three CDRs selected from: (a) CDR-L1, comprising the amino acid sequence of SEQ ID NO:148, (b) CDR-L2, comprising the amino acid sequence of SEQ ID NO:149, and (c) CDR-L3, comprising the amino acid sequence of SEQ ID NO:150.

[0384] In another embodiment, an anti-S-HBs antibody comprises one or more of the CDR sequences of the VL of SEQ ID NO:159. In one aspect, an anti-S-HBs antibody comprises one or more (preferably all three) of the light chain CDR amino acid sequences of the VL domain of SEQ ID NO: 159 and a framework of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity to the framework amino acid sequence of the VL domain of SEQ ID NO:159. Optionally the sequence identity is 95% or 98%.

[0385] In another aspect, an anti-S-HBs antibody is provided, wherein the antibody comprises a VH sequence as in any of the aspects provided above, and a VL sequence as in any of the aspects provided above.

[0386] For instance, in one exemplary embodiment, the antibody comprises a VH domain comprising CDR-H3 of SEQ ID NO: 147; and a VL domain comprising CDR-L3 of SEQ ID NO: 150. Optionally the VH domain further comprises CDR-H2 of SEQ ID NO: 146.

[0387] In another exemplary embodiment, the antibody comprises:

[0388] i) a VH domain comprising the following CDRs (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:145; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 146; and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:147; or a variant thereof in which one, two or three amino acids in one or more of CDR-H1, CDR-H2 or CDR-H3 are substituted with another amino acid; and

[0389] ii) a VL domain comprising the following CDRs (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:148; (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 149; and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO:150; or a variant thereof in which one, two or three amino acids in one or more of CDR-L1, CDR-L2 or CDR-L3 are substituted with another amino acid.

[0390] In another exemplary embodiment, the antibody comprises:

[0391] i) a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 160; and

[0392] ii) a light chain variable domain (VL) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 159.

[0393] In another exemplary embodiment, the anti-S-HBs antibody comprises (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:145; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:146; (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 147; (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:148; (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:149; and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:150, and a VH domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 160, and a VL domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:159. In one aspect, the VH domain has at least 95% sequence identity to the amino acid sequence of SEQ ID NO:160. In one aspect, the VL domain has at least 95% sequence identity to the amino acid sequence of SEQ ID NO 159. In one embodiment, the antibody specifically binds to S-HBs. In another embodiment, the antibody binds to S-HBs having a dissociation constant (KD) that is up to 10 fold reduced or up to 10 fold increased when compared to the dissociation constant (KD) of an antibody comprising a VH sequence of SEQ ID NO:160 and a VL sequence of SEQ ID NO:159.

[0394] In one aspect, the antibody comprises the VH and VL sequences in SEQ ID NO:160 and SEQ ID NO:159, respectively, including post-translational modifications of those sequences.

[0395] In a further aspect, the antibody may comprise the full length light chain of SEQ ID NO: 161 and / or the full length heavy chain of SEQ ID NO: 162 or 271.

[0396] In a further aspect, the invention provides an antibody that binds to the same epitope as the anti-S-HBs antibody provided herein. For example, in certain aspects, an antibody is provided that binds to the same epitope as an anti-S-HBs antibody comprising a VH sequence of SEQ ID NO: 160 and a VL sequence of SEQ ID NO:159. In certain aspects, an antibody is provided that binds to one or more the following residues of S-HBs of SEQ ID NO: 253: C121, K141, D144, and / or G145. Optionally the antibody may further bind one or more of C139, C147, C149, I152 and / or W156. The antibody may comprise any of the sequences as defined above.

[0397] In a further aspect, the invention provides an antibody that competes for binding to S-HBs with an anti-S-HBs antibody provided herein.

[0398] Antibodies as described in this section may, in some embodiments, have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the binding activity of a reference antibody Bc1.229 to S-HBs (e.g., of SEQ ID NO:253), when assessed in the same assay, e.g., an ELISA or flow cytometry assay.

[0399] Additionally or alternatively, antibodies as described in this section may have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the binding activity of reference antibody Bc1.229 to one or more of the proteins of SEQ ID NO: 254-262 (e.g., to at least SEQ ID NO: 257), optionally each of the proteins of SEQ ID NO: 254 to 262, when assessed in the same assay, e.g., an ELISA or flow cytometry assay.

[0400] Reference antibody Bc1.229 has a VH sequence of SEQ ID NO: 160 and a VL sequence of SEQ ID NO:159. It has a full length heavy chain of SEQ ID NO 162 or 271 and a full length light chain of SEQ ID NO: 161. SEQ ID NO: 271 comprises the IgG1 constant region expressed by vector LT615368.1, as used in the examples.

[0401] In some embodiments, the antibody as described in this section may bind to S-HBs (e.g., of SEQ ID NO: 253) with a KD value which is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the KD value of reference antibody Bc1.229 to the same antigen, when assessed in the same assay.

[0402] Additionally or alternatively, the antibody may bind to one or more of SEQ ID NO: 254-262 (e.g., to at least SEQ ID NO: 257), optionally each of the proteins of SEQ ID NO: 254-262, with a KD value which is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the KD value of reference antibody Bc1.229 to the same antigen, when assessed in the same assay.

[0403] In some embodiments, the antibody as described in this section may bind to S-HBs (e.g., of SEQ ID NO: 253) with an EC50 that is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the EC50 of reference antibody Bc1.229, as measured by ELISA or by flow cytometry. Alternatively or additionally, the antibody may bind one or more, or to each of the proteins of SEQ ID NO: 254-262, optionally at least to a protein of SEQ ID NO: 257, with an EC50 that is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the EC50 of reference antibody Bc1.229, as measured by ELISA or by flow cytometry.

[0404] In some embodiments antibodies as described in this section may have or retain in vitro neutralizing activity against HBV genotype A, B, C and / or D, optionally all of A, B, C and D. For example, antibodies as described in this section may have or retain in vitro neutralizing activity against HBV genotype D, e.g., with an IC50 value of ≤1 ng / ml, optionally ≤100 pg / ml.

[0405] In another embodiment, the antibody may have an IC50 value for neutralization of HBV genotype A, B, C and / or D, optionally at least D, optionally all of A, B, C and D, which is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the IC50 value of reference antibody Bc1.229 against the same genotype, when assessed using the same assay (e.g., an in vitro neutralization assay as described herein).

[0406] In another embodiment, the antibody may have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the in vivo neutralizing activity of reference antibody Bc1.229 against HBV genotype A, B, C and / or D, optionally at least D, optionally all of A, B, C and D, when assessed using the same assay (e.g., an assay as described herein).

[0407] Optionally the antibody can suppress virus viremia in vivo e.g., in an individual infected with HBV genotype A, B, C or D, optionally D. Optionally, the antibody may have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the in vivo viremia suppressing activity of reference antibody Bc1.229 against HBV genotype A, B, C and / or D, optionally at least D, optionally all of A, B, C and D, when assessed using the same assay (e.g., an assay as described herein).J.

[0408] In one aspect, the invention provides an antibody comprising a VH domain comprising at least one, at least two, or all three VH CDR sequences selected from (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:163; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:164; and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:165. In another aspect, the antibody comprises a VH domain comprising the following CDRs (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:163; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:164; and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 165; or a variant thereof in which one, two or three amino acids in one or more of CDR-H1, CDR-H2 or CDR-H3 are substituted with another amino acid.

[0409] In one aspect, the VH domain may further comprise one or more heavy chain framework sequences selected from (a) a heavy chain frame work region 1 (HC-FR1) of SEQ ID NO: 169 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, (b) a heavy chain frame work region 2 (HC-FR2) of SEQ ID NO:170, or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto (c) a heavy chain frame work region 3 (HC-FR3) SEQ ID NO:171, or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto and (d) a heavy chain frame work region 4 (HC-FR4) of SEQ ID NO:172 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto. Optionally, the VH domain comprises each of the heavy chain framework sequences as defined in (a) to (d). Optionally the percentage sequence identity is 95%. Optionally the percentage sequence identity is 98%.

[0410] In another aspect, an anti-S-HBs antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 178. In one aspect, an anti-S-HBs antibody comprises a heavy chain variable domain (VH) sequence having at least 95%, sequence identity to the amino acid sequence of SEQ ID NO:178. In certain aspects, a VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-S-HBs antibody comprising that sequence retains the ability to bind to S-HBs. In certain aspects, a total of 1 to 10 amino acids have been substituted, inserted and / or deleted in SEQ ID NO: 178. In certain aspects, substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs). Optionally, the anti-S-HBs antibody comprises the VH sequence in SEQ ID NO: 178, including post-translational modifications of that sequence. In a particular aspect, the VH comprises one, two or three CDRs selected from: (a) CDR-H1, comprising the amino acid sequence of SEQ ID NO 163, (b) CDR-H2, comprising the amino acid sequence of SEQ ID NO: 164, and (c) CDR-H3, comprising the amino acid sequence of SEQ ID NO: 165.

[0411] In another aspect, an anti-S-HBs antibody comprises one or more of the heavy chain CDR sequences of the VH of SEQ ID NO:178. In one aspect, an anti-S-HBs antibody comprises one or more (preferably all three) of the heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO:178 and a framework of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity to the framework amino acid sequence of the VH domain of SEQ ID NO:178. Optionally the sequence identity is 95% or 98%.

[0412] In another aspect, the invention provides an antibody comprising a VL domain comprising at least one, at least two, or all three VL CDR sequences selected from (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:166; (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 167; and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO:168. In another aspect, the antibody comprises a VL domain comprising the following CDRs (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:166; (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 167; and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 168; or a variant thereof in which one, two or three amino acids in one or more of CDR-L1, CDR-L2 or CDR-L3 are substituted with another amino acid.

[0413] In one aspect, the anti-S-HBs antibody VL domain may further comprise one or more light chain framework sequences selected from (a) a light chain frame work region 1 (LC-FR1) of SEQ ID NO: 173 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, (b) a light chain frame work region 2 (LC-FR2) of SEQ ID NO:174 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, (c) a light chain frame work region 3 (LC-FR3) of SEQ ID NO:175 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, and (d) a light chain frame work region 4 (LC-FR4) of SEQ ID NO:176 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto. Optionally, the VL domain comprises each of the light chain framework sequences as defined in (a) to (d). Optionally the percentage sequence identity is 95%. Optionally the percentage sequence identity is 98%.

[0414] In another aspect, an anti-S-HBs antibody is provided, wherein the antibody comprises a light chain variable domain (VL) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 177. In one aspect, an anti-S-HBs antibody comprises a light chain variable domain (VL) sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 177. In certain aspects, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-S-HBs antibody comprising that sequence retains the ability to bind to S-HBs. In certain aspects, a total of 1 to 10 amino acids have been substituted, inserted and / or deleted in SEQ ID NO:177. In certain aspects, the substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs). Optionally, the anti-S-HBs antibody comprises the VL sequence in SEQ ID NO:177, including post-translational modifications of that sequence. In a particular aspect, the VL comprises one, two or three CDRs selected from: (a) CDR-L1, comprising the amino acid sequence of SEQ ID NO:166, (b) CDR-L2, comprising the amino acid sequence of SEQ ID NO:167, and (c) CDR-L3, comprising the amino acid sequence of SEQ ID NO:168.

[0415] In another embodiment, an anti-S-HBs antibody comprises one or more of the CDR sequences of the VL of SEQ ID NO:177. In one aspect, an anti-S-HBs antibody comprises one or more (preferably all three) of the light chain CDR amino acid sequences of the VL domain of SEQ ID NO: 177 and a framework of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity to the framework amino acid sequence of the VL domain of SEQ ID NO:177. Optionally the sequence identity is 95% or 98%.

[0416] In another aspect, an anti-S-HBs antibody is provided, wherein the antibody comprises a VH sequence as in any of the aspects provided above, and a VL sequence as in any of the aspects provided above.

[0417] For instance, in one exemplary embodiment, the antibody comprises a VH domain comprising CDR-H3 of SEQ ID NO: 165; and a VL domain comprising CDR-L3 of SEQ ID NO: 168. Optionally the VH domain further comprises CDR-H2 of SEQ ID NO: 164.

[0418] In another exemplary embodiment, the antibody comprises:

[0419] i) a VH domain comprising the following CDRs (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:163; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 164; and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:165; or a variant thereof in which one, two or three amino acids in one or more of CDR-H1, CDR-H2 or CDR-H3 are substituted with another amino acid; and

[0420] ii) a VL domain comprising the following CDRs (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:166; (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 167; and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO:168; or a variant thereof in which one, two or three amino acids in one or more of CDR-L1, CDR-L2 or CDR-L3 are substituted with another amino acid.

[0421] In another exemplary embodiment, the antibody comprises:

[0422] i) a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 178; and

[0423] ii) a light chain variable domain (VL) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 177.

[0424] In another exemplary embodiment, the anti-S-HBs antibody comprises (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:163; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:164; (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 165; (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:166; (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:167; and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:168, and a VH domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 178, and a VL domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:177. In one aspect, the VH domain has at least 95% sequence identity to the amino acid sequence of SEQ ID NO:178. In one aspect, the VL domain has at least 95% sequence identity to the amino acid sequence of SEQ ID NO 177. In one embodiment, the antibody specifically binds to S-HBs. In another embodiment, the antibody binds to S-HBs having a dissociation constant (KD) that is up to 10 fold reduced or up to 10 fold increased when compared to the dissociation constant (KD) of an antibody comprising a VH sequence of SEQ ID NO:178 and a VL sequence of SEQ ID NO:177.

[0425] In one aspect, the antibody comprises the VH and VL sequences in SEQ ID NO: 178 and SEQ ID NO:177, respectively, including post-translational modifications of those sequences.

[0426] In a further aspect, the antibody may comprise the full length light chain of SEQ ID NO: 179 and / or the full length heavy chain of SEQ ID NO: 180 or 272.

[0427] In a further aspect, the invention provides an antibody that binds to the same epitope as the anti-S-HBs antibody provided herein. For example, in certain aspects, an antibody is provided that binds to the same epitope as an anti-S-HBs antibody comprising a VH sequence of SEQ ID NO: 178 and a VL sequence of SEQ ID NO:177. In certain aspects, an antibody is provided that binds to the following residues of S-HBs of SEQ ID NO: 253: C121, C138, C139, C147 and / or C149. Optionally the antibody may additionally bind to one or more of L109, R122, T123, C124, M133, Y134, S136, K141 and / or I152. The antibody may comprise any of the sequences as defined above.

[0428] In a further aspect, the invention provides an antibody that competes for binding to S-HBs with an anti-S-HBs antibody provided herein.

[0429] Antibodies as described in this section may, in some embodiments, have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the binding activity of a reference antibody Bc8.159 to S-HBs (e.g., of SEQ ID NO:253), when assessed in the same assay, e.g., an ELISA assay or a flow cytometry assay.

[0430] Additionally or alternatively, antibodies as described in this section may have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the binding activity of reference antibody Bc8.159 to one or more of the proteins of SEQ ID NO: 254-262 (e.g., to at least SEQ ID NO: 257), optionally each of the proteins of SEQ ID NO: 254 to 262, when assessed in the same assay, e.g., an ELISA assay or a flow cytometry assay.

[0431] Reference antibody Bc8.159 has a VH sequence of SEQ ID NO:178 and a VL sequence of SEQ ID NO:177. It has a full length heavy chain of SEQ ID NO: 180 or 272 and a full length light chain of SEQ ID NO: 179. SEQ ID NO: 272 comprises the IgG1 constant region expressed by vector LT615368.1, as used in the examples.

[0432] In some embodiments, the antibody as described in this section may bind to S-HBs (e.g., of SEQ ID NO: 253) with a KD value which is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the KD value of reference antibody Bc8.159 to the same antigen, when assessed in the same assay.

[0433] Additionally or alternatively, the antibody may bind to one or more of SEQ ID NO: 254-262 (e.g., to at least SEQ ID NO: 257), optionally each of the proteins of SEQ ID NO: 254-262, with a KD value which is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the KD value of reference antibody Bc8.159 to the same antigen, when assessed in the same assay.

[0434] In some embodiments, the antibody as described in this section may bind to S-HBs (e.g., of SEQ ID NO: 253) with an EC50 that is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the EC50 of reference antibody Bc8.159, as measured by ELISA or by flow cytometry. Alternatively or additionally, the antibody may bind one or more, or to each of the proteins of SEQ ID NO: 254-262, optionally at least to a protein of SEQ ID NO: 257, with an EC50 that is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the EC50 of reference antibody Bc8.159, as measured by ELISA or by flow cytometry.

[0435] In some embodiments antibodies as described in this section may have or retain in vitro neutralizing activity against HBV genotype A, B, C and / or D, optionally all of A, B, C and D. For example, antibodies as described in this section may have or retain in vitro neutralizing activity against HBV genotype D, e.g., with an IC50 value of ≤1 ng / ml, optionally ≤100 pg / ml.

[0436] In another embodiment, the antibody may have an IC50 value for neutralization of HBV genotype A, B, C and / or D, optionally at least D, optionally all of A, B, C and D, which is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the IC50 value of reference antibody Bc8.159 against the same genotype, when assessed using the same assay (e.g., an in vitro neutralization assay as described herein).

[0437] In another embodiment, the antibody may have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the in vivo neutralizing activity of reference antibody Bc8.159 against HBV genotype A, B, C and / or D, optionally at least D, optionally all of A, B, C and D, when assessed using the same assay (e.g., an assay as described herein).

[0438] Optionally the antibody can suppress virus viremia in vivo e.g., in an individual infected with HBV genotype A, B, C or D, optionally D. Optionally, the antibody may have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the in vivo viremia suppressing activity of reference antibody Bc8.159 against HBV genotype A, B, C and / or D, optionally at least D, optionally all of A, B, C and D, when assessed using the same assay (e.g., an assay as described herein).K.

[0439] In one aspect, the invention provides an antibody comprising a VH domain comprising at least one, at least two, or all three VH CDR sequences selected from (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:181; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:182; and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:183. In another aspect, the antibody comprises a VH domain comprising the following CDRs (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:181; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:182; and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 183; or a variant thereof in which one, two or three amino acids in one or more of CDR-H1, CDR-H2 or CDR-H3 are substituted with another amino acid.

[0440] In one aspect, the VH domain may further comprise one or more heavy chain framework sequences selected from (a) a heavy chain frame work region 1 (HC-FR1) of SEQ ID NO: 187 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, (b) a heavy chain frame work region 2 (HC-FR2) of SEQ ID NO:188, or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto (c) a heavy chain frame work region 3 (HC-FR3) SEQ ID NO:189, or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto and (d) a heavy chain frame work region 4 (HC-FR4) of SEQ ID NO:190 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto. Optionally, the VH domain comprises each of the heavy chain framework sequences as defined in (a) to (d). Optionally the percentage sequence identity is 95%. Optionally the percentage sequence identity is 98%.

[0441] In another aspect, an anti-S-HBs antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 196. In one aspect, an anti-S-HBs antibody comprises a heavy chain variable domain (VH) sequence having at least 95%, sequence identity to the amino acid sequence of SEQ ID NO: 196. In certain aspects, a VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-S-HBs antibody comprising that sequence retains the ability to bind to S-HBs. In certain aspects, a total of 1 to 10 amino acids have been substituted, inserted and / or deleted in SEQ ID NO: 196. In certain aspects, substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs). Optionally, the anti-S-HBs antibody comprises the VH sequence in SEQ ID NO: 196, including post-translational modifications of that sequence. In a particular aspect, the VH comprises one, two or three CDRs selected from: (a) CDR-H1, comprising the amino acid sequence of SEQ ID NO 181, (b) CDR-H2, comprising the amino acid sequence of SEQ ID NO: 182, and (c) CDR-H3, comprising the amino acid sequence of SEQ ID NO: 183.

[0442] In another aspect, an anti-S-HBs antibody comprises one or more of the heavy chain CDR sequences of the VH of SEQ ID NO:196. In one aspect, an anti-S-HBs antibody comprises one or more (preferably all three) of the heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO:196 and a framework of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity to the framework amino acid sequence of the VH domain of SEQ ID NO: 196. Optionally the sequence identity is 95% or 98%.

[0443] In another aspect, the invention provides an antibody comprising a VL domain comprising at least one, at least two, or all three VL CDR sequences selected from (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:184; (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 185; and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO:186. In another aspect, the antibody comprises a VL domain comprising the following CDRs (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:184; (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO:185; and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 186; or a variant thereof in which one, two or three amino acids in one or more of CDR-L1, CDR-L2 or CDR-L3 are substituted with another amino acid.

[0444] In one aspect, the anti-S-HBs antibody VL domain may further comprise one or more light chain framework sequences selected from (a) a light chain frame work region 1 (LC-FR1) of SEQ ID NO: 191 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, (b) a light chain frame work region 2 (LC-FR2) of SEQ ID NO:192 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, (c) a light chain frame work region 3 (LC-FR3) of SEQ ID NO:193 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, and (d) a light chain frame work region 4 (LC-FR4) of SEQ ID NO:194 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto. Optionally, the VL domain comprises each of the light chain framework sequences as defined in (a) to (d). Optionally the percentage sequence identity is 95%. Optionally the percentage sequence identity is 98%.

[0445] In another aspect, an anti-S-HBs antibody is provided, wherein the antibody comprises a light chain variable domain (VL) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 195. In one aspect, an anti-S-HBs antibody comprises a light chain variable domain (VL) sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:195. In certain aspects, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-S-HBs antibody comprising that sequence retains the ability to bind to S-HBs. In certain aspects, a total of 1 to 10 amino acids have been substituted, inserted and / or deleted in SEQ ID NO:195. In certain aspects, the substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs). Optionally, the anti-S-HBs antibody comprises the VL sequence in SEQ ID NO: 195, including post-translational modifications of that sequence. In a particular aspect, the VL comprises one, two or three CDRs selected from: (a) CDR-L1, comprising the amino acid sequence of SEQ ID NO:184, (b) CDR-L2, comprising the amino acid sequence of SEQ ID NO:185, and (c) CDR-L3, comprising the amino acid sequence of SEQ ID NO:186.

[0446] In another embodiment, an anti-S-HBs antibody comprises one or more of the CDR sequences of the VL of SEQ ID NO:195. In one aspect, an anti-S-HBs antibody comprises one or more (preferably all three) of the light chain CDR amino acid sequences of the VL domain of SEQ ID NO: 195 and a framework of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity to the framework amino acid sequence of the VL domain of SEQ ID NO:195. Optionally the sequence identity is 95% or 98%.

[0447] In another aspect, an anti-S-HBs antibody is provided, wherein the antibody comprises a VH sequence as in any of the aspects provided above, and a VL sequence as in any of the aspects provided above.

[0448] For instance, in one exemplary embodiment, the antibody comprises a VH domain comprising CDR-H3 of SEQ ID NO:183; and a VL domain comprising CDR-L3 of SEQ ID NO: 186. Optionally the VH domain further comprises CDR-H2 of SEQ ID NO: 182.

[0449] In another exemplary embodiment, the antibody comprises:

[0450] i) a VH domain comprising the following CDRs (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:181; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 182; and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:183; or a variant thereof in which one, two or three amino acids in one or more of CDR-H1, CDR-H2 or CDR-H3 are substituted with another amino acid; and

[0451] ii) a VL domain comprising the following CDRs (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:184; (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 185; and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO:186; or a variant thereof in which one, two or three amino acids in one or more of CDR-L1, CDR-L2 or CDR-L3 are substituted with another amino acid.

[0452] In another exemplary embodiment, the antibody comprises:

[0453] i) a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 196; and

[0454] ii) a light chain variable domain (VL) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 195.

[0455] In another exemplary embodiment, the anti-S-HBs antibody comprises (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:181; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:182; (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 183; (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:184; (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:185; and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:186, and a VH domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 196, and a VL domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:195. In one aspect, the VH domain has at least 95% sequence identity to the amino acid sequence of SEQ ID NO:196. In one aspect, the VL domain has at least 95% sequence identity to the amino acid sequence of SEQ ID NO 195. In one embodiment, the antibody specifically binds to S-HBs. In another embodiment, the antibody binds to S-HBs having a dissociation constant (KD) that is up to 10 fold reduced or up to 10 fold increased when compared to the dissociation constant (KD) of an antibody comprising a VH sequence of SEQ ID NO:196 and a VL sequence of SEQ ID NO:195.

[0456] In one aspect, the antibody comprises the VH and VL sequences in SEQ ID NO: 196 and SEQ ID NO:195, respectively, including post-translational modifications of those sequences.

[0457] In a further aspect, the antibody may comprise the full length light chain of SEQ ID NO: 197 and / or the full length heavy chain of SEQ ID NO: 198 or 273.

[0458] In a further aspect, the invention provides an antibody that binds to the same epitope as the anti-S-HBs antibody provided herein. For example, in certain aspects, an antibody is provided that binds to the same epitope as an anti-S-HBs antibody comprising a VH sequence of SEQ ID NO: 196 and a VL sequence of SEQ ID NO:195. In certain aspects, an antibody is provided that binds to the following residues of S-HBs of SEQ ID NO: 253: C121, C124, C137, C138, C139, C147 and / or C149, optionally also to I152. Optionally the antibody further binds to one or more of V106, P108, W156 and / or F161. The antibody may comprise any of the sequences as defined above.

[0459] In a further aspect, the invention provides an antibody that competes for binding to S-HBs with an anti-S-HBs antibody provided herein.

[0460] Antibodies as described in this section may, in some embodiments, have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the binding activity of a reference antibody Bc1.128 to S-HBs (e.g., of SEQ ID NO:253), when assessed in the same assay e.g., an ELISA assay or a flow cytometry assay.

[0461] Additionally or alternatively, antibodies as described in this section may have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the binding activity of reference antibody Bc1.128 to one or more of the proteins of SEQ ID NO: 254-262 (e.g., to at least SEQ ID NO: 257), optionally each of the proteins of SEQ ID NO: 254 to 262, when assessed in the same assay e.g., an ELISA assay or a flow cytometry assay.

[0462] Reference antibody Bc1.128 has a VH sequence of SEQ ID NO: 196 and a VL sequence of SEQ ID NO:195. It has a full length heavy chain of SEQ ID NO: 198 or 273 and a full length light chain of SEQ ID NO: 197. SEQ ID NO: 273 comprises the IgG1 constant region expressed by vector LT615368.1, as used in the examples.

[0463] In some embodiments, the antibody described in this section may bind to S-HBs (e.g., of SEQ ID NO: 253) with a KD value which is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the KD value of reference antibody Bc1.128 to the same antigen, when assessed in the same assay.

[0464] Additionally or alternatively, the antibody may bind to one or more of SEQ ID NO: 254-262 (e.g., to at least SEQ ID NO: 257), optionally each of the proteins of SEQ ID NO: 254-262, with a KD value which is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the KD value of reference antibody Bc1.128 to the same antigen, when assessed in the same assay.

[0465] In some embodiments, the antibody as described in this section may bind to S-HBs (e.g., of SEQ ID NO: 253) with an EC50 that is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the EC50 of reference antibody Bc1.128, as measured by ELISA or by flow cytometry. Alternatively or additionally, the antibody may bind one or more, or to each of the proteins of SEQ ID NO: 254-262, optionally at least to a protein of SEQ ID NO: 257, with an EC50 that is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the EC50 of reference antibody Bc1.128, as measured by ELISA or by flow cytometry.

[0466] In some embodiments antibodies as described in this section may have or retain in vitro neutralizing activity against HBV genotype A, B, C and / or D, optionally all of A, B, C and D. For example, antibodies as described in this section may have or retain in vitro neutralizing activity against HBV genotype D, e.g., with an IC50 value of ≤10 ng / ml, optionally ≤1 ng / ml.

[0467] In another embodiment, the antibody may have an IC50 value for neutralization of HBV genotype A, B, C and / or D, optionally at least D, optionally all of A, B, C and D, which is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the IC50 value of reference antibody Bc1.128 against the same genotype, when assessed using the same assay (e.g., an in vitro neutralization assay as described herein).

[0468] In another embodiment, the antibody may have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the in vivo neutralizing activity of reference antibody Bc1.128 against HBV genotype A, B, C and / or D, optionally at least D, optionally all of A, B, C and D, when assessed using the same assay (e.g., an assay as described herein).

[0469] Optionally the antibody can suppress virus viremia in vivo e.g., in an individual infected with HBV genotype A, B, C or D, optionally D. Optionally, the antibody may have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the in vivo viremia suppressing activity of reference antibody Bc1.128 against HBV genotype A, B, C and / or D, optionally at least D, optionally all of A, B, C and D, when assessed using the same assay (e.g., an assay as described herein).L.

[0470] In one aspect, the invention provides an antibody comprising a VH domain comprising at least one, at least two, or all three VH CDR sequences selected from (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:199; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:200; and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:201. In another aspect, the antibody comprises a VH domain comprising the following CDRs (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:199; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:200; and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 201; or a variant thereof in which one, two or three amino acids in one or more of CDR-H1, CDR-H2 or CDR-H3 are substituted with another amino acid.

[0471] In one aspect, the VH domain may further comprise one or more heavy chain framework sequences selected from (a) a heavy chain frame work region 1 (HC-FR1) of SEQ ID NO: 205 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, (b) a heavy chain frame work region 2 (HC-FR2) of SEQ ID NO:206, or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto (c) a heavy chain frame work region 3 (HC-FR3) SEQ ID NO:207, or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto and (d) a heavy chain frame work region 4 (HC-FR4) of SEQ ID NO:208 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto. Optionally, the VH domain comprises each of the heavy chain framework sequences as defined in (a) to (d). Optionally the percentage sequence identity is 95%. Optionally the percentage sequence identity is 98%.

[0472] In another aspect, an anti-S-HBs antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:214. In one aspect, an anti-S-HBs antibody comprises a heavy chain variable domain (VH) sequence having at least 95%, sequence identity to the amino acid sequence of SEQ ID NO: 214. In certain aspects, a VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-S-HBs antibody comprising that sequence retains the ability to bind to S-HBs. In certain aspects, a total of 1 to 10 amino acids have been substituted, inserted and / or deleted in SEQ ID NO: 214. In certain aspects, substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs). Optionally, the anti-S-HBs antibody comprises the VH sequence in SEQ ID NO: 214, including post-translational modifications of that sequence. In a particular aspect, the VH comprises one, two or three CDRs selected from: (a) CDR-H1, comprising the amino acid sequence of SEQ ID NO 199, (b) CDR-H2, comprising the amino acid sequence of SEQ ID NO: 200, and (c) CDR-H3, comprising the amino acid sequence of SEQ ID NO: 201.

[0473] In another aspect, an anti-S-HBs antibody comprises one or more of the heavy chain CDR sequences of the VH of SEQ ID NO:214. In one aspect, an anti-S-HBs antibody comprises one or more (preferably all three) of the heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO:214 and a framework of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity to the framework amino acid sequence of the VH domain of SEQ ID NO:214. Optionally the sequence identity is 95% or 98%.

[0474] In another aspect, the invention provides an antibody comprising a VL domain comprising at least one, at least two, or all three VL CDR sequences selected from (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:202; (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 203; and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO:204. In another aspect, the antibody comprises a VL domain comprising the following CDRs (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:202; (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO:203; and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 204; or a variant thereof in which one, two or three amino acids in one or more of CDR-L1, CDR-L2 or CDR-L3 are substituted with another amino acid.

[0475] In one aspect, the anti-S-HBs antibody VL domain may further comprise one or more light chain framework sequences selected from (a) a light chain frame work region 1 (LC-FR1) of SEQ ID NO: 209 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, (b) a light chain frame work region 2 (LC-FR2) of SEQ ID NO:210 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, (c) a light chain frame work region 3 (LC-FR3) of SEQ ID NO:211 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, and (d) a light chain frame work region 4 (LC-FR4) of SEQ ID NO:212 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto. Optionally, the VL domain comprises each of the light chain framework sequences as defined in (a) to (d). Optionally the percentage sequence identity is 95%. Optionally the percentage sequence identity is 98%.

[0476] In another aspect, an anti-S-HBs antibody is provided, wherein the antibody comprises a light chain variable domain (VL) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:213. In one aspect, an anti-S-HBs antibody comprises a light chain variable domain (VL) sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:213. In certain aspects, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-S-HBs antibody comprising that sequence retains the ability to bind to S-HBs. In certain aspects, a total of 1 to 10 amino acids have been substituted, inserted and / or deleted in SEQ ID NO:213. In certain aspects, the substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs). Optionally, the anti-S-HBs antibody comprises the VL sequence in SEQ ID NO:213, including post-translational modifications of that sequence. In a particular aspect, the VL comprises one, two or three CDRs selected from: (a) CDR-L1, comprising the amino acid sequence of SEQ ID NO:202, (b) CDR-L2, comprising the amino acid sequence of SEQ ID NO:203, and (c) CDR-L3, comprising the amino acid sequence of SEQ ID NO:204.

[0477] In another embodiment, an anti-S-HBs antibody comprises one or more of the CDR sequences of the VL of SEQ ID NO:213. In one aspect, an anti-S-HBs antibody comprises one or more (preferably all three) of the light chain CDR amino acid sequences of the VL domain of SEQ ID NO: 213 and a framework of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity to the framework amino acid sequence of the VL domain of SEQ ID NO:213. Optionally the sequence identity is 95% or 98%.

[0478] In another aspect, an anti-S-HBs antibody is provided, wherein the antibody comprises a VH sequence as in any of the aspects provided above, and a VL sequence as in any of the aspects provided above.

[0479] For instance, in one exemplary embodiment, the antibody comprises a VH domain comprising CDR-H3 of SEQ ID NO:201; and a VL domain comprising CDR-L3 of SEQ ID NO: 204. Optionally the VH domain further comprises CDR-H2 of SEQ ID NO: 200.

[0480] In another exemplary embodiment, the antibody comprises:

[0481] i) a VH domain comprising the following CDRs (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:199; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 200; and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:201; or a variant thereof in which one, two or three amino acids in one or more of CDR-H1, CDR-H2 or CDR-H3 are substituted with another amino acid; and

[0482] ii) a VL domain comprising the following CDRs (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:202; (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 203; and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO:204; or a variant thereof in which one, two or three amino acids in one or more of CDR-L1, CDR-L2 or CDR-L3 are substituted with another amino acid.

[0483] In another exemplary embodiment, the antibody comprises:

[0484] i) a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 214; and

[0485] ii) a light chain variable domain (VL) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 213.

[0486] In another exemplary embodiment, the anti-S-HBs antibody comprises (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:199; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:200; (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 201; (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:202; (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:203; and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:204, and a VH domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 214, and a VL domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:213. In one aspect, the VH domain has at least 95% sequence identity to the amino acid sequence of SEQ ID NO:214. In one aspect, the VL domain has at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 213. In one embodiment, the antibody specifically binds to S-HBs. In another embodiment, the antibody binds to S-HBs having a dissociation constant (KD) that is up to 10 fold reduced or up to 10 fold increased when compared to the dissociation constant (KD) of an antibody comprising a VH sequence of SEQ ID NO:214 and a VL sequence of SEQ ID NO:213.

[0487] In one aspect, the antibody comprises the VH and VL sequences in SEQ ID NO:214 and SEQ ID NO:213, respectively, including post-translational modifications of those sequences.

[0488] In a further aspect, the antibody may comprise the full length light chain of SEQ ID NO: 215 and / or the full length heavy chain of SEQ ID NO: 216 or 274.

[0489] In a further aspect, the invention provides an antibody that binds to the same epitope as the anti-S-HBs antibody provided herein. For example, in certain aspects, an antibody is provided that binds to the same epitope as an anti-S-HBs antibody comprising a VH sequence of SEQ ID NO: 214 and a VL sequence of SEQ ID NO:213. In certain aspects, an antibody is provided that binds to residue F179 of S-HBs of SEQ ID NO:253. The antibody may comprise any of the sequences as defined above.

[0490] In a further aspect, the invention provides an antibody that competes for binding to S-HBs with an anti-S-HBs antibody provided herein.

[0491] Antibodies as described in this section may, in some embodiments, have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the binding activity of a reference antibody Bc4.204 to S-HBs (e.g., of SEQ ID NO: 253), when assessed in the same assay e.g., an ELISA assay or a flow cytometry assay. Additionally or alternatively, antibodies as described in this section may have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the binding activity of reference antibody Bc4.204 to proteins having the sequence of SEQ ID NO: 254, 255, 256, 257, 258, 260 and / or 262, when assessed in the same assay, optionally at least to SEQ ID NO: 257 e.g., an ELISA assay or a flow cytometry assay.

[0492] Reference antibody Bc4.204 has a VH sequence of SEQ ID NO:214 and a VL sequence of SEQ ID NO:213. It has a full length heavy chain of SEQ ID NO: 216 or 274 and a full length light chain of SEQ ID NO: 215. SEQ ID NO: 274 comprises the IgG1 constant region expressed by vector LT615368.1, as used in the examples.

[0493] In some embodiments, the antibody described in this section may bind to S-HBs (e.g., of SEQ ID NO: 253) with a KD value which is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the KD value of reference antibody Bc4.204 to the same antigen, when assessed in the same assay. Additionally or alternatively, the antibody may bind to one or more of SEQ ID NO: 254, 255, 256, 257, 258, 260 and / or 262 (e.g., to at least SEQ ID NO: 257), optionally each of the proteins of SEQ ID NO: 254-262, with a KD value which is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the KD value of reference antibody Bc4.204 to the same antigen, when assessed in the same assay.

[0494] In some embodiments, the antibody as described in this section may bind to S-HBs (e.g., of SEQ ID NO: 253) with an EC50 that is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the EC50 of reference antibody Bc4.204, as measured by ELISA or by flow cytometry. Alternatively or additionally, the antibody may bind one or more, or to each of, the proteins having the sequence of SEQ ID NO: 254, 255, 256, 257, 258, 260 and / or 262, optionally at least to a protein of SEQ ID NO: 257, with an EC50 that is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the EC50 of reference antibody Bc4.204, as measured by ELISA or by flow cytometry.

[0495] In some embodiments antibodies as described in this section may have or retain in vitro neutralizing activity against HBV genotype A, B, C and / or D, optionally all of A, B, C and D. For example, antibodies as described in this section may have or retain in vitro neutralizing activity against HBV genotype D, e.g., with an IC50 value of ≤10 ng / ml, optionally ≤1 ng / ml.

[0496] In another embodiment, the antibody may have an IC50 value for neutralization of HBV genotype A, B, C and / or D, optionally at least D, optionally all of A, B, C and D, which is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the IC50 value of reference antibody Bc4.204 against the same genotype, when assessed using the same assay (e.g., an in vitro neutralization assay as described herein).

[0497] In another embodiment, the antibody may have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the in vivo neutralizing activity of reference antibody Bc4.204 against HBV genotype A, B, C and / or D, optionally at least D, optionally all of A, B, C and D, when assessed using the same assay (e.g., an assay as described herein).

[0498] Optionally the antibody can suppress virus viremia in vivo e.g., in an individual infected with HBV genotype A, B, C or D, optionally D. Optionally, the antibody may have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the in vivo viremia suppressing activity of reference antibody Bc4.204 against HBV genotype A, B, C and / or D, optionally at least D, optionally all of A, B, C and D, when assessed using the same assay (e.g., an assay as described herein).M.

[0499] In one aspect, the invention provides an antibody comprising a VH domain comprising at least one, at least two, or all three VH CDR sequences selected from (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:217; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:218; and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:219. In another aspect, the antibody comprises a VH domain comprising the following CDRs (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:217; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:218; and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 219; or a variant thereof in which one, two or three amino acids in one or more of CDR-H1, CDR-H2 or CDR-H3 are substituted with another amino acid.

[0500] In one aspect, the VH domain may further comprise one or more heavy chain framework sequences selected from (a) a heavy chain frame work region 1 (HC-FR1) of SEQ ID NO: 223 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, (b) a heavy chain frame work region 2 (HC-FR2) of SEQ ID NO:224, or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto (c) a heavy chain frame work region 3 (HC-FR3) SEQ ID NO:225, or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto and (d) a heavy chain frame work region 4 (HC-FR4) of SEQ ID NO:226 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto. Optionally, the VH domain comprises each of the heavy chain framework sequences as defined in (a) to (d). Optionally the percentage sequence identity is 95%. Optionally the percentage sequence identity is 98%.

[0501] In another aspect, an anti-S-HBs antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:232. In one aspect, an anti-S-HBs antibody comprises a heavy chain variable domain (VH) sequence having at least 95%, sequence identity to the amino acid sequence of SEQ ID NO: 232. In certain aspects, a VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-S-HBs antibody comprising that sequence retains the ability to bind to S-HBs. In certain aspects, a total of 1 to 10 amino acids have been substituted, inserted and / or deleted in SEQ ID NO: 232. In certain aspects, substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs). Optionally, the anti-S-HBs antibody comprises the VH sequence in SEQ ID NO: 232, including post-translational modifications of that sequence. In a particular aspect, the VH comprises one, two or three CDRs selected from: (a) CDR-H1, comprising the amino acid sequence of SEQ ID NO 217, (b) CDR-H2, comprising the amino acid sequence of SEQ ID NO: 218, and (c) CDR-H3, comprising the amino acid sequence of SEQ ID NO: 219.

[0502] In another aspect, an anti-S-HBs antibody comprises one or more of the heavy chain CDR sequences of the VH of SEQ ID NO:232. In one aspect, an anti-S-HBs antibody comprises one or more (preferably all three) of the heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO:232 and a framework of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity to the framework amino acid sequence of the VH domain of SEQ ID NO:232. Optionally the sequence identity is 95% or 98%.

[0503] In another aspect, the invention provides an antibody comprising a VL domain comprising at least one, at least two, or all three VL CDR sequences selected from (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:220; (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 221; and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO:222. In another aspect, the antibody comprises a VL domain comprising the following CDRs (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:220; (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO:221; and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 222; or a variant thereof in which one, two or three amino acids in one or more of CDR-L1, CDR-L2 or CDR-L3 are substituted with another amino acid.

[0504] In one aspect, the anti-S-HBs antibody VL domain may further comprise one or more light chain framework sequences selected from (a) a light chain frame work region 1 (LC-FR1) of SEQ ID NO: 227 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, (b) a light chain frame work region 2 (LC-FR2) of SEQ ID NO:228 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, (c) a light chain frame work region 3 (LC-FR3) of SEQ ID NO:229 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, and (d) a light chain frame work region 4 (LC-FR4) of SEQ ID NO:230 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto. Optionally, the VL domain comprises each of the light chain framework sequences as defined in (a) to (d). Optionally the percentage sequence identity is 95%. Optionally the percentage sequence identity is 98%.

[0505] In another aspect, an anti-S-HBs antibody is provided, wherein the antibody comprises a light chain variable domain (VL) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:231. In one aspect, an anti-S-HBs antibody comprises a light chain variable domain (VL) sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:231. In certain aspects, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-S-HBs antibody comprising that sequence retains the ability to bind to S-HBs. In certain aspects, a total of 1 to 10 amino acids have been substituted, inserted and / or deleted in SEQ ID NO:231. In certain aspects, the substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs). Optionally, the anti-S-HBs antibody comprises the VL sequence in SEQ ID NO:231, including post-translational modifications of that sequence. In a particular aspect, the VL comprises one, two or three CDRs selected from: (a) CDR-L1, comprising the amino acid sequence of SEQ ID NO:220, (b) CDR-L2, comprising the amino acid sequence of SEQ ID NO:221, and (c) CDR-L3, comprising the amino acid sequence of SEQ ID NO:222.

[0506] In another embodiment, an anti-S-HBs antibody comprises one or more of the CDR sequences of the VL of SEQ ID NO:231. In one aspect, an anti-S-HBs antibody comprises one or more (preferably all three) of the light chain CDR amino acid sequences of the VL domain of SEQ ID NO: 231 and a framework of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity to the framework amino acid sequence of the VL domain of SEQ ID NO:231. Optionally the sequence identity is 95% or 98%.

[0507] In another aspect, an anti-S-HBs antibody is provided, wherein the antibody comprises a VH sequence as in any of the aspects provided above, and a VL sequence as in any of the aspects provided above.

[0508] For instance, in one exemplary embodiment, the antibody comprises a VH domain comprising CDR-H3 of SEQ ID NO:219; and a VL domain comprising CDR-L3 of SEQ ID NO: 222. Optionally the VH domain further comprises CDR-H2 of SEQ ID NO: 218.

[0509] In another exemplary embodiment, the antibody comprises:

[0510] i) a VH domain comprising the following CDRs (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:217; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 218; and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:219; or a variant thereof in which one, two or three amino acids in one or more of CDR-H1, CDR-H2 or CDR-H3 are substituted with another amino acid; and

[0511] ii) a VL domain comprising the following CDRs (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:220; (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 221; and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO:222; or a variant thereof in which one, two or three amino acids in one or more of CDR-L1, CDR-L2 or CDR-L3 are substituted with another amino acid.

[0512] In another exemplary embodiment, the antibody comprises:

[0513] i) a heavy chain variable domain (VI) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 232; and

[0514] ii) a light chain variable domain (VL) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 231.

[0515] In another exemplary embodiment, the anti-S-HBs antibody comprises (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:217; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:218; (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 219; (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:220; (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:221; and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:222, and a VH domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 232, and a VL domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:231. In one aspect, the VH domain has at least 95% sequence identity to the amino acid sequence of SEQ ID NO:232. In one aspect, the VL domain has at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 231. In one embodiment, the antibody specifically binds to S-HBs. In another embodiment, the antibody binds to S-HBs having a dissociation constant (KD) that is up to 10 fold reduced or up to 10 fold increased when compared to the dissociation constant (KD) of an antibody comprising a VH sequence of SEQ ID NO:232 and a VL sequence of SEQ ID NO:231.

[0516] In one aspect, the antibody comprises the VH and VL sequences in SEQ ID NO:232 and SEQ ID NO:231, respectively, including post-translational modifications of those sequences.

[0517] In a further aspect, the antibody may comprise the full length light chain of SEQ ID NO: 233 and / or the full length heavy chain of SEQ ID NO: 234 or 275.

[0518] In a further aspect, the invention provides an antibody that binds to the same epitope as the anti-S-HBs antibody provided herein. For example, in certain aspects, an antibody is provided that binds to the same epitope as an anti-S-HBs antibody comprising a VH sequence of SEQ ID NO: 232 and a VL sequence of SEQ ID NO:231. In certain aspects, an antibody is provided that binds to the following residues of S-HBs of SEQ ID NO: 253: W165 and / or R169, and optionally M103. The antibody may comprise any of the sequences as defined above.

[0519] In a further aspect, the invention provides an antibody that competes for binding to S-HBs with an anti-S-HBs antibody provided herein.

[0520] Antibodies as described in this section may, in some embodiments, have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the binding activity of a reference antibody Bc1.263 to S-HBs (e.g., of SEQ ID NO: 253), when assessed in the same assay, e.g., an ELISA assay or a flow cytometry assay.

[0521] Additionally or alternatively, antibodies as described in this section may have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the binding activity of reference antibody Bc1.263 to one or more of the proteins of SEQ ID NO: 254-262 (e.g., to at least SEQ ID NO: 257), optionally to each of the proteins of SEQ ID NO: 254 to 262, when assessed in the same assay, e.g., an ELISA assay or a flow cytometry assay.

[0522] Reference antibody Bc1.263 has a VH sequence of SEQ ID NO:232 and a VL sequence of SEQ ID NO:231. It has a full length heavy chain of SEQ ID NO: 234 or 275 and a full length light chain of SEQ ID NO: 233. SEQ ID NO: 275 comprises the IgG1 constant region expressed by vector LT615368.1, as used in the examples.

[0523] In some embodiments, the antibody as described in this section may bind to S-HBs (e.g., of SEQ ID NO: 253) with a KD value which is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the KD value of reference antibody Bc1.263 to the same antigen, when assessed in the same assay.

[0524] Additionally or alternatively, the antibody may bind to one or more of SEQ ID NO: 254-262 (e.g., to at least SEQ ID NO: 257), optionally each of the proteins of SEQ ID NO: 254-262, with a KD value which is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the KD value of reference antibody Bc1.263 to the same antigen, when assessed in the same assay.

[0525] In some embodiments, the antibody as described in this section may bind to S-HBs (e.g., of SEQ ID NO: 253) with an EC50 that is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the EC50 of reference antibody Bc1.263, as measured by ELISA or by flow cytometry. Alternatively or additionally, the antibody may bind one or more, or to each of the proteins of SEQ ID NO: 254-262, optionally at least to a protein of SEQ ID NO: 257, with an EC50 that is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the EC50 of reference antibody Bc1.263, as measured by ELISA or by flow cytometry.

[0526] In some embodiments antibodies as described in this section may have or retain in vitro neutralizing activity against HBV genotype A, B, C and / or D, optionally all of A, B, C and D. For example, antibodies as described in this section may have or retain in vitro neutralizing activity against HBV genotype D, e.g., with an IC50 value of ≤100 pg / ml, optionally ≤10 pg / ml.

[0527] In another embodiment, the antibody may have an IC50 value for neutralization of HBV genotype A, B, C and / or D, optionally at least D, optionally all of A, B, C and D, which is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the IC50 value of reference antibody Bc1.263 against the same genotype, when assessed using the same assay (e.g., an in vitro neutralization assay as described herein).

[0528] In another embodiment, the antibody may have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the neutralizing activity of reference antibody Bc1.263 against HBV genotype A, B, C and / or D, optionally at least D, optionally all of A, B, C and D, when assessed using the same assay (e.g., an assay as described herein).

[0529] Optionally the antibody can suppress virus viremia in vivo e.g., in an individual infected with HBV genotype A, B, C or D, optionally D. Optionally, the antibody may have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the in vivo viremia suppressing activity of reference antibody Bc1.263 against HBV genotype A, B, C and / or D, optionally at least D, optionally all of A, B, C and D, when assessed using the same assay (e.g., an assay as described herein).N.

[0530] In one aspect, the invention provides an antibody comprising a VH domain comprising at least one, at least two, or all three VH CDR sequences selected from (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:235; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:236; and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:237. In another aspect, the antibody comprises a VH domain comprising the following CDRs (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:235; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:236; and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 237; or a variant thereof in which one, two or three amino acids in one or more of CDR-H1, CDR-H2 or CDR-H3 are substituted with another amino acid.

[0531] In one aspect, the VH domain may further comprise one or more heavy chain framework sequences selected from (a) a heavy chain frame work region 1 (HC-FR1) of SEQ ID NO: 241 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, (b) a heavy chain frame work region 2 (HC-FR2) of SEQ ID NO:242, or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto (c) a heavy chain frame work region 3 (HC-FR3) SEQ ID NO:243, or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto and (d) a heavy chain frame work region 4 (HC-FR4) of SEQ ID NO:244 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto. Optionally, the VH domain comprises each of the heavy chain framework sequences as defined in (a) to (d). Optionally the percentage sequence identity is 95%. Optionally the percentage sequence identity is 98%.

[0532] In another aspect, an anti-S-HBs antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:250. In one aspect, an anti-S-HBs antibody comprises a heavy chain variable domain (VH) sequence having at least 95%, sequence identity to the amino acid sequence of SEQ ID NO: 250. In certain aspects, a VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-S-HBs antibody comprising that sequence retains the ability to bind to S-HBs. In certain aspects, a total of 1 to 10 amino acids have been substituted, inserted and / or deleted in SEQ ID NO: 250. In certain aspects, substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs). Optionally, the anti-S-HBs antibody comprises the VH sequence in SEQ ID NO: 250, including post-translational modifications of that sequence. In a particular aspect, the VH comprises one, two or three CDRs selected from: (a) CDR-H1, comprising the amino acid sequence of SEQ ID NO 235, (b) CDR-H2, comprising the amino acid sequence of SEQ ID NO: 236, and (c) CDR-H3, comprising the amino acid sequence of SEQ ID NO: 237.

[0533] In another aspect, an anti-S-HBs antibody comprises one or more of the heavy chain CDR sequences of the VH of SEQ ID NO:250. In one aspect, an anti-S-HBs antibody comprises one or more (preferably all three) of the heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO:250 and a framework of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity to the framework amino acid sequence of the VH domain of SEQ ID NO:250. Optionally the sequence identity is 95% or 98%.

[0534] In another aspect, the invention provides an antibody comprising a VL domain comprising at least one, at least two, or all three VL CDR sequences selected from (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:238; (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 239; and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO:240. In another aspect, the antibody comprises a VL domain comprising the following CDRs (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:238; (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO:239; and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 240; or a variant thereof in which one, two or three amino acids in one or more of CDR-L1, CDR-L2 or CDR-L3 are substituted with another amino acid.

[0535] In one aspect, the anti-S-HBs antibody VL domain may further comprise one or more light chain framework sequences selected from (a) a light chain frame work region 1 (LC-FR1) of SEQ ID NO: 245 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, (b) a light chain frame work region 2 (LC-FR2) of SEQ ID NO:246 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, (c) a light chain frame work region 3 (LC-FR3) of SEQ ID NO:247 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, and (d) a light chain frame work region 4 (LC-FR4) of SEQ ID NO:248 or a variant having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto. Optionally, the VL domain comprises each of the light chain framework sequences as defined in (a) to (d). Optionally the percentage sequence identity is 95%. Optionally the percentage sequence identity is 98%.

[0536] In another aspect, an anti-S-HBs antibody is provided, wherein the antibody comprises a light chain variable domain (VL) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:249. In one aspect, an anti-S-HBs antibody comprises a light chain variable domain (VL) sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:249. In certain aspects, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-S-HBs antibody comprising that sequence retains the ability to bind to S-HBs. In certain aspects, a total of 1 to 10 amino acids have been substituted, inserted and / or deleted in SEQ ID NO:249. In certain aspects, the substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs). Optionally, the anti-S-HBs antibody comprises the VL sequence in SEQ ID NO:249, including post-translational modifications of that sequence. In a particular aspect, the VL comprises one, two or three CDRs selected from: (a) CDR-L1, comprising the amino acid sequence of SEQ ID NO:238, (b) CDR-L2, comprising the amino acid sequence of SEQ ID NO:239, and (c) CDR-L3, comprising the amino acid sequence of SEQ ID NO:240.

[0537] In another embodiment, an anti-S-HBs antibody comprises one or more of the CDR sequences of the VL of SEQ ID NO:249. In one aspect, an anti-S-HBs antibody comprises one or more (preferably all three) of the light chain CDR amino acid sequences of the VL domain of SEQ ID NO: 249 and a framework of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity to the framework amino acid sequence of the VL domain of SEQ ID NO:249. Optionally the sequence identity is 95% or 98%.

[0538] In another aspect, an anti-S-HBs antibody is provided, wherein the antibody comprises a VH sequence as in any of the aspects provided above, and a VL sequence as in any of the aspects provided above.

[0539] For instance, in one exemplary embodiment, the antibody comprises a VH domain comprising CDR-H3 of SEQ ID NO:237; and a VL domain comprising CDR-L3 of SEQ ID NO: 240. Optionally the VH domain further comprises CDR-H2 of SEQ ID NO: 236.

[0540] In another exemplary embodiment, the antibody comprises:

[0541] i) a VH domain comprising the following CDRs (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:235; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 236; and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:237; or a variant thereof in which one, two or three amino acids in one or more of CDR-H1, CDR-H2 or CDR-H3 are substituted with another amino acid; and

[0542] ii) a VL domain comprising the following CDRs (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:238; (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 239; and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO:240; or a variant thereof in which one, two or three amino acids in one or more of CDR-L1, CDR-L2 or CDR-L3 are substituted with another amino acid.

[0543] In another exemplary embodiment, the antibody comprises:

[0544] i) a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 250; and

[0545] ii) a light chain variable domain (VL) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 249.

[0546] In another exemplary embodiment, the anti-S-HBs antibody comprises (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:235; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:236; (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 237; (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:238; (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:239; and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:240, and a VH domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 250, and a VL domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:249. In one aspect, the VH domain has at least 95% sequence identity to the amino acid sequence of SEQ ID NO:250. In one aspect, the VL domain has at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 249. In one embodiment, the antibody specifically binds to S-HBs. In another embodiment, the antibody binds to S-HBs having a dissociation constant (KD) that is up to 10 fold reduced or up to 10 fold increased when compared to the dissociation constant (KD) of an antibody comprising a VH sequence of SEQ ID NO:250 and a VL sequence of SEQ ID NO:249.

[0547] In one aspect, the antibody comprises the VH and VL sequences in SEQ ID NO:250 and SEQ ID NO:249, respectively, including post-translational modifications of those sequences.

[0548] In a further aspect, the antibody may comprise the full length light chain of SEQ ID NO: 251 and / or the full length heavy chain of SEQ ID NO: 252 or 276.

[0549] In a further aspect, the invention provides an antibody that binds to the same epitope as the anti-S-HBs antibody provided herein. For example, in certain aspects, an antibody is provided that binds to the same epitope as an anti-S-HBs antibody comprising a VH sequence of SEQ ID NO: 250 and a VL sequence of SEQ ID NO:249. In certain aspects, an antibody is provided that binds to the following residues of S-HBs of SEQ ID NO: 253: C124, C137, C138 and / or C139; optionally R122, C149, and / or I152; and optionally W156. The antibody may comprise any of the sequences as defined above.

[0550] In a further aspect, the invention provides an antibody that competes for binding to S-HBs with an anti-S-HBs antibody provided herein.

[0551] Antibodies as described in this section may, in some embodiments, have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the binding activity of a reference antibody Bv4.105 to S-HBs (e.g., of SEQ ID NO:253), when assessed in the same assay, e.g., an ELISA assay or a flow cytometry assay.

[0552] Additionally or alternatively, antibodies as described in this section may have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the binding activity of reference antibody Bv4.105 to one or more, optionally each of the proteins of SEQ ID NO: 257, 258, 259, 260, and / or 261, optionally at least to SEQ ID NO: 257, when assessed in the same assay e.g., an ELISA assay or a flow cytometry assay.

[0553] Reference antibody Bv4.105 has a VH sequence of SEQ ID NO:250 and a VL sequence of SEQ ID NO:249. It has a full length heavy chain of SEQ ID NO: 252 or 276 and a full length light chain of SEQ ID NO: 251. SEQ ID NO: 276 comprises the IgG1 constant region expressed by vector LT615368.1, as used in the examples.

[0554] In some embodiments, the antibody described in this section may bind to S-HBs (e.g., of SEQ ID NO: 253) with a KD value which is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the KD value of reference antibody Bv4.105 to the same antigen, when assessed in the same assay.

[0555] Additionally or alternatively, the antibody may bind to one or more, optionally each of the proteins of SEQ ID NO: 257, 258, 259, 260, and / or 261, optionally at least to SEQ ID NO: 257, with a KD value which is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the KD value of reference antibody Bv4.105 to the same antigen, when assessed in the same assay.

[0556] In some embodiments, the antibody as described in this section may bind to S-HBs (e.g., of SEQ ID NO: 253) with an EC50 that is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the EC50 of reference antibody Bv4.105, as measured by ELISA or by flow cytometry. Alternatively or additionally, the antibody may bind to one or more, optionally each, of the proteins of SEQ ID NO: 257, 258, 259, 260, and / or 261, optionally at least to SEQ ID NO: 257, with an EC50 that is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the EC50 of reference antibody Bv4.105, as measured by ELISA or by flow cytometry.

[0557] In some embodiments antibodies as described in this section may have or retain in vitro neutralizing activity against HBV genotype D, E, F, and / or H, optionally all of genotypes D, E, F and H. For example, antibodies as described in this section may have or retain in vitro neutralizing activity against HBV genotype D, e.g., with an IC50 value of ≤100 pg / ml, optionally ≤10 pg / ml.

[0558] In another embodiment, the antibody may have an IC50 value for neutralization of HBV genotype D, E, F, G and / or H, optionally at least D, optionally all of D, E, F, G and / or H, which is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the IC50 value of reference antibody Bv4.105 against the same genotype, when assessed using the same assay (e.g., an in vitro neutralization assay as described herein).

[0559] In another embodiment, the antibody may have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the neutralizing activity of reference antibody Bv4.105 against HBV genotype D, E, F, G and / or H, optionally at least D, optionally all of D, E, F, G and H, when assessed using the same assay (e.g., an assay as described herein).

[0560] Optionally the antibody can suppress virus viremia in vivo e.g., in an individual infected with HBV genotype D, E, F, G or H, optionally D. Optionally, the antibody may have or retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the in vivo viremia suppressing activity of reference antibody Bv4.105 against HBV genotype D, E, F, G and / or H, optionally at least D, optionally all of D, E, F, G and H, when assessed using the same assay (e.g., an assay as described herein).

[0561] In general, an anti-S-HBs antibody according to any aspect of the present invention (including any of A-N above) may be a monoclonal antibody, including a chimeric, humanized or human antibody. In one aspect, an anti-S-HBs antibody is an antibody fragment, e.g., a Fv, Fab, Fab′, scFv, diabody, or F(ab′) 2 fragment.

[0562] In another general aspect, the antibody may be a full-length antibody, e.g., an intact IgG1, IgG2, IgG3 antibody or other antibody class or isotype as defined herein.

[0563] The C-terminal lysine (Lys447) of the full-length antibody may be either present or absent. In another aspect, the C-terminal glycine (Gly446) and the C-terminal lysine (Lys447) may be either present or absent.

[0564] In a further aspect, an anti-S-HBs antibody according to any of the above aspects may incorporate any of the features, singly or in combination, as described in Sections 1-7 below:1. Antibody Affinity

[0565] In certain aspects, an antibody provided herein has a dissociation constant (KD) against the target protein of ≤1 μM, ≤100 nM, ≤10 nM, ≤1 nM, ≤0.1 nM, ≤0.01 nM, or ≤0.001 nM (e.g., 10−8 M or less, e.g., from 10−8 M to 10−13 M, e.g., from 10−9 M to 10−13 M).

[0566] In other aspects, an antibody provided herewith has or retains a KD which is which is no more than 50, 10, 9, 8, 7, 6, 5, 4, 3, or 2 fold higher than, or is less than or equal to, the KD value of a reference antibody against the target protein when assessed in the same assay, wherein the reference antibody is selected from the group consisting of Bc1.187, Bv4.115, Bc8.159, Bv6.172, Bc1.229, Bc8.111, Bc1.128, Bc3.106, Bc1.180, Bv4.104, Bc8.104, Bc4.204, Bc1.263 and Bv4.105.

[0567] In one aspect, KD is measured using a BIACORE® surface plasmon resonance assay. For example, an assay using a BIACORE®-2000 or a BIACORE®-3000 (BIAcore, Inc., Piscataway, NJ) is performed at 25° C. with immobilized antigen CM5 chips at ~10 response units (RU). In one aspect, carboxymethylated dextran biosensor chips (CM5, BIACORE, Inc.) are activated with N-ethyl-N′-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) according to the supplier's instructions. Antigen is diluted with 10 mM sodium acetate, pH 4.8, to 5 μg / ml (~0.2 μM) before injection at a flow rate of 5 μl / minute to achieve approximately 10 response units (RU) of coupled protein. Following the injection of antigen, 1 M ethanolamine is injected to block unreacted groups. For kinetics measurements, two-fold serial dilutions of Fab (0.78 nM to 500 nM) are injected in PBS with 0.05% polysorbate 20 (TWEEN-20™) surfactant (PBST) at 25° C. at a flow rate of approximately 25 μl / min. Association rates (kon) and dissociation rates (koff) are calculated using a simple one-to-one Langmuir binding model (BIACORE® Evaluation Software version 3.2) by simultaneously fitting the association and dissociation sensorgrams. The equilibrium dissociation constant (KD) is calculated as the ratio koff / kon. See, e.g., Chen et al., J. Mol. Biol. 293:865-881 (1999). If the on-rate exceeds 106 M−1 s−1 by the surface plasmon resonance assay above, then the on-rate can be determined by using a fluorescent quenching technique that measures the increase or decrease in fluorescence emission intensity (excitation=295 nm; emission=340 nm, 16 nm band-pass) at 25° C. of a 20 nM anti-antigen antibody (Fab form) in PBS, pH 7.2, in the presence of increasing concentrations of antigen as measured in a spectrometer, such as a stop-flow equipped spectrophometer (Aviv Instruments) or a 8000-series SLM-AMINCO™ spectrophotometer (ThermoSpectronic) with a stirred cuvette.

[0568] In another aspect, ELISA can be used to calculate KD values, e.g., as described in Friguet et al J Immunol. Methods (1985) 77 (2): 305-19.2. Antibody Fragments

[0569] In certain aspects, an antibody provided herein is an antibody fragment.

[0570] In one aspect, the antibody fragment is a Fab, Fab′, Fab′-SH, or F(ab′) 2 fragment, in particular a Fab fragment. Papain digestion of intact antibodies produces two identical antigen-binding fragments, called “Fab” fragments containing each the heavy- and light-chain variable domains (VH and VL, respectively) and also the constant domain of the light chain (CL) and the first constant domain of the heavy chain (CH1). The term “Fab fragment” thus refers to an antibody fragment comprising a light chain comprising a VL domain and a CL domain, and a heavy chain fragment comprising a VH domain and a CH1 domain. “Fab′ fragments” differ from Fab fragments by the addition of residues at the carboxy terminus of the CH1 domain including one or more cysteines (SEQ ID NO: 285) from the antibody hinge region. Fab′-SH are Fab′ fragments in which the cysteine residue(s) of the constant domains bear a free thiol group. Pepsin treatment yields an F(ab′)2 fragment that has two antigen-binding sites (two Fab fragments) and a part of the Fc region. For discussion of Fab and F(ab′)2 fragments comprising salvage receptor binding epitope residues and having increased in vivo half-life, see U.S. Pat. No. 5,869,046.

[0571] In another aspect, the antibody fragment is a diabody, a triabody or a tetrabody. “Diabodies” are antibody fragments with two antigen-binding sites that may be bivalent or bispecific. See, for example, EP 404,097; WO 1993 / 01161; Hudson et al., Nat. Med. 9:129-134 (2003); and Hollinger et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993). Triabodies and tetrabodies are also described in Hudson et al., Nat. Med. 9:129-134 (2003).

[0572] In a further aspect, the antibody fragment is a single chain Fab fragment. A “single chain Fab fragment” or “scFab” is a polypeptide consisting of an antibody heavy chain variable domain (VH), an antibody heavy chain constant domain 1 (CH1), an antibody light chain variable domain (VL), an antibody light chain constant domain (CL) and a linker, wherein said antibody domains and said linker have one of the following orders in N-terminal to C-terminal direction: a) VH-CH1-linker-VL-CL, b) VL-CL-linker-VH-CH1, c) VH-CL-linker-VL-CH1 or d) VL-CH1-linker-VH-CL. In particular, said linker is a polypeptide of at least 30 amino acids, preferably between 32 and 50 amino acids. Said single chain Fab fragments are stabilized via the natural disulfide bond between the CL domain and the CH1 domain. In addition, these single chain Fab fragments might be further stabilized by generation of interchain disulfide bonds via insertion of cysteine residues (e.g., position 44 in the variable heavy chain and position 100 in the variable light chain according to Kabat numbering).

[0573] In another aspect, the antibody fragment is single-chain variable fragment (scFv). A “single-chain variable fragment” or “scFv” is a fusion protein of the variable domains of the heavy (VH) and light chains (VL) of an antibody, connected by a linker. In particular, the linker is a short polypeptide of 10 to 25 amino acids and is usually rich in glycine for flexibility, as well as serine or threonine for solubility, and can either connect the N-terminus of the VH with the C-terminus of the VL, or vice versa. This protein retains the specificity of the original antibody, despite removal of the constant regions and the introduction of the linker. For a review of scFv fragments, see, e.g., Plückthun, in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., (Springer-Verlag, New York), pp. 269-315 (1994); see also WO 93 / 16185; and U.S. Pat. Nos. 5,571,894 and 5,587,458.

[0574] In another aspect, the antibody fragment is a single-domain antibody. “Single-domain antibodies” are antibody fragments comprising all or a portion of the heavy chain variable domain or all or a portion of the light chain variable domain of an antibody. In certain aspects, a single-domain antibody is a human single-domain antibody (Domantis, Inc., Waltham, MA; see, e.g., U.S. Pat. No. 6,248,516 B1).

[0575] Antibody fragments can be made by various techniques, including but not limited to proteolytic digestion of an intact antibody as well as recombinant production by recombinant host cells (e.g., E. coli), as described herein.3. Chimeric and Humanized Antibodies

[0576] In certain aspects, an antibody provided herein is a chimeric antibody. Certain chimeric antibodies are described, e.g., in U.S. Pat. No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984)). In one example, a chimeric antibody comprises a non-human variable region (e.g., a variable region derived from a mouse, rat, hamster, rabbit, or non-human primate, such as a monkey) and a human constant region. In a further example, a chimeric antibody is a “class switched” antibody in which the class or subclass has been changed from that of the parent antibody. Chimeric antibodies include antigen-binding fragments thereof.

[0577] In certain aspects, a chimeric antibody is a humanized antibody. Typically, a non-human antibody is humanized to reduce immunogenicity to humans, while retaining the specificity and affinity of the parental non-human antibody. Generally, a humanized antibody comprises one or more variable domains in which the CDRs (or portions thereof) are derived from a non-human antibody, and FRs (or portions thereof) are derived from human antibody sequences. A humanized antibody optionally will also comprise at least a portion of a human constant region. In some aspects, some FR residues in a humanized antibody are substituted with corresponding residues from a non-human antibody (e.g., the antibody from which the CDR residues are derived), e.g., to restore or improve antibody specificity or affinity.

[0578] Humanized antibodies and methods of making them are reviewed, e.g., in Almagro and Fransson,Front. Biosci. 13:1619-1633 (2008), and are further described, e.g., in Riechmann et al., Nature 332:323-329 (1988); Queen et al., Proc. Nat'l Acad. Sci. USA 86:10029-10033 (1989); U.S. Pat. Nos. 5,821,337, 7,527,791, 6,982,321, and 7,087,409; Kashmiri et al., Methods 36:25-34 (2005) (describing specificity determining region (SDR) grafting); Padlan, Mol. Immunol. 28:489-498 (1991) (describing “resurfacing”); Dall'Acqua et al., Methods 36:43-60 (2005) (describing “FR shuffling”); and Osbourn et al., Methods 36:61-68 (2005) and Klimka et al., Br. J. Cancer, 83:252-260 (2000) (describing the “guided selection” approach to FR shuffling).

[0579] Human framework regions that may be used for humanization include but are not limited to: framework regions selected using the “best-fit” method (see, e.g., Sims et al. J. Immunol. 151:2296 (1993)); framework regions derived from the consensus sequence of human antibodies of a particular subgroup of light or heavy chain variable regions (see, e.g., Carter et al. Proc. Natl. Acad. Sci. USA, 89:4285 (1992); and Presta et al. J. Immunol., 151:2623 (1993)); human mature (somatically mutated) framework regions or human germline framework regions (see, e.g., Almagro and Fransson, Front. Biosci. 13:1619-1633 (2008)); and framework regions derived from screening FR libraries (see, e.g., Baca et al., J. Biol. Chem. 272:10678-10684 (1997) and Rosok et al., J. Biol. Chem. 271:22611-22618 (1996)).4. Human Antibodies

[0580] In certain aspects, an antibody provided herein is a human antibody. Human antibodies can be produced using various techniques known in the art. Human antibodies are described generally in van Dijk and van de Winkel, Curr. Opin. Pharmacol. 5:368-74 (2001) and Lonberg, Curr. Opin. Immunol. 20:450-459 (2008).

[0581] Human antibodies may be prepared by administering an immunogen to a transgenic animal that has been modified to produce intact human antibodies or intact antibodies with human variable regions in response to antigenic challenge. Such animals typically contain all or a portion of the human immunoglobulin loci, which replace the endogenous immunoglobulin loci, or which are present extrachromosomally or integrated randomly into the animal's chromosomes. In such transgenic mice, the endogenous immunoglobulin loci have generally been inactivated. For review of methods for obtaining human antibodies from transgenic animals, see Lonberg, Nat. Biotech. 23:1117-1125 (2005). See also, e.g., U.S. Pat. Nos. 6,075,181 and 6,150,584 describing XENOMOUSE™ technology; U.S. Pat. No. 5,770,429 describing HUMAB® technology; U.S. Pat. No. 7,041,870 describing K-M MOUSE® technology, and U.S. Patent Application Publication No. US 2007 / 0061900, describing VELOCIMOUSE® technology). Human variable regions from intact antibodies generated by such animals may be further modified, e.g., by combining with a different human constant region.

[0582] Human antibodies can also be made by hybridoma-based methods. Human myeloma and mouse-human heteromyeloma cell lines for the production of human monoclonal antibodies have been described. (See, e.g., Kozbor J. Immunol., 133:3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987); and Boerner et al., J. Immunol., 147:86 (1991).) Human antibodies generated via human B-cell hybridoma technology are also described in Li et al., Proc. Natl. Acad. Sci. USA, 103:3557-3562 (2006). Additional methods include those described, for example, in U.S. Pat. No. 7,189,826 (describing production of monoclonal human IgM antibodies from hybridoma cell lines) and Ni, Xiandai Mianyixue, 26 (4): 265-268 (2006) (describing human-human hybridomas). Human hybridoma technology (Trioma technology) is also described in Vollmers and Brandlein, Histology and Histopathology, 20 (3): 927-937 (2005) and Vollmers and Brandlein, Methods and Findings in Experimental and Clinical Pharmacology, 27 (3): 185-91 (2005).

[0583] Human antibodies may also be generated by isolating variable domain sequences selected from human-derived phage display libraries. Such variable domain sequences may then be combined with a desired human constant domain. Techniques for selecting human antibodies from antibody libraries are described below.5. Library-Derived Antibodies

[0584] In certain aspects, an antibody provided herein is derived from a library. Antibodies of the invention may be isolated by screening combinatorial libraries for antibodies with the desired activity or activities. Methods for screening combinatorial libraries are reviewed, e.g., in Lerner et al. in Nature Reviews 16:498-508 (2016). For example, a variety of methods are known in the art for generating phage display libraries and screening such libraries for antibodies possessing the desired binding characteristics. Such methods are reviewed, e.g., in Frenzel et al. in mAbs 8:1177-1194 (2016); Bazan et al. in Human Vaccines and Immunotherapeutics 8:1817-1828 (2012) and Zhao et al. in Critical Reviews in Biotechnology 36:276-289 (2016) as well as in Hoogenboom et al. in Methods in Molecular Biology 178:1-37 (O'Brien et al., ed., Human Press, Totowa, NJ, 2001) and in Marks and Bradbury in Methods in Molecular Biology 248:161-175 (Lo, ed., Human Press, Totowa, NJ, 2003).

[0585] In certain phage display methods, repertoires of VH and VL genes are separately cloned by polymerase chain reaction (PCR) and recombined randomly in phage libraries, which can then be screened for antigen-binding phage as described in Winter et al. in Annual Review of Immunology 12:433-455 (1994). Phage typically display antibody fragments, either as single-chain Fv (scFv) fragments or as Fab fragments. Libraries from immunized sources provide high-affinity antibodies to the immunogen without the requirement of constructing hybridomas. Alternatively, the naive repertoire can be cloned (e.g., from human) to provide a single source of antibodies to a wide range of non-self and also self antigens without any immunization as described by Griffiths et al. in EMBO Journal 12:725-734 (1993). Furthermore, naive libraries can also be made synthetically by cloning unrearranged V-gene segments from stem cells, and using PCR primers containing random sequence to encode the highly variable CDR3 regions and to accomplish rearrangement in vitro, as described by Hoogenboom and Winter in Journal of Molecular Biology 227:381-388 (1992). Patent publications describing human antibody phage libraries include, for example: U.S. Pat. Nos. 5,750,373; 7,985,840; 7,785,903 and 8,679,490 as well as US Patent Publication Nos. 2005 / 0079574, 2007 / 0117126, 2007 / 0237764 and 2007 / 0292936.

[0586] Further examples of methods known in the art for screening combinatorial libraries for antibodies with a desired activity or activities include ribosome and mRNA display, as well as methods for antibody display and selection on bacteria, mammalian cells, insect cells or yeast cells. Methods for yeast surface display are reviewed, e.g., in Scholler et al. in Methods in Molecular Biology 503:135-56 (2012) and in Cherf et al. in Methods in Molecular biology 1319:155-175 (2015) as well as in Zhao et al. in Methods in Molecular Biology 889:73-84 (2012). Methods for ribosome display are described, e.g., in He et al. in Nucleic Acids Research 25:5132-5134 (1997) and in Hanes et al. in PNAS 94:4937-4942 ...

Claims

1. An antibody that binds to small hepatitis B virus surface antigen (S-HBs), wherein the antibody comprises:(i) a heavy chain variable domain (VH) comprising (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:1, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:2, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:3, and a light chain variable domain (VL) comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:5, and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:6; or(ii) a heavy chain variable domain (VH) comprising (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:19, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 20, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:21, and a light chain variable domain (VL) comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:22, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:23, and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:24; or(iii) a heavy chain variable domain (VH) comprising (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:37, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 38, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:39, and a light chain variable domain (VL) comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:40, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:41, and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:42; or(iv) a heavy chain variable domain (VH) comprising (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:55, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 56, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:57, and a light chain variable domain (VL) comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:58, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:59, and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:60; or(v) a heavy chain variable domain (VH) comprising (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:73, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 74, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:75, and a light chain variable domain (VL) comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:76, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:77, and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:78; or(vi) a heavy chain variable domain (VH) comprising (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:91, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 92, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:93, and a light chain variable domain (VL) comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:94, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:95, and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:96; or(vii) a heavy chain variable domain (VH) comprising (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:109, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 110, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:111, and a light chain variable domain (VL) comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:112, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:113, and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:114; or(viii) a heavy chain variable domain (VH) comprising (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 127, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 128, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:129, and a light chain variable domain (VL) comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:130, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:131, and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:132; or(ix) a heavy chain variable domain (VH) comprising (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:145, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 146, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:147, and a light chain variable domain (VL) comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:148, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:149, and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 150; or(x) a heavy chain variable domain (VH) comprising (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:163, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 164, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:165, and a light chain variable domain (VL) comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:166, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:167, and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:168; or(xi) a heavy chain variable domain (VH) comprising (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:181, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 182, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:183, and a light chain variable domain (VL) comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:184, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:185, and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 186; or(xii) a heavy chain variable domain (VH) comprising (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:199, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 200, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:201, and a light chain variable domain (VL) comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:202, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:203, and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:204; or(xiii) a heavy chain variable domain (VH) comprising (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:217, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 218, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:219, and a light chain variable domain (VL) comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:220, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:221, and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:222; or(xiv) a heavy chain variable domain (VH) comprising (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:235, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 236, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:237, and a light chain variable domain (VL) comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:238, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:239, and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:240.

2. The antibody of claim 1, wherein the antibody comprises:(a) a VH sequence of SEQ ID NO: 34 and a VL sequence of SEQ ID NO: 33; or(b) a VH sequence of SEQ ID NO: 52 and a VL sequence of SEQ ID NO: 51; or(c) a VH sequence of SEQ ID NO: 70 and a VL sequence of SEQ ID NO: 69; or(d) a VH sequence of SEQ ID NO: 88 and a VL sequence of SEQ ID NO: 87; or(e) a VH sequence of SEQ ID NO: 106 and a VL sequence of SEQ ID NO: 105; or(f) a VH sequence of SEQ ID NO: 124 and a VL sequence of SEQ ID NO: 123; or(g) a VH sequence of SEQ ID NO: 142 and a VL sequence of SEQ ID NO: 141; or(h) a VH sequence of SEQ ID NO: 160 and a VL sequence of SEQ ID NO: 159; or(i) a VH sequence of SEQ ID NO: 178 and a VL sequence of SEQ ID NO: 177; or(j) a VH sequence of SEQ ID NO: 196 and a VL sequence of SEQ ID NO: 195; or(k) a VH sequence of SEQ ID NO: 214 and a VL sequence of SEQ ID NO: 213; or(l) a VH sequence of SEQ ID NO: 232 and a VL sequence of SEQ ID NO: 231; or(m) a VH sequence of SEQ ID NO: 250 and a VL sequence of SEQ ID NO: 249.

3. An antibody that binds to small hepatitis B virus surface antigen (S-HBs), wherein the antibody comprisesa heavy chain variable domain (VH) comprising (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:1, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:2, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:3, anda light chain variable domain (VL) comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:4, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:5, and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:6.

4. The antibody of claim 3, comprising a sequence selected from the group consisting of(a) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:16;(b) a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:15; and(c) a VH sequence as defined in (a) and a VL sequence as defined in (b).

5. The antibody of claim 3, comprising a VH sequence of SEQ ID NO: 16 and a VL sequence of SEQ ID NO: 15.

6. The antibody of claim 3, which has neutralizing activity against a genome D HBV in vivo or in vitro.

7. The antibody of claim 3, which is a monoclonal antibody.

8. The antibody of claim 3, which is a human or chimeric antibody.

9. The antibody of claim 3, which is an antibody fragment that binds S-HBs.

10. The antibody of claim 3, which is a full-length IgG antibody.

11. The antibody of claim 3 comprising a heavy chain of SEQ ID NO:18 or 263 and a light chain of SEQ ID NO:17.

12. The antibody of claim 10, comprising an Fc region with one or more substitutions therein which improve binding of the Fc region to FcRn.

13. The antibody of claim 12, wherein said substitutions are selected from the group consisting of:i) M252Y, S254T and T256E;ii) M428L, N434A and Y436T;iii) N434A; andiv) T307H and N434H.

14. An antibody of claim 13, comprising a light chain of SEQ ID NO: 17 and a heavy chain of SEQ ID NO: 18 or 263 modified by substitutions selected from the group consisting of:i) M252Y, S254T and T256E;ii) M428L, N434A and Y436T;iii) N434A; andiv) T307H and N434H.

15. An isolated nucleic acid encoding the antibody of claim 3.

16. A host cell comprising the nucleic acid of claim 15.

17. A method of producing an antibody that binds to S-HBs comprising culturing the host cell of claim 16 under conditions suitable for the expression of the antibody.

18. The method of claim 17, further comprising recovering the antibody from the host cell.

19. A pharmaceutical composition comprising the antibody of claim 3 and a pharmaceutically acceptable carrier.

20. The pharmaceutical composition of claim 19, further comprising an additional therapeutic agent.

21. The pharmaceutical composition of claim 20, wherein the additional therapeutic agent is selected from: an siRNA targeted to an HBV sequence; a nucleotide analog reverse-transcriptase inhibitor or a nucleoside analogue, INFα or pegylated INF-α; a therapeutic vaccine; a TLR agonist; and / or a checkpoint inhibitor.

22. A method of treating an individual having hepatitis B comprising administering to the individual an effective amount of the antibody of claim 3.

23. The method of claim 22 further comprising administering an additional therapeutic agent to the individual.

24. The method of claim 23, wherein the additional therapeutic agent is selected from the group consisting of: an siRNA targeted to an HBV sequence; a nucleotide analog reverse-transcriptase inhibitor or a nucleoside analogue; INFα or pegylated IFN-α; a therapeutic vaccine; a TLR agonist; and / or a checkpoint inhibitor.

25. The method of claim 22, wherein said hepatitis B is chronic hepatitis B.

Citation Information

Patent Citations

  • fc mutants with altered binding to fcrn

    JP2008519860A

  • Human binding molecules that bind to and neutralize hepatitis B virus and uses thereof

    JP2016504015A

  • Antibodies that potently neutralize hepatitis b virus and uses thereof

    JP2018535650A

  • Method for treating the patients suffering from viral hepatitis b with cholestatic component

    RU2165772C1

  • Method for treatment of chronic viral hepatitis b and c

    RU2217153C1